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Abstract 
Candida biofilms have become an increasingly important clinical problem. The 
widespread use of antibiotics, frequent use of indwelling medical devices, and a 
trend towards increased patient immuno-suppression has resulted in a creation 
of opportunity for clinically important yeasts to form biofilms. Whilst there is 
growing evidence of the importance of Candida biofilms in clinical medicine, not 
all clinical isolates are able to form biofilms. There is therefore a fundamental 
gap in understanding exactly what drives biofilm formation and its clinical 
implications. These structures have become increasingly recognised as a 
significant clinical problem. One of the major reasons behind this is the impact 
that these have upon treatment, as antifungal therapy often fails and surgical 
intervention is required. This places a large financial burden on health care 
providers. Therefore, the discovery of alternative antifungal agents to be used in 
the treatment of fungal biofilms is in great demand for the management of these 
infections. 
A panel of Candida albicans bloodstream isolates were assessed for their biofilm 
forming ability by using the crystal violet assay and measuring cellular surface 
hydrophobicity. Scanning electron microscopy was used to visualise differences 
in the clinical biofilms. The impact of amphotericin B (AMB) treatment was 
determined next by broth microdilution method to assess differences in 
susceptibility profiles of the clinical isolates. The virulence of these clinical 
isolates was evaluated in vivo using a Galleria mellonella model and 
transcriptional analysis used to assess the expression of various genes associated 
with C. albicans biofilm formation within clinical isolates. Extracellular DNA 
(eDNA) in clinical biofilms was quantified using a microplate fluorescence assay 
and chitinase activity measured using a biochemical assay. Moreover, the 
potential of a novel antimicrobial agent Carbohydrate-derived fulvic acid (CHD-
FA) was assessed against a panel of fungal and bacterial species. The mechanism 
of action of CHD-FA was determined using membrane assays include ATP release, 
and propidium iodide fluorescence, with various inhibitors used to determine 
whether CHD-FA activity is affected by known resistance mechanisms. Finally, 
the immunomodulatory properties of CHD-FA were investigated using ELISA and 
PCR arrays. 
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The results from this study have shown C. albicans biofilm formation is 
differential within clinical isolates, where those with high biofilm formation 
(HBF) predominately consisted of hyphal cells, were more virulent in vivo and 
had decreased susceptibility to AMB, when compared to those with low biofilm 
formation (LBF). Furthermore, transcriptional analysis identified a number of 
genes that positively correlated with C. albicans biofilm formation. The novel 
agent carbohydrate-derived fulvic acid (CHD-FA) was shown to not only be highly 
active against C. albicans biofilms, but also against a range or orally relevant 
bacteria through non-specific membrane activity. Furthermore, CHD-FA was 
shown to down-regulate a number of pro-inflammatory mediators in an oral 
epithelial cell line. 
In conclusion, this study has characterised C. albicans clinical isolates based on 
their biological characteristics, where clear difference in virulence and 
antifungal treatment have been shown. It may be possible to develop a panel of 
genetic markers that could be used as a diagnostic tool for detecting biofilm 
formation in clinical isolates. CHD-FA is a microbiocidal compound that may 
serve as a potential novel antiseptic agent for the treatment of oral candidiasis 
and other candidal biofilm infections, whereby the immunomodulatory 
properties of CHD-FA could be exploited for controlling inflammation in a 
number of diseases. 
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Ch.1 Clinical significance of fungal biofilms 
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1.1 Introduction 
Fungi represent a significant burden of infection within the hospital population. 
There are a number of factors that predispose us to invasive fungal infections 
including, the use of broad-spectrum antibiotics, presence of indwelling 
catheters, immuno-suppression or disruption of mucosal barriers due to surgery, 
chemotherapy and radiotherapy (Odds, 1988). Candida is the third most common 
cause of bloodstream infections (BSI) in patients requiring intensive care in the 
US (Wisplinghoff et al., 2004) and the most common etiologic agent of fungal 
related biofilm infections. C. albicans, normally a commensal of human mucosal 
surfaces yet an opportunistic pathogen in immunocompromised patients, has the 
ability to form biofilms on a number of medical devices including central venous 
catheters (CVC) and a variety of prostheses.  These surfaces are ideal for the 
colonisation of Candida spp. and allow the development of mature biofilm 
communities where planktonic cells can detach cause an acute candidaemia 
and/or disseminated infection. Furthermore, a study investigating the 
pathogenicity of cells dispersed from biofilms had shown a greater association 
with mortality than equivalent planktonic yeasts (Uppuluri et al., 2010). 
Infections associated with medical devices are essentially difficult to eradicate, 
with the only method of controlling such an infection being long-term use of 
antifungals and the removal of the implant. Although C. albicans remains the 
dominant species responsible for human disease, C. glabrata, C. parapsilosis, C. 
dublininensis, C. krusei and C. tropicalis (Ramage et al., 2006, Shin et al., 2002, 
Tumbarello et al., 2007) are associated with biofilm formation and contribute to 
device-related bloodstream infections. 
This chapter provides a review of the current literature around fungal biofilms, 
the use of current antifungal strategies use clinically and highlights the 
importance of identifying novel antimicrobials. Some aspects of this chapter 
have been published in: 
Ramage G, Rajendran R, Sherry L and Williams C. 2012. Fungal biofilm 
resistance. Int J Microbiol:528521. Epub 2012 Feb 8. 
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1.2 Biofilms  
Historically, microbiologists have studied free-floating planktonic cells in pure 
culture. However, it is now widely accepted a link exists between sessile 
(surface attached and heterogeneous) cells, microbial pathogenesis and human 
infection (Costerton et al., 1995). It is apparent that a wide range of fungi 
alternate between planktonic cells and multi-cellular communities, known as 
biofilms. It has been estimated that up to 80% of all microorganisms in the 
environment exist in sessile communities (Donlan, 2002). Biofilms are defined as 
a group of microorganisms with the ability to attach to surfaces, and or one 
another, and are enclosed within a self-produced extracellular polymeric matrix 
(Ramage et al., 2009). 
It has been estimated that 65% of all clinical infections are due to the presence 
of a biofilm, which considering these structures are highly associated with 
antimicrobial resistance makes the management of such infections difficult 
within the clinical setting (Donlan and Costerton, 2002). In recent years it has 
been appreciated that fungal species have the ability to form biofilms and have 
a significant impact clinically (Ramage et al., 2009, Sayed et al., 2012a, Fanning 
and Mitchell, 2012). The main reason to why C. albicans is the most studied 
Candida spp. is because it is a highly adaptable opportunistic pathogen with 
excellent biofilm activity on a number of substrates (Ramage et al., 2006). C. 
albicans is a dimorphic microorganism that can exist either as yeast or as hyphal 
cells and form the foundations of a complex multicellular biofilm. 
The adhesion and colonisation of biological and innate surfaces, such as the oral 
mucosa or denture acrylic substrates, is commonplace for C. albicans (Ellepola 
and Samaranayake, 1998, Holmes et al., 2002, Radford et al., 1999, Williams et 
al., 2011). The initial attachment to the surface is controlled by a number of 
factors, including the flow of the surrounding medium (urine, blood, saliva, 
mucus), pH, temperature, osmolarity, bacteria, presence of antimicrobial 
agents, and host immune factors (Hawser et al., 1998a, Baillie and Douglas, 
2000, Richard et al., 2005, Ramage et al., 2002d, Ramage et al., 2008, Chandra 
et al., 2001b). C. albicans biofilms have defined phases of development that 
have been described through the use of defined model systems (Al-Fattani and 
Douglas, 2004, Baillie and Douglas, 1998a, Chandra et al., 2001a, Garcia-Sanchez 
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et al., 2004, Nikawa et al., 2003, Ramage et al., 2001a, Ramage et al., 2008), as 
shown in Figure 1.1. These key phases include presence of an appropriate 
substratum, adhesion, colonisation, extracellular matrix (ECM) production, 
biofilm maturation and dispersal (Blankenship and Mitchell, 2006, Chandra et 
al., 2001a, Ramage et al., 2001b).  
  
Figure 1.1 - Stages of C. albicans biofilm development.  
There are three stages of biofilm formation, early – adhesion and germination (0 – 8 h), 
intermediate – hyphal development and ECM production (9 -18 h) and maturation (19-24 
h), which is followed by dispersal of yeast cells. Circles = yeast cells, black lines = 
hyphae, blue = extracellular matrix (Chandra et al., 2001a).  
Simplistically, yeast cells attach to a surface via adhesins including, agglutinin 
like sequence protein Als3p and the cell wall protein Eap1p (Zhao et al., 2006, Li 
et al., 2007). This leads to the formation of microcolonies and the morphology of 
Ch.1 Clinical significance of fungal biofilms 
5 
 
yeast cells switches to pseudo- and true-hyphae by the regulator Efg1p (Ramage 
et al., 2002d), to form a complex network of hyphal structures with budding 
yeast cells distributed throughout.  
Next, as the biofilm matures, a glucan rich extracellular matrix (ECM) 
encompasses the structure (Nett et al., 2010c), providing a protective barrier 
from host defences, antimicrobial agents and environmental stresses. During the 
development of a mature biofilm, a hypoxic environment is created which 
induces the up-regulation of glycolytic genes that control filamentation 
(Bonhomme et al., 2011). Finally, planktonic yeast cells are able to disperse 
from the mature biofilm and colonise a new surface to begin the development of 
a new biofilm (Uppuluri et al., 2010). The process of biofilm formation is 
complex, controlled by a variety of transcription factors including Bcr1p, Ace2p, 
Efg1p and Zap1p, all of which are involved in sophisticated molecular pathways 
(Finkel and Mitchell, 2011, Nobile and Mitchell, 2006, Zhao et al., 2006, Fanning 
et al., 2012). Figure 1.2 illustrates our current understanding of the genes 
involved in C. albicans biofilm development and maintenance. The importance 
of understanding this entire process cannot be understated as it enables us to 
fully comprehend the mechanisms involved in the process and exploit these for 
the clinical management of such infections.  
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Figure 1.2 - Genes involved for C. albicans biofilm formation.  
A complex molecular pathway is involved in the C. albicans biofilm development 
process, where genes are responsible for the progression from the adherence stage to 
biofilm dispersal through activation and inhibition of certain genes (Finkel and Mitchell, 
2011).  
1.3 Clinical relevance 
C. albicans biofilms are able to develop in a number of body sites in the human 
host, including indwelling medical devices; prosthetic heart valves, breast 
implants and central venous catheters (Ramage et al., 2006). Figure 1.3 
illustrates some of the key sites that can be impacted by C. albicans biofilms. 
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Figure 1.3 – Key sites of the human host impacted by C. albicans biofilms.  
Adapted from (Ramage and Williams, 2013). 
1.3.1 Oral Cavity 
The oral cavity is one of the initial entrance sites for microorganisms, and is an 
area that a range of multispecies microbial biofilms can be found (Jakubovics, 
2010). Biofilms are responsible for oral diseases such as caries, periodontal 
disease and mucosal infections (Peyyala et al., 2013, Yamakami et al., 2013). 
Analysis of the oral fungal microbiome revealed 74 culturable and 11 non-
culturable genera from twenty healthy individuals (Ghannoum et al., 2010), of 
which Candida species were the most dominant. Oral candidosis is one of the 
most well studied fungal biofilm infections and affects both soft and hard tissue. 
The interaction between Candida species, bacterial species and a number of 
host factors allow the formation of complex biofilms (Dongari-Bagtzoglou et al., 
2009, Rautemaa and Ramage, 2011). This infection is commonly observed in 
immunocompromised patients including those on long term corticosteroid 
treatments, diabetes patients and those with a human immunodeficiency virus 
(HIV) infection. Acute candidiasis is also referred to pseudomembranous 
candidiasis (PC) and has been estimated that to affect ~5% of newborns and 10% 
of the elderly population (Samaranayake et al., 2009a). PC is clinically 
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represented by white, curd-like patches found on the tongue and other mucous 
membranes which can be removed upon gentle scraping, leaving an area of 
inflammation, as shown in Figure 1.4. Oral leukoplakia is classified as chronic 
candidiasis and represents itself as persistent white lesions on the inside of the 
cheeks (Figure 1.4). These lesions have been described as potentially 
carcinogenic and occur with specific risk factors including tobacco and alcohol 
consumption (van der Waal, 2009, Marichalar-Mendia et al., 2010). 
 
Figure 1.4 – Classifications of oral candidiasis.  
Acute candidiasis – oral cavity contains white patches that can be removed upon gentle 
scraping (http://depts.washington.edu/hivaids/oral/case1/discussion). Chronic 
candidiasis - white areas of the inner cheek are persistent and not easily removed 
(http://www.exodontia.info/CandidalLeukoplakia).  
Denture induced stomatitis (DIS) is another infection of the oral cavity, which is 
directly caused by Candida species on a denture prosthesis (Pereira-Cenci et al., 
2008). The disease is typically linked to an ill-fitting upper fitting denture sitting 
adjacent to the oral mucosa, providing an environment for Candida spp. to form 
biofilms (Ramage et al., 2004), where C. albicans remains the species most 
isolated. The severity of DIS is characterised by the degree of inflammation on 
the palate, defined by Newton’s classification (NT) (Newton, 1962), as shown in 
Figure 1.5. 
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Figure 1.5 – Newton’s classification of DIS types. 
(I) localised erythema, (II) moderate erythema, (III) severe erythema (Rautemaa and 
Ramage, 2011).  
A number of factors are considered when defining the severity of DIS including, 
colour, texture and overall appearance. Type I is characterised by small areas of 
pinpoint hyperaemia, type II is identified by more diffused erythema that covers 
most of the palate and type III is found with severe erythema and granular 
inflammation. Recently, NT3 was associated predominantly with C. albicans 
(Coco et al., 2008) and subsequent in vitro analysis of clinical isolates found that 
biofilm formation positively correlated with disease severity and the release of 
secreted aspartyl proteinases (SAP) (Ramage et al., 2012a). This finding not only 
highlights the importance of these enzymes in biofilm formation but also agrees 
with other studies where they have been shown to contribute to Candida 
virulence and pathogenicity in vivo (Naglik et al., 2006, Naglik et al., 2004, 
Naglik et al., 2003). Furthermore, in addition to tissue damage, Saps have 
recently been shown to be involved in filamentation via the activation of the Cek 
MAPK pathway (Puri et al., 2012), a defining feature of biofilm development 
(Ramage et al., 2002d). Altogether these studies have suggested a physical and 
regulatory role for proteolytic enzymes in C. albicans biofilms.  
C. albicans has been shown to interact with other Candida species in DIS 
patients, particularly with C. glabrata, as these two species were frequently co-
isolated from patients with severe inflammation (Coco et al., 2008). As C. 
glabrata is unable to form hyphae it is hypothesised that this organism gains 
entry to the host via its interactions with C. albicans. A further study has 
confirmed this by showing the invasion of an in vitro reconstituted epithelial 
biofilm model by C. glabrata, assisted by C. albicans (Silva et al., 2011a). 
Currently the mechanisms by which C. albicans assists C. glabrata invasion are 
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yet to be defined. However, it could be argued that specific enzymes involved in 
tissue damage promote increased invasion of C. albicans hyphae that in turn 
allows the entry of C. glabrata and contributes to host pathogenicity. Therefore, 
the use of in vivo models would be of much importance for studying the 
pathogenesis of DIS (Nett et al., 2010b). 
Candida species do not exclusively adhere to dentures and mucosal surfaces, as 
they have also been found in periodontal pockets, orthodontic appliances and on 
the enamel surface (Arslan et al., 2008, de Carvalho et al., 2006, Sardi et al., 
2010). A recent study has showed C. albicans yeast cells were highly prevalent 
within a mixed species subgingival biofilm in patients with moderate to severe 
periodontitis (Canabarro et al., 2012). However, it is yet to be established if the 
C. albicans present within these biofilms contribute to disease pathogenesis. It 
has been shown recently that the increased prevalence of Candida was linked to 
an alteration in the oral bacterial flora. Patients with higher Candida loads had a 
less diverse microbial population and were dominated by streptococci 
(Kraneveld et al., 2012). Many studies have investigated the relationship 
between C. albicans and oral streptococci and have shown an increase in 
colonisation of mucosal surfaces and biofilm formation by these bacteria when 
grown in the presence of Candida (Diaz et al., 2012, Silverman et al., 2010, Xu 
et al., 2013). Specifically, the interaction between Streptococcus gordonii and 
C. albicans involves the surface proteins SspB and Als3p, respectively, which are 
responsible for increased biofilm formation (Silverman et al., 2010). Therefore, 
consideration of bacterial-fungal interactions in mixed species biofilms must be 
considered when managing oral candidosis, particularly in terms of the 
antimicrobial strategy.  
1.3.2 Upper Respiratory Tract 
Facial prosthesis is an example of one of number of head and neck related 
devices shown to allow the adherence and growth of Candida biofilms, 
particularly with respect to polymicrobial infections (Ariani et al., 2012). 
Specifically, C. albicans and C. glabrata are the most frequently isolated 
Candida species found associated with voice prosthesis biofilms (Buijssen et al., 
2012, Ell, 1996). These species are known to bind to salivary proteins (Holmes et 
al., 2006), and are often found co-habiting with bacterial species (Kania et al., 
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2010). These are important in the clinical setting as they can impact the 
patients impede speech, swallowing and respiration (Sayed et al., 2012a) and 
restrict airflow (Elving et al., 2001).  
Ventilator associated pneumonia (VAP) is also of particular interest when 
considering upper airway infections due to the close proximity of the oral cavity 
to the trachea and bronchioles. Previous studies with patients suspected of 
having VAP have shown an increased mortality rate when Candida species are 
present, compared to bacterial counts alone (Delisle et al., 2011). However, the 
question of whether Candida species is a marker of VAP or is a direct cause of 
disease remains unanswered. The use of broad-spectrum antibiotics may be a 
possible reason for the prevalence of Candida in VAP, where recently more than 
half of patients with fungi present were colonised with C. albicans (Serban et 
al., 2010). Within the intensive care unit (ICU) VAP has been significantly 
controlled through the use of oral rinses containing chlorhexidine (Stonecypher, 
2010, Caserta et al., 2012), therefore, confirms the benefits of good oral 
hygiene upon other infections.  
1.3.3 Lower Respiratory Tract 
Biofilm associated infections are frequently associated with the respiratory tract 
where the presence of fungal biofilms in the lungs are able to contribute to the 
infection. Respiratory diseases including invasive pulmonary aspergillosis (IPA), 
allergic bronchopulmonary aspergillosis (ABPA) and aspergilloma are due to the 
presence of a filamentous moulds such as Aspergillus fumigatus (Denning, 1998). 
It is not surprising that A. fumigatus can adhere to and form multispecies 
biofilms in this environment as this organism is ubiquitous with thousands of 
conidia readily inhaled daily (Richardson, 2009). It is of no doubt that 
Pseudomonas aeruginosa is one of the major prokaryotic organisms isolated in 
these infections (Singh et al., 2000) and along with A. fumigatus, are frequently 
isolated from cystic fibrous (CF) patients (Mowat et al., 2010). Recent reports 
have identified that co-infection with these two opportunistic pathogens reduces 
lung function, when compared to mono-species infections (Amin et al., 2010, 
Gangell et al., 2011). A similar observation was made with P. aeruginosa and 
Candida species (Chotirmall et al., 2010). The understanding to how these 
organisms are able to interact with one another and cause polymicrobial 
Ch.1 Clinical significance of fungal biofilms 
12 
 
infections is still under investigation. Both organisms have been shown to impact 
one another through various mechanisms. P. aeruginosa has been shown to 
adhere to Candida hyphae, form biofilms and elicit antimicrobial activity (Hogan 
and Kolter, 2002) due to the release of phenazines (Gibson et al., 2009, Morales 
et al., 2010). In contrast, C. albicans releases farnesol, a quorum sensing 
molecule, that down-regulates cell to cell signalling in P. aeruginosa causing 
pyocyanin levels to decrease (Cugini et al., 2007), a toxin that is normally 
involved in killing of competing organisms. Therefore, the pathogenesis of CF 
lies with the interactions between these opportunistic pathogens. 
1.3.4 Gastrointestinal tract 
It has been estimated that up to 80% of healthy adults have their gastrointestinal 
(GI) tract colonised by Candida spp. (Damman et al., 2012). However, 
immunocompromised patients may suffer from candidiasis of the GI tract if 
colonisation becomes chronic (Kumamoto, 2011). The GI tract is another location 
prone to of polymicrobial infections, where prokaryotes and eukaryotes interact 
with one another and contribute to the level of disease. Unlike the competitive 
inhibition found in the lung, polymicrobial infections in the GI tract have been 
shown to be beneficial to the organisms in vivo (Mason et al., 2012). For 
example, C. albicans was able to influence the composition of non-pathogenic 
bacteria of the gut microbiota. Furthermore, co-infection with C. albicans and 
Escherichia coli has revealed a synergistic relationship (Klaerner et al., 1997). 
1.3.5 Urinary tract 
The urinary tract is home to a variety of bacteria and fungi that are able to 
prevent infections including sexually transmitted diseases (STDs), vaginosis and 
urinary tract infections (UTIs). The presence of Candida spp. in these infections 
is known as candiduria and has been estimated to account for 10-15% of all UTIs 
(Kauffman et al., 2000, Lundstrom and Sobel, 2001). Furthermore, Candida is 
responsible for other infections of the urinary tract, including prostatitis, 
pyelonephritis and cystitis (Kauffman et al., 2011, Sobel et al., 2011). In some 
cases, the implementation of urethral stents is required to help treat a UTI. 
However, this provides a surface for Candida to adhere to and allows for biofilm 
formation (Reid et al., 1992, Harriott et al., 2010). Within the ICU, the use of 
urinary catheters contributes to a number of healthcare associated fungal 
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infections (Yang et al., 2013) and candiduria should be recognised as a marker 
for invasive candidiasis in these patients (Kauffman et al., 2011).  
Another infection cause by Candida species is vulvovaginal candidiasis. Up to 75% 
of woman experience an episode of vulvovaginal candidiasis at some point during 
their life and 5% have recurring candidiasis, showing the importance of this 
organism at this body site. As with oral candidiasis, many factors contribute to 
the pathogenesis of this infection including the use of antibiotics and hormone 
imbalances. Lactobacilli are abundant in this area and are thought to help 
control the numbers of Candida through the production of lactic acid (Gajer et 
al., 2012), however this is still unproven (McMillan et al., 2011).  
1.3.6 Wounds 
Chronic wounds that fail to heal clinically impact patient care, particularly foot 
ulcers and tend to be due to the presence of microbial biofilms (Seth et al., 
2012). Although bacteria are the most pathogenic organisms isolated from these 
sites, there is evidence to suggest that fungi also play a role in these infections 
(Branski et al., 2009). Recent analysis of leg ulcers using a metagenomic 
approach has identified the presence of Candida and Aspergillus species 
(Wolcott et al., 2009). In addition, a recent study showed that fungi could be 
isolated from 23% of all chronic wounds formed at various sites (Dowd et al., 
2011), with the majority of these being Candida species. Furthermore, when 
mixed polymicrobial infections were considered fungi accounted for greater than 
50% of all cases. Although this study failed to determine any correlation between 
Candida and Staphylococcus, previous investigations have identified a positive 
relationship with Staphylococcus aureus binding to the hyphae in C. albicans 
biofilms through the adhesion Als3p. This is similar to other polymicrobial 
infections including the interaction between Streptococcus gordonni and C. 
glabrata within the oral cavity (Coco et al., 2008, Harriott and Noverr, 2009, 
Silverman et al., 2010).  
1.3.7 Biomaterials 
The use of temporary and fixed biomaterials provides a substrate for Candida 
species to adhere to and initiate biofilm formation and in turn can cause 
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systemic candidiasis. A list of implantable devices where Candida biofilms can 
develop is shown in Table 1.1 (Ramage et al., 2006).  
Table 1.1 - Implantable medical devices in which Candida biofilms develop 
(Ramage et al., 2006) 
 
Furthermore, other predisposing factors for invasive infection include; the use of 
broad-spectrum antibiotics, parenteral nutrition and immuno-suppression due to 
chemotherapy and radiotherapy, and disruption of mucosal barriers due to 
surgery (Odds, 1988). Candida species are the most dominant fungi isolated in 
these infections and are the third most common cause of BSI in patients within 
the ICU (Wisplinghoff et al., 2004). These infections are difficult to treat, as 
removal of the biomaterials in addition to long-term antifungal therapy, may be 
required to resolve such infections. 
Intravascular catheters are a typical example of a medical device that can 
become colonised with Candida spp., allowing for the development of mature 
biofilms from which cells can disperse and cause acute candidaemia. Recently it 
was shown that cells dispersed from a biofilm were associated with greater 
cytotoxicity and had a higher mortality rate than their equivalent planktonic 
yeast cells (Uppuluri et al., 2010). Therefore it is no surprise that studies have 
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been investigating the role of different biofilm phenotypes within the clinical 
setting. An initial study identified biofilm formation and inadequate antifungal 
therapy amongst the top risk factors responsible for mortality rates in 
candidaemia patients (Tumbarello et al., 2007). The correlation between biofilm 
formation and patient mortality was not only true for C. albicans but was also 
the case for non-albicans species such as C. parapsilosis. Furthermore, a follow 
up study by the same group identified the presence of a Candida biofilm forming 
isolate could be predicted based on a number of patient factors including 
diabetes mellitus and the use of catheters (Tumbarello et al., 2012). These 
biofilm forming isolates also had a financial impact with increased lengths of 
stay in hospital and greater use of antifungals, which in turn carried a greater 
risk of mortality. Despite these findings, caveats to such studies include the 
methodologies employed to assess biofilm formation. In these studies, XTT and 
spectrophotometric transmittance were used to determine whether an isolate 
displayed biofilm growth, rather than using a technique that directly measures 
biofilm biomass (Taff et al., 2012a, Kuhn et al., 2003). Non-albicans species such 
as C. glabrata do not form true hyphae (Kuhn et al., 2002a), and as a result form 
scant biofilms, though the data in these studies indicate otherwise. Biofilm 
formation in non-albicans species was found to be significantly greater than C. 
albicans (Tumbarello et al., 2012), as found in a separate study elsewhere 
(Pannanusorn et al., 2012). Nevertheless, methodology aside, this does not take 
away the importance of these clinical studies in terms of highlighting biofilm 
formation in all Candida species, particularly in the presence of indwelling 
biomaterials. 
C. glabrata is currently increasing in candidaemia patients, and was involved in 
one of the earliest cases of biofilm related disease within patients with 
intravenous catheters (Valdivieso et al., 1976). Despite candidaemia being the 
cause of death in these terminally ill patients, the removal of the devices was 
able to halt the disease, similar to another study around the same time 
(Berkowitz et al., 1979). C. glabrata is known to form biofilms on a range of 
devices including patients with, but not limited; to endocarditis (Heffner and 
Franklin, 1978), prosthetic joints (Goodman et al., 1983) and venous catheters 
(Paige et al., 1987). Therefore, it is of no surprise that catheters represented a 
risk factor of C. glabrata candidaemia (Fortun et al., 2012).  
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Another important species of Candida in biofilm related infections is C. 
parapsilosis. Similarities between this species and C. albicans in their ability to 
form biofilms has been linked to the key transcriptional biofilm regulator BCR1 
(Ding et al., 2011). Although C. parapsilosis can adhere to biomaterials such as 
prosthetic knees, hip joints and breast implants (Wada et al., 1998, Fox and Lee, 
2012, Younkin et al., 1984), it is more commonly associated with being a 
pathogen in neonates with indwelling catheters (Pammi et al., 2013a). 
Furthermore, C. parapsilosis biofilm forming ability in vitro and in vivo has been 
demonstrated in bioprosthetic heart valves and catheter related disease (Mansur 
et al., 1996, Negri et al., 2012).  
The biomaterials mentioned above do not represent the complete range of 
surfaces that can be potentially colonised with Candida species, but does 
however provide an insight into the clinical importance of fungal biofilms within 
the host. Therefore, as fungal biofilms grow and persist in a variety of locations 
including the environment, careful clinical management is required to overcome 
these infections. 
1.4 Clinical management 
The importance of studying Candida biofilms is to ascertain new therapeutics 
and techniques to manage these infections clinically as these are associated with 
high morbidity and mortality. In addition to controlling fungal biofilms through 
the use of established antifungals and novel therapies, the method by which 
Candida infections are diagnosed could also improve clinical outcomes.  
1.4.1 Diagnostic approaches 
Currently there are no defined diagnostics for Candida biofilm infections, as the 
most appropriate type of clinical specimen and the location it is retrieved from 
are yet to be determined as a reliable source for diagnosis. Specimens can be 
collected from implanted devices (dentures, catheters, implants etc) or directly 
from infected tissues by means of body fluids (blood, urine, sputum etc), swabs 
and biopsies, amongst other specimens and used for diagnostics tests including 
but not limited to; standard culture, MALDI-TOF, quantitative PCR (qPCR) and 
enzyme-linked immunosorbent assay (ELISA) (Ramage and Williams, 2013).  
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A defined diagnostic that is able to detect the presence of bacterial biofilms has 
received some interest recently (Hall-Stoodley et al., 2012). However, such a 
task is difficult as these organisms are responsible for a range of complex 
infections therefore one defined factor may not be suitable for all. In regards to 
fungal biofilms, a number of potential factors could be considered when 
determining the presence of a biofilm: microscopic investigation to determine 
organism phenotype (yeast, hyphae); host status predisposing to infection 
(medical device, immunocompromised); failed antifungal therapy due to non 
biofilm active agent and clinical representation of fungal infection(Ramage and 
Williams, 2013) .  
Another hurdle to overcome in the diagnosis of biofilm infections is the 
accessibility of infection for sampling. The oral cavity is a highly accessible 
environment where a swab or a sonicate sample from dentures is easy to 
retrieve (Coco et al., 2008, Samaranayake et al., 1986). If sampling can be taken 
directly from the biomaterial, such as the tip from a catheter (Tchekmedyian et 
al., 1986, Park et al., 2010) and voice prosthesis (Sayed et al., 2012b), it can be 
easily be determined whether the medical device is the source of infection. In 
contrast, CF patients presenting with a chest infection may require a 
bronchoalveolar lavage (BAL) to diagnose the infection using microscopic 
techniques (Chotirmall et al., 2010, De Vos et al., 2006), which is clinically more 
challenging to obtain. Furthermore, the use of culture and microscopic analysis 
may be less important due to recent developments in rapid molecular techniques 
(Dowd et al., 2011), including qPCR (Buess et al., 2012). Despite this there are 
still issues with using these molecular assays, one of which being that detection 
of DNA does not correlate with a defined biofilm phenotype. Instead, 
transcriptional targets that have been shown to be essential in C. albicans 
biofilm formation (Nobile et al., 2012) may provide a more reliable diagnostic 
for the detection of biofilms. Many fungi undergo morphological switching during 
biofilm formation and therefore genes involved in this process may aid in the 
development of a biofilm diagnostic. Such gene targets in C. albicans could 
include EFG1, a transcription factor required for regulating cellular morphology 
and virulence (Connolly et al., 2013). Strains defective in this gene fail to 
undergo yeast to hyphal switching (Lo et al., 1997, Sudbery, 2011) and are 
unable to invade reconstituted human epithelia (Dieterich et al., 2002).  
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Currently, antimicrobial testing is carried out using planktonic cells and 
therefore does not take in to consideration how therapy may be impacted if a 
biofilm is present. As technology continues to advance, the idea of a biofilm 
molecular diagnostic becomes more likely, which would in turn decrease the 
time taken to diagnose infections and direct more effective and timely 
treatment. 
1.4.2 Current antifungal therapies 
Although prevention of fungal infections is easier than treatment, a number of 
fungistatic and fungicidal agents exist to combat fungal diseases which promote 
including physical disruption of biofilm biomass and the removal from 
biomaterials which may be harbouring biofilm structures (Ramage and Williams, 
2013). In fact, guidelines published recently in relation to catheter-related 
infections have indicated in the first instance there should be the removal of 
such devices, if possible (Cornely et al., 2012). The impact this has clinically has 
differential results depending on which antifungal therapy is used.  A recent 
study determined the removal of the CVC within 24 to 48 h of antifungal 
initiation was not associated with any clinical benefit, however this may be due 
to echinocandins (ECN) and liposomal AMB being highly active against Candida 
biofilms (Nucci et al., 2010). In contrast, a prospective randomised trial 
concluded the removal of a catheter was beneficial with the duration of 
candidaemia shortened, when comparing AMB deoxycholate to fluconazole (FLZ) 
(Rex et al., 1995). Furthermore, when several clinical trials were considered 
using meta-analysis, it was shown the removal of CVCs significantly correlated 
with a reduction in mortality (Andes et al., 2012).  
However, it may not be possible to remove these devices in all situations 
whether it is due to host status or location of the biomaterial. Therefore 
treatment of these infections must be given using antifungals agents, although 
there is little evidence to suggest the most appropriate therapy for the 
treatment of Candida biomaterial infections (O'Grady et al., 2011). Saying this, 
one potential treatment option for device-related infections is the use of 
antifungal lock therapy (ALT), with several case studies highlighted in a recent 
review supporting its use clinically, when appropriate (Walraven and Lee, 2013). 
Although the number of studies using ALT is limited, polyene (POL) agents were 
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most frequently used and had success rates of 76.9% and 60% when AMB (Arnow 
and Kushner, 1991, Johnson et al., 1994, Krzywda et al., 1995, Benoit et al., 
1995, Viale et al., 2001, Angel-Moreno et al., 2005, Wu and Lee, 2007) and 
liposomal AMB (Castagnola et al., 2005, Buckler et al., 2008) were used, 
respectively, with negative blood cultures apparent after 14 days therapy. 
Another agent used in ALT was caspofungin, however only one study showed the 
effectiveness of this agent against C. lipolytica (Ozdemir et al., 2011). Overall, 
these studies illustrate the potential use of ALT in fungal biofilm infections, 
particularly using POL and ECN formulations (Cornely et al., 2012).   
The use of POL and ECN against C. albicans biofilm infections is based upon a 
number of in vitro studies, where they were shown to be highly active 
(Bachmann et al., 2002, Kuhn et al., 2002b). Also, a number of studies have set 
out to test the potential use of ALT against a range of Candida species, 
comparing various antifungal agents (Walraven and Lee, 2013). When 
investigating ECN, micafungin (MFG) and caspofungin (MFG) both had high anti-
biofilm activity, yet failed to fully eradicate the biofilm (Cateau et al., 2011, 
Cateau et al., 2008), with liposomal AMB killing biofilms significantly quicker 
than those treated with ECN (Ramage et al., 2013). Surprisingly, in a separate 
ALT study it was shown that azoles (highly inactive biofilm agents) were more 
active against C. albicans and C. glabrata biofilms than AMB and CSP (Ko et al., 
2010). This finding was unexpected as it is well documented that azoles (AZL) 
are inactive against Candida biofilms in vitro (Ramage et al., 2013) and in vivo 
(Andes et al., 2004, Kucharikova et al., 2010).  
The success rate of each class of antifungal has been assessed in animal catheter 
models (Lazzell et al., 2009, Schinabeck et al., 2004, Mukherjee et al., 2009), 
where it was shown that liposomal AMB significantly reduced the C. albicans 
burden in all subjects, whereas the same concentration of FLZ was ineffective 
(Schinabeck et al., 2004). Furthermore, AMB deoxycholate and CSP were both 
used in rabbit catheter models and showed a significant reduction in C. albicans 
colony counts cultured from the catheter by 81% and 100%, respectively (Shuford 
et al., 2006). When considering these ALT studies altogether, it is evident the 
production of an effective and concise therapy for the treatment of catheter 
infections is possible. This is particularly desirable for biofilm infections where 
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the removal of the catheter is not an option due to the status of the host or the 
location of the device.  
When considering biofilm infections of other medical devices, such as prosthetic 
heart valves, removal of the device is not as simple as infections originating 
from catheters. Infective endocarditis caused by Candida species remains rare 
and tends to be recognised after a case of candidaemia, with most patients 
already having a healthcare-associated infection (HAI) (Falcone et al., 2009). 
Prognosis is poor, with mortality rates higher than 50%, with 30% of survivors 
relapsing (Ellis et al., 2001). The best treatment method for this infection is 
surgery combined with antifungal therapy (Ellis et al., 2001, Falcone et al., 
2009). However, if this is not an option then liposomal AMB and CSP should be 
used to treat this infection (Boland et al., 2011).  
Candida biofilms are also responsible for infections not associated with a 
medical device, including those of wounds and joints. The normal treatment for 
wound biofilms would be the removal of infected and dead tissue. However, in a 
recent study the use of liposomal AMB in conjunction with either voriconazole 
(VRZ) and posaconazole (PSZ) was a more popular choice in more complicated 
wound infections (Warkentien et al., 2012). The effective use of AZL in wound 
infections may suggest that the structure of fungal biofilms may differ in this 
anatomical site to fungal biofilms found on biomaterials, as AZL have shown to 
be normally unresponsive to biofilm infections. However, the main finding here 
is that combinational antifungal therapy is a more effective treatment option 
than monotherapy.  
Combination treatment is also used in the management of oral fungal infections 
including DIS and oral candidiasis, whereby antimicrobials in the form of denture 
cleansers or oral rinses are combined with brushing to mechanically disrupt the 
biofilm (Grimoud et al., 2005, Rautemaa and Ramage, 2011). However despite 
this, it has been shown that the removal of oral biofilms completely is actually 
quite rare (Ramage et al., 2011a, Ramage et al., 2012d, Jose et al., 2010). In 
exceptional cases antifungal treatment may be given topically and AZL tend to 
be the primary option. This in itself presents a problem as the use of AZL in 
recurring oral biofilm infections can lead to the emergence of resistant strains 
(Rautemaa et al., 2007). In summary, this confirms that despite the use of 
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various antifungal strategies, Candida biofilms persist due to a number of 
resistance mechanisms and meaning additional therapeutics are required to 
treat biofilm infections.  
1.5 Studying biofilm resistance  
Initial studies of biofilm resistance mechanisms were basic, investigating 
antifungal effects purely at the phenotypic level through descriptive analyses. 
The pioneering work by Julia Douglas’s group working on C. albicans biofilms 
utilised some of the earliest models, from which quantitative assessment using 
dry weight measurements, tetrazolium salt (MTT) reduction assays and 
incorporation of [3H] leucine were described (Hawser and Douglas, 1994, Hawser 
and Douglas, 1995). These simple static models were expanded to include flow 
cell models, which was shown to alter antifungal susceptibility (Hawser et al., 
1998a). However, typically these models were cumbersome, requiring expert 
handling, long processing times and the use of specialised equipment not 
generally available. Therefore, methods for rapid high throughput testing were 
preferable, and around this time the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino)-carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method 
was described for investigating yeast adhesion and susceptibility (Hawser, 1996, 
Hawser et al., 1998b). This assay measures the collective metabolic activity of 
the cells within a biofilm and is used as the basis for developing a standardized 
high throughput susceptibility screen on Candida biofilms (Chandra et al., 2001a, 
Ramage et al., 2001a). The XTT assay is non-invasive and non-destructive, 
requiring minimal post-processing of samples compared to other methods; such 
as viable cell counts (Nett et al., 2011a). Using this technique multiple 
microtitre plates can be processed simultaneously without compromising 
accuracy. A caveat to its use is that is does not quantify biofilm dependant 
characteristics, such as biomass or morphological status, and caution must be 
exercised when evaluating XTT data from different isolates as there is often 
dramatic variability between strains (Kuhn et al., 2003). Therefore, it should 
only be used for direct comparison of a treated isolate to an untreated control 
rather than absolute quantification of biofilm formation per se. The next 
breakthrough in high throughput biofilm testing has recently been described 
where nano-production of C. albicans biofilms is achievable, creating 768 
equivalent and spatially distinct nano-biofilms on a single glass microarray 
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(Srinivasan et al., 2011). However, it remains to be determined whether there is 
an assay system sensitive enough to quantify the metabolic activity of each 
nano-biofilm.  
As mentioned, the presence of flowing liquid over the biofilm can alter 
antifungal sensitivity (Hawser et al., 1998a). There is a growing range of flow 
systems utilized to model biofilm development (Elving et al., 2003, Garcia-
Sanchez et al., 2004, Mercier-Bonin et al., 2004, Ramage et al., 2008, Khot et 
al., 2006). For example, a ‘seed and feed’ modified Robbin’s device that permits 
multiple biofilms to be formed under constant flow conditions, cylindrical 
cellulose filters, constant depth film fermenters, perfusion fermenters, flow 
chambers and a Robbin’s device have all been described (Baillie and Douglas, 
1998a, Baillie and Douglas, 1999, Chandra et al., 2001a, Chandra et al., 2001b, 
Lamfon et al., 2003, Ramage et al., 2008). The Lopez-Ribot group described a 
simple flow model based on a gravity fed flow method that enabled the group to 
demonstrate that biofilms were thicker and more resistant to POL and ECN by 4- 
and 2 –fold, respectively (Uppuluri et al., 2009a). Interestingly, perfusion of 
biofilms created under flow with these two antifungal agents showed time and 
dose dependant activity, which were potent against cells dispersed from the 
biofilm (Uppuluri et al., 2011). These systems will prove useful for future 
investigations of invasive candidiasis where biofilms are common, particularly 
for catheter related infections in the ICU, where there is a growing interest in 
catheter-lock therapy (Ghannoum et al., 2011, Mukherjee et al., 2009). In 
addition, there are now also a significant number of biofilm models available for 
in vivo investigations, and many of these have been utilised to elucidate biofilm 
resistance mechanisms (Nett and Andes, 2006), including an implanted chamber 
under the skin (Rajendran et al., 2011), catheter models (Andes et al., 2004, 
Schinabeck et al., 2004), vaginal model (Harriott et al., 2010) and a denture 
model (Nett et al., 2010b). 
1.5.1 Fungal biofilm resistance mechanisms 
One of the defining characteristics of biofilms is their increased resistance to 
antimicrobial agents. When it comes to the treatment of fungal biofilms, up to 
1000-fold higher concentrations of antifungal agents are required to effectively 
kill the biofilm structure than is required for their planktonic counterparts (Di 
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Bonaventura et al., 2006, Ramage et al., 2001a, Tre-Hardy et al., 2008). Despite 
some antifungal agents being efficacious against biofilms, particularly the ECN 
and liposomal AMB formulations, the adaptive resistance exhibited by these 
complex structures has promoted detailed investigation (Kuhn et al., 2002b, 
Ramage et al., 2002c, Bachmann et al., 2003, Bachmann et al., 2002, Mowat et 
al., 2008).  
Antifungal resistance is both complex and multifaceted. It can be inducible in 
response to a compound, or an irreversible genetic change resulting from 
prolonged exposure. Specifically, these include alterations or over-expression of 
target molecules, active extrusion through efflux pumps, limited diffusion, 
tolerance and cell density, which are all characterised mechanisms utilised by 
fungi to combat the effects of antifungal treatment (Niimi et al., 2010). 
Planktonic cells generally rely on irreversible genetic changes to maintain a 
resistant phenotype, whereas biofilms are able to persist due to their physical 
presence and the density of the population, which provides an almost inducible 
resistant phenotype irrespective of defined genetic alterations. Figure 1.6 
provides an overview of some of the pivotal factors associated with fungal 
biofilm resistance. 
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Figure 1.6 – Schematic overview of fungal biofilm resistance mechanisms.  
Generic overview of key biofilm resistance mechanisms associated with C. albicans, but 
which are likely to be common to other fungi. This figure illustrates the density and 
complexity of the C. albicans biofilm, with different morphotypes present surrounded 
by extracellular matrix (ECM). The arrows represent the different factors that drive 
antifungal resistance within the biofilm, including density, stress, persisters, ECM, 
efflux, over-expressed targets and the general physiology of the biofilm. These have 
been placed according to their contribution to resistance, with those that have a 
greater effect closer to the middle and those with less impact at the edges (Ramage et 
al., 2012c).  
1.5.1.1  Physiological state 
The general physiological state of cells in sessile populations has also been 
implicated to influence the susceptibility profiles of biofilms. Metabolic dye 
assays (e.g. XTT-based assays) confirm that cells within biofilms are undergoing 
mitochondrial respiration during development (Chandra et al., 2001a, Hawser, 
1996, Ramage et al., 2001a, Kuhn et al., 2003, Mowat et al., 2008). Other 
factors including the effect of growth rate on C. albicans biofilm resistance have 
also been studied, and varying growth rates were shown to play no role in 
resistance to AMB (Baillie and Douglas, 1998a). Similarly, biofilms of C. albicans 
grown under glucose and iron limited conditions were shown to be highly 
resistant to AMB (Baillie and Douglas, 1998b). Furthermore, studies of biofilms 
grown under anaerobic conditions demonstrated resistance to high levels of AMB 
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and different AZL antifungals (Dumitru et al., 2004). Nevertheless, factors 
including pH, temperature, oxygen availability and other environmental stresses 
will alter the biofilm architecture and possibly antifungal sensitivity 
(Kucharikova et al., 2011, Pettit et al., 2010). Therefore, whilst the 
physiological state of the cell may have a minor role in resistance (e.g. 
dormancy), it is more likely that more complex factors are involved.  
1.5.1.2  Cell density 
The architecture of biofilms is highly ordered to enable the perfusion of 
nutrients and expulsion of waste products. Mature biofilms, whilst densely 
populated, exhibit spatial heterogeneity with microcolonies and water channels 
being present (Chandra et al., 2001a, Lawrence et al., 1991, de Beer et al., 
1994). Cell density is therefore an important resistance factor within complex 
biofilm populations of yeast and filamentous fungal biofilms, particularly 
towards AZL. It was demonstrated that both planktonic and resuspended C. 
albicans biofilm cells exhibited AZL sensitivity at low cell numbers (103 
cells/mL), which became increasingly resistant as the density of the cells 
increased (Perumal et al., 2007), a phenomenon also been demonstrated in A. 
fumigatus (Lass-Florl et al., 2003). It has been shown in C. albicans that phase-
dependant antifungal resistance occurs (Mowat et al., 2008, Mukherjee et al., 
2003), which support the idea that the physical density of the cells within the 
biofilm produces recalcitrance to antifungal agents.  
Within dense biofilms there is cooperation between individual cells through 
quorum sensing. Quorum sensing gives microorganisms the ability to 
communicate and coordinate their behaviour via the secretion of signalling 
molecules in a population dependent manner (Miller and Bassler, 2001). This was 
first described in C. albicans when Hornby and colleagues identified farnesol 
(3,7,11-trimethyl-2,6,10-dodecatrien-1-ol) (Hornby et al., 2001). Exposing C. 
albicans to exogenous farnesol results in genome wide responses, including 
activation of genes involved in drug resistance (CaFCR1 and CaPDR16) (Cao et 
al., 2005, Enjalbert and Whiteway, 2005). It has now been shown that quorum 
sensing in C. albicans is driven by the two component regulatory system of 
Chk1p (Kruppa et al., 2004). However, when deleted the chk1 strain shows a 
similar AZL resistance profile to that of wild type (Perumal et al, 2007), 
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indicating that the regulatory circuit controlling biofilm resistance may be yet to 
be discovered, or cell density is not a defined biofilm resistance factor. 
However, given that ECN are highly effective against biofilms suggests cell 
density has a limited effect against this compound (Bachmann et al., 2002). In 
addition, previous work has shown that disrupted biofilms that are resuspended 
and tested using the Clinical and Laboratory Standards Institute (CLSI) 
methodology in comparison to planktonic cells retain a resistant phenotype 
(Rajendran et al., 2011, Ramage et al., 2002a), indicating alternative 
mechanisms of resistance. 
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1.5.1.3  Over expression of drug targets 
The AZL are generally fungistatic against yeasts. The fungistatic nature of the 
AZL towards C. albicans induces a strong directional selection on the surviving 
population to evolve drug resistance (Anderson, 2005, Cowen, 2008).  In fact, 
high levels of AZL resistance in C. albicans clinical isolates often accumulate 
through multiple mechanisms including the alteration of ERG11 (Anderson, 
2005). Figure 1.7 illustrates the molecular mechanisms contributing to fungal 
biofilm resistance, including those involved in AZL resistance. 
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Figure 1.7 - Molecular mechanisms of fungal biofilm resistance. 
Antifungal drug resistance in fungal biofilms is both complex and multi-factorial. The 
diagram illustrates the mechanisms of different class of antifungal agent action AZL, 
POL and ECN and resistance: (a) The layer of ECM present in the biofilm shields the cells 
from antifungal agents by binding and reduced penetration; (b) The membrane 
transporter system ABC and MFS efflux pumps extrudes antifungal molecules and 
reduces the intracellular concentration; (c) Mutation in ERG, CYP51 and FKS1 genes 
alters the drug target leading to cross resistance; (d) Antifungal pressure induces stress 
responses, such as the calcineurin signalling pathway, which is activated and coping 
responses occurs through up-regulation of various signal transducers.  
AZL actively target the 14 α-demethylase enzyme encoded by ERG11, blocking 
ergosterol biosynthesis and leading to depletion of the ergosterol content of 
membranes. This ultimately results in the accumulation of toxic sterol 
intermediates, such as 14-methylergosta-8,24(28)-dien-3b,6a-diol, which 
inhibits growth (Akins, 2005, Cannon et al., 2007). The principle drug target, 
ERG11p, can develop point mutations or be overexpressed (Akins, 2005, Cannon 
Ch.1 Clinical significance of fungal biofilms 
29 
 
et al., 2007, White, 1997). Common mutations in the ERG11 that confer 
moderate AZL resistance are S405F, Y132H, R467K and G464S (Marichal et al., 
1999, Perea et al., 2001, Sanglard et al., 1998).  
Given the importance of ergosterol as a target of AZL and the high level 
resistance exhibited by these structures, then the sterol composition of C. 
albicans biofilms has been investigated. Sterol analyses showed that ergosterol 
levels were significantly decreased in intermediate (12 h) and mature phases (48 
h), compared to those in early-phase biofilms (6 h) (Mukherjee et al., 2003). In 
contrast, in one of the first C. albicans biofilm studies to use microarray analysis 
over-expression of CaERG25 and CaERG11 was reported (Garcia-Sanchez et al., 
2004). Alteration of ergosterols in biofilm membranes may explain their 
resistance to both AZL and POL derived antifungal agents. For example, C. 
albicans biofilms cultured in a flow cell for 36 h were compared to planktonic 
cells, where it was shown that a subpopulation of blastospores from the biofilm 
were 10 times more resistant to AMB than planktonic populations (Khot et al., 
2006). Transcriptional analysis of this biofilm subpopulation for genes from the 
beta-1,6-glucan pathways indicated a possible association between the high 
level of resistance and up-regulation of CaSKN1 and CaKRE1 in the biofilm 
blastospore population. Therefore, changes in both the cell membrane and the 
cell wall may be important determinants of resistance in the biofilm. Subsequent 
work in C. albicans has shown that transcriptional responses in young and mature 
biofilms after exposure to high doses of FLZ or AMB induced differential 
antifungal drug responses (Nailis et al., 2010b). Exposure of both young and 
mature biofilms to FLZ induced up-regulation of genes encoding enzymes 
involved in ergosterol biosynthesis (CaERG1, CaERG3, CaERG11 and CaERG25), 
particularly biofilms exposed for longer periods (22 h). Whereas, treatment of 
both young and mature biofilms with AMB resulted in an overexpression of 
CaSKN1, with only a modest up-regulation of CaKRE1. Removal of the antifungal 
in this study depleted further transcriptional changes, except for CaSKN1, which 
was impacted by prior FLZ exposure. It was speculated that this related to 
biofilm regrowth. Increased ergosterol gene expression was also reported in vivo 
in a C. albicans CVC biofilm model, demonstrating the importance of the 
molecule within the biofilm (Nett et al., 2009).  
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Induction of ergosterol genes has also been described in C. dubliniensis, where 
incubation with FLZ and formation of biofilm was coupled with up-regulation of 
the CdERG3 and CdERG25 (Borecka-Melkusova et al., 2009). Moreover, up-
regulation of genes involved in ergosterol biosynthesis has been described in C. 
parapsilosis biofilms (Rossignol et al., 2009), which are also resistant to AZL 
antifungal therapy (Katragkou et al., 2008). Overall these data highlight the 
importance of ergosterol in biofilm resistance, particularly with respect to 
azoles, which indirectly inhibit their biosynthesis. Recent studies have shown 
that simvastatin, which impairs cholesterol metabolism in humans, is capable of 
inhibiting C. albicans biofilms, thus providing a potential novel strategy of 
combating these tenacious infections (Liu et al., 2009).  
1.5.1.4  Efflux pump mediated resistance 
The primary molecular mechanism leading to high level AZL resistance in C. 
albicans is the increased efflux of drug, mediated mostly by the ATP-binding 
cassette (ABC) and the major facilitator superfamily (MFS) transporters 
(Albertson et al., 1996, Lopez-Ribot et al., 1999, Sanglard et al., 1997). The ABC 
transporters in C. albicans constitute a multi-gene family, which includes several 
CDR genes (CDR1-4) (Prasad et al., 1995, Walsh et al., 1997). The ABC 
transporters include a membrane pore composed of transmembrane segments 
and two ABCs on the cytosolic side of the membrane, which provide the energy 
source for the pump (Higgins, 1992, Balzi and Goffeau, 1995). Importantly, 
multiple antifungal agents can be substrates for these transporters and thus 
their over-expression can lead to cross-resistance between different drugs, 
particularly AZL. Among members of the MFS, which are secondary transporters 
and use proton-motive force across the plasma membrane, the MDR1 gene 
encodes a major facilitator that has been implicated in C. albicans AZL 
resistance, and its over-expression leads to exclusive FLZ resistance (White, 
1997, Williams et al., 2011). ECN sensitivity is unaffected by efflux pumps (Niimi 
et al., 2006).  
Genes encoding for drug efflux pumps have been reported in biofilms to be 
differentially regulated during development and upon exposure to antimicrobial 
agents include CaCDR1, CaCDR2 and CaMDR1 (Lepak et al., 2006, Mateus et al., 
2004, Mukherjee et al., 2003, Ramage et al., 2002a). In the first study to 
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investigate the role of efflux pumps it was demonstrated that expression of 
genes encoding both types of efflux pumps were up-regulated during the course 
of biofilm formation and development. Both CaCDR1 and CaCDR2 were up-
regulated in 24 and 48 h biofilms, whereas CaMDR1 was transiently up-regulated 
at 24 h (Ramage et al., 2002a). However, their contribution to resistance in the 
biofilm phenotype was placed in doubt when a set of C. albicans isogenic strains 
deficient in efflux pumps, carrying single and double deletion mutations (cdr1, 
cdr2, mdr1, cdr1/cdr2 and mdr/cdr1), rendered planktonic cells 
hypersusceptible to FLZ, retained their resistant phenotype during biofilm 
growth. In a subsequent investigation C. albicans biofilms were formed through 
three distinct developmental phases that were associated with high FLZ 
resistance. Again the same set of isogenic C. albicans strains were utilised and it 
was shown that 6 h old biofilms formed by double and triple mutants were >4 to 
16-fold more susceptible to FLZ than the wild-type strain (Mukherjee et al., 
2003). At 12 and 48 h all the strains became highly resistant to this AZL, 
indicating lack of involvement of efflux pumps in resistance at late stages of 
biofilm formation. In cell density studies, the efflux pump isogenic strains 
remain hypersensitive at low cell concentrations yet resistant at high cell 
concentrations and in biofilm, indicating a contributory resistance role of cell 
density (Perumal et al., 2007). Nevertheless, similar to the study by Ramage and 
coworkers (Ramage et al., 2002a), C. albicans biofilms were shown to express 
CaCDR and CaMDR1 genes in all three phases (6, 12 and 48 h), whilst planktonic 
cells expressed these genes transiently. In fact, GFP promoter studies have 
shown induction of efflux pumps after 15 min adherence to provide a tolerant 
biofilm phenotype (Mateus et al., 2004). Animal studies have also shown that 
biofilms formed on implanted catheters expressed efflux pumps (Andes et al., 
2004, Nett et al., 2009). Transcript up-regulation of CaCDR2 at 12 h (1.5-fold) 
and CaMDR1 at both 12 h (2.1-fold) and 24 h (1.9-fold) was demonstrated (Nett 
et al., 2009). In C. glabrata similar results are reported, where expression of 
CgCDR1 and CgCDR2 was investigated during the early (6 h), intermediate (15 h), 
and mature (48 h) phases of biofilm development. At 6 h and 15 h the biofilms 
exhibited approximately 1.5- and 3.3-fold upregulation of CgCDR1 and 0.5- and 
3.1-fold upregulation of CgCDR2, respectively, in comparison to planktonic cells 
(Won Song et al., 2008). Expression of CtMDR in C. tropicalis biofilms has also 
been reported (Bizerra et al., 2008). 
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Collectively, the available literature supports the hypothesis that efflux pumps 
are an important, but not an exclusive determinant of C. albicans biofilm 
resistance to AZL (Morschhauser, 2010, Cannon et al., 2009). Their primary role 
may be for homeostasis within complex environments to protect themselves 
from acute toxicity (Piddock, 2006). However, within clinical environments 
exposure to AZL drugs may enhance the levels of efflux pump expression, 
therefore either contributing towards or inducing clinical resistance (Bueid et 
al., 2010). However, it is likely that they play a greater protective (resistance) 
role in the early phases of biofilm growth until the production of ECM, one of the 
primary mechanisms of biofilm resistance. 
1.5.1.5  Extracellular matrix 
The ECM is a defining characteristic of fungal biofilms, providing the cells 
protection from hostile factors such as host immunity and antifungal agents 
(Ramage et al., 2009). C. albicans ECM was shown to increase when biofilms are 
grown under dynamic flow conditions (Al-Fattani and Douglas, 2004, Baillie and 
Douglas, 2000, Hawser et al., 1998a). However, subsequent work has shown that 
while diffusion is hampered by the ECM, penetration of antifungal drugs is not 
thought to play a key role in biofilm resistance (Al-Fattani and Douglas, 2004). 
Recent studies have provided new insights that suggest the chemical composition 
of the ECM and its regulation may play a central role in resistance. 
The composition of the ECM in C. albicans and C. tropicalis biofilms is complex, 
comprising of protein, hexosamine, phosphorus, uronic acid and carbohydrates 
(Al-Fattani and Douglas, 2006). It has been well established that extracellular 
DNA (eDNA) has been found within the ECM of bacterial biofilms (Allesen-Holm 
et al., 2006, Vilain et al., 2009). However it was not until recently the 
importance of eDNA in C. albicans biofilms was established (Martins et al., 
2010). Here it was shown that eDNA contributes to the structural integrity and 
maintenance of C. albicans biofilms and the addition of DNase decreases biofilm 
biomass. Furthermore, DNase treatment improved the efficacy of POL and ECN, 
but this was not the case with AZL (Martins et al., 2011).  
One of the principle carbohydrate components of the ECM is beta-1,3 glucans. 
Treatment of C. albicans biofilms with beta-1,3 glucanase helps detach biofilms 
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from a substrate (Al-Fattani and Douglas, 2006). Its contribution is confirmed in 
a series of investigations by the Andes group where it was shown to increase in 
C. albicans biofilm cell walls compared to planktonic organisms, and was also 
detected in the surrounding biofilm milieu and as part of the ECM (Nett et al., 
2007). Beta-1,3 glucans have also been shown to increase in investigations of 
three specific phases of biofilm development grown on both denture acrylic and 
catheter substrates (Yeater et al., 2007). Its contribution to resistance was 
realised when it was also shown that biofilm cell walls bound 4 to 5-fold more 
AZL than equivalent planktonic cells, and culture supernatant bound a 
quantifiable amount of this antifungal agent. Moreover, beta-1,3 glucanase 
markedly improved the activity of both FLZ and AMB. Addition of exogenous 
biofilm ECM and commercial beta-1,3 glucan also reduced the activity of FLZ 
against planktonic C. albicans in vitro (Nett et al., 2007). The group have 
recently shown that the ECM -1,3 glucan is synthesised from FKS1 using a 
defined knockout and over-expressing strain (Nett et al., 2010c). This study also 
demonstrated that beta-1,3, glucan is responsible for sequestering AZL, acting as 
a ‘drug sponge’ and conferring resistance on C. albicans biofilms (Nett et al., 
2010c). Further studies have shown that they are also responsible for 
sequestering ECN, pyrimidines, and POL (Nett et al., 2010c). This has been 
confirmed independently where AMB was shown to physically bind C. albicans 
biofilms and beta-glucans (Vediyappan et al., 2010). Subsequent studies have 
identified a role for CaSMI1, a gene involved in cell wall glucans, in biofilm ECM 
production and development of a drug resistant phenotype, which appears to act 
through transcription factor CaRLMP and glucan synthase FKS1p (Nett et al., 
2011b). 
In addition to CaFKS1, a zinc-response transcription factor CaZAP1 has been 
shown to be a negative regulator of ECM soluble beta-1,3 glucan in both in vitro 
and in vivo (Nobile et al., 2009). Conversely, two glucoamylases, CaGCA1 and 
CaGCA2, are thought to have positive roles in ECM production. A group of alcohol 
dehydrogenases CaADH5, CaCSH1, and CaLFD6 also have roles in matrix 
production, with CaADH5 acting positively, and CaCSH1 and CaLFD6 acting 
negatively (Nobile et al., 2009). It is thought that these alcohol dehydrogenases 
generate quorum-sensing aryl and acyl alcohols, which co-ordinate biofilm 
maturation. Collectively, it appears that C. albicans ECM production is highly 
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regulated and is a key resistance factor. It is also present in a number of other 
Candida spp., including C. glabrata, C. parapsilosis, C. tropicalis and C. 
dubliniensis (Silva et al., 2009, Silva et al., 2011b).  
Therefore, ECM clearly plays a critical role in biofilm resistance, particularly for 
C. albicans, about which we currently understand the greatest. It is one of the 
most significant and regulated resistance mechanisms utilised in the biofilm 
phenotype. 
1.5.1.6  Persisters 
Persister cells are an important mechanism of resistance in chronic infections 
(Fauvart et al., 2011) and a mechanism of resistance that has gathered some 
attention recently in fungal biofilms (Bink et al., 2011, LaFleur et al., 2006, 
Lewis, 2008). Persister cells are “dormant variants of regular cells that form 
stochastically in microbial populations and are highly tolerant to antibiotics” 
(Lewis, 2010). In C. albicans biofilms a small subset of yeast cells have been 
described that are highly resistant to AMB following adhesion, which is 
independent to up-regulation of efflux pumps and cell membrane composition 
(Khot et al., 2006, LaFleur et al., 2006). C. albicans persisters have been 
detected only in biofilms and not in planktonic populations (LaFleur et al., 
2006). Re-inoculation of cells that survived killing by AMB produced a new 
biofilm with a new subpopulation of persisters, suggesting that these were not 
mutants but phenotypic variants of the wild type, and that attachment to a 
substratum initiated dormancy. The presence of persisters in C. krusei and C. 
parapsilosis biofilms treated with AMB has also been described (Al-Dhaheri and 
Douglas, 2008). It was further hypothesized that the periodic application of 
antimicrobial agents may select for strains with increased levels of persister 
cells, so 150 isolates of C. albicans and C. glabrata were obtained from cancer 
patients who were at high risk for the development of oral candidiasis and who 
had been treated with topical chlorhexidine once a day. It was shown that the 
persister levels of the isolates varied from 0.2 to 9%, and strains isolated from 
patients with long-term carriage had high levels of persisters, whereas those 
from transient carriage did not (Lafleur et al., 2010). Therefore, in this clinically 
relevant scenario prolonged and ineffectual antifungal treatment may be 
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beneficial to the biofilm population, which may be responsible for antimicrobial 
drug failure and relapsing infections. 
The role of reactive oxygen species (ROS) in sessile C. albicans cells was 
investigated as they are know to be induced by high concentrations of 
miconazole, allowing 1-2% of miconazole-tolerant cells to persist (Vandenbosch 
et al., 2010). Superoxide dismutases (SOD) were found to be differentially 
expressed by micronazole treated sessile C. albicans cells compared to 
untreated cells. Inhibition of superoxide dismutase resulted in a 18-fold 
reduction of the miconazole-tolerant persister cells and increased endogenous 
ROS levels in these cells (Bink et al., 2011). In biofilms from strains lacking 
sod4/sod5Δ at least 3-fold less miconazole-tolerant persisters were observed and 
ROS levels were increased compared to the isogenic wild type. Therefore, 
miconazole-tolerant persisters are linked to the ROS-detoxifying activity of SOD. 
Whether this is the definitive molecular basis for C. albicans persister cells or a 
tolerance mechanism still remains to be determined, but these subpopulations 
are clearly another important fungal biofilm resistance mechanism. 
1.5.1.7  Tolerance 
Stress responses have become more fully recognised as defined mechanisms of 
antifungal resistance.  Pathogenic fungi encounter a range of physiological 
stresses from different environments, including temperature changes, ionic 
stress, changes in osmolarity, and oxidative stress, such as that experienced in 
the phagosomes of neutrophils (Cannon et al., 2007). These stresses are sensed 
through various receptors, which elicit responses through conserved signalling 
pathways. One of the most important is the mitogen-activated protein kinase 
(MAPK) signal transduction network (Cannon et al., 2007). It was first shown that 
the MAPK Mck1p, which is activated by contact stress, is involved in biofilm 
development. Moreover, the null mutant (mck1Δ) biofilms were AZL sensitive, in 
contrast to the sessile wild type and both planktonic strains. This indicates that 
Mck1p is involved in biofilm resistance through a stress pathway (Kumamoto, 
2005).  
Calcineurin is a Ca2+-calmodulin-activated serine/threonine-specific protein 
phosphatase that plays many critical stress roles in the fungal cell, including 
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amongst other things antifungal drug responses (Steinbach et al., 2007).  In 
planktonic cells, calcineurin is critical for C. albicans survival during AZL 
treatment (Sanglard et al., 2003). Inhibiting calcineurin pharmacologically or 
impairing calcineurin function genetically, has synergistic activity with FLZ and 
renders the AZL fungicidal against C. albicans (Onyewu et al., 2003). Calcineurin 
has also been implicated in mediating resistance to the AZL in both in vitro and 
in vivo models of biofilm formation (Uppuluri et al., 2008). C. albicans cells in 
biofilms are up to 1,000-fold more resistant to FLZ than planktonic cells, 
indicating that inhibitors could be used in combinations as novel therapeutic 
interventions to treat or prevent biofilms, whereas C. dubliniensis calcineurin 
inhibitors were unable to form biofilms (Chen et al., 2011). Similar studies have 
evaluated the efficacy of a VRZ-MFG combination against C. albicans biofilms. 
VRZ significantly antagonized the fungicidal effect of MFG against biofilms. To 
investigate the mechanism of antagonism, an inhibitor of calcineurin was 
evaluated, which reversed the VRZ-induced resistance to MFG (Kaneko et al., 
2010a).  This study also suggested that heat shock protein 90 (Hsp90p) molecular 
chaperone played a role in this antagonism. HSP90 regulates complex cellular 
circuitry in eukaryotes and potentiates the emergence and maintenance of 
resistance to AZL and ECN in C. albicans, at least in part via calcineurin (Cowen 
and Lindquist, 2005). It physically interacts with the catalytic subunit of 
calcineurin, keeping it stable and poised for activation (Singh et al., 2009). A 
recent study demonstrated led by the Cowen group demonstrated that genetic 
depletion of HSP90 reduced C. albicans biofilm growth and maturation in vitro, 
and interestingly impaired dispersal of biofilm cells (Robbins et al., 2011). It also 
abrogated resistance of C. albicans biofilms to the AZL, which was also shown in 
vivo. Furthermore, depletion of HSP90 led to reduction of calcineurin and MKC1 
in planktonic but not biofilm conditions, suggesting that HSP90 regulates drug 
resistance through different mechanisms. A marked decrease in matrix glucan 
levels were also observed, providing a mechanism through which HSP90 might 
regulate biofilm AZL resistance. In A. fumigatus, pharmacological depletion of 
HSP90 led to reduced resistance to the ECN (Robbins et al., 2011). Moreover, a 
recent investigation of the C. glabrata biofilm proteome demonstrated up-
regulation of a heat shock protein (Hsp12p) and other stress proteins (Trx1p, 
Pep4p) (Seneviratne et al., 2010). Therefore, targeting HSP90 may provide a 
novel strategy for treating fungal biofilm infections. 
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1.6 Alternative therapies 
1.6.1 Physical interference 
One of the main challenges faced by antifungal effectiveness is the ECM, which 
acts acts as a physical barrier preventing the penetration of drugs. Therefore, 
novel therapies that are able to disrupt the ECM are highly sought after. This is 
particularly true for use as denture cleansers due to current agents being 
ineffective against fungal biofilms, unless used on a daily basis (Jose et al., 
2010, Ramage et al., 2012d). One way of overcoming the ECM would be to 
directly target components of the ECM such as eDNA as this has been shown to 
improve antifungal treatment (Martins et al., 2011, Taff et al., 2012b). With the 
recent finding of eDNA being present in C. albicans biofilms (Martins et al., 
2010), it was shown that combinational therapy of AMB and CSP with DNase 
significantly improved antifungal sensitivity (Martins et al., 2011). Therefore, 
the penetration of such antifungals could be enhanced by combining therapy 
with a biofilm disruptive agent such as Dornase Alfa Pulmozyme®, currently used 
for the breakdown of DNA present in mucus of CF patients. Furthermore, C. 
parapsilosis biofilms have been shown to be more sensitive to AZL treatment 
when used in conjunction with ambroxol, a mucoactive agent used in respiratory 
infections (Pulcrano et al., 2012). Other anti-biofilm agents shown to have 
disruptive properties against fungal biofilms include N-acetylcysteine (NAC) 
(Aslam and Darouiche, 2011), ester lauroyl glucose (Dusane et al., 2008) and 
alginate lyase (Bugli et al., 2012, Papi et al., 2012). Overall, these studies 
illustrate the potential of biofilm disruption agents have as an alternative or 
complementary therapy for treating fungal biofilms.  
Silver has been known to have broad-spectrum antimicrobial activity for some 
time now. Silver interferes with DNA replication and in turn denatures proteins, 
leading to the inhibition of oxidative enzymes (Kim et al., 2007). The production 
of silver nanoparticles has been shown to impact C. albicans and C. glabrata 
biofilms at various stages of development (Monteiro et al., 2011, Monteiro et al., 
2012b) and have been utilised in various experimental models including the 
release from hydrogels used in chronic wounds and denture acrylic (Humphreys 
et al., 2011, Monteiro et al., 2012a).  
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Another strategy that has been shown to effectively prevent fungal biofilm 
formation on biomaterials is coating the surface with chitosan, a naturally-
occurring polysaccharide from shellfish (Carlson et al., 2008). This agent has 
activity against both bacterial and fungal biofilms, including Candida species 
(Martinez et al., 2010) and is thought to inhibit biofilms through the interference 
of cell membranes.  
1.6.2 Microbial interference 
From the infections detailed earlier, it is evident that polymicrobial interactions 
contribute to fungal biofilm formation. However, it is possible to utilise these 
interactions to help control the formation of Candida biofilms. One possibility is 
by the use of probiotics, whereby one organism can control or inhibit the growth 
of another (Meurman, 2005). An example of this has been shown whereby the 
release of biosurfactants from Streptococcus thermophilus B prevented the 
adhesion of Candida species on silicone (Busscher et al., 1997). Many probiotics 
are found in dairy products and therefore easily consumed, including 
Lactobacillus lactis that has been shown to play a role in controlling Candida 
biofilms (Rodrigues et al., 2006, Rodrigues et al., 2004). However, conflicting 
evidence exists around the use of Saccharomyces boulardii as a probiotic. 
Despite this organism being able to control C. albicans biofilm formation by the 
inhibition of filamentation (Murzyn et al., 2010), it has also been found to 
possibly cause fungaemia within immunocompromised patients (Santino et al., 
2014).  
A number of secondary metabolites isolated from various organisms have been 
shown to have potential in the treatment of fungal infections. An environmental 
strain of A. fumigatus produced a prenylated indole alkaloid called waikialoid A, 
identified to having inhibitory properties towards C. albicans biofilms (Wang et 
al., 2012b). In addition, the release of mutanobactin by S. mutans, a hybrid 
peptide metabolite, has been shown to inhibit C. albicans biofilm formation by 
preventing morphological switching (Wang et al., 2012a, Joyner et al., 2010). 
The shared aims of these studies are the utilisation of molecules isolated from 
organisms and using these to inhibit hyphal development and biofilm formation 
within C. albicans. 
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The relationships between bacteria and fungi have been shown previously to 
have serious implications on health, particularly within the lung of CF patients. 
However, the interactions between fungi and P. aeruginosa have found C. 
albicans and A. fumigatus hyphae and biofilm development can be inhibited 
through the secretion of quorum sensing molecules such as decanol, dodecanol 
and 3-oxo-C12 homoserine lactone (Hogan et al., 2004, Mowat et al., 2010). 
Another quorum sensing molecule shown to have anti-biofilm activity against a 
range of Candida and Aspergillus species is farnesol, whereby the molecule can 
cause apoptosis and behave as a cell wall stressor impacting morphogenesis and 
cellular development (Albuquerque and Casadevall, 2012, Ramage et al., 2002b). 
Despite these findings, contradicting in vivo studies have shown an increase in 
mortality in mice when farnesol was administered, suggesting that this molecule 
could contribute to disease pathogenesis (Navarathna et al., 2007). However, 
with antifungal resistance currently increasing, any molecules that have activity 
against fungal biofilms warrant further investigation (Guo et al., 2013).  
1.6.3 Natural antifungals 
Alternative therapies including the use of natural compounds are of great 
interest clinically as they are thought to be less toxic to the host, fairly cheap 
and the generation of resistant phenotypes appears to be less common compared 
to current antifungals used. One of the most documented naturals is tea tree oil 
(TTO), an essential oil obtained from the leaves of Melaleuca alternifolia. TTO is 
made up of a various components including sesquiterpenes, monoterpenes and 
alcohols, with the active ingredient being terpinene-4-ol (Carson et al., 2006). 
Studies have shown the antifungal activity of these agents against C. albicans 
through the inhibition of biofilm formation (De Prijck et al., 2010, Ramage et 
al., 2012b). Furthermore, in vivo studies have shown terpinen-4-ol is able to 
prevent the development of oral candidiasis within a murine model (Ninomiya et 
al., 2012).  
In addition to the antimicrobial properties natural compounds have to offer, 
agents that are also anti-inflammatory are of increased value for the treatment 
of fungal infections. TTO is an example of a compound with dual action as it is 
able to down-regulate key pro-inflammatory mediators including IL-8 (Ramage et 
al., 2012b), a similar finding was also found when using proanthocyanidins 
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isolated from cranberries (Feldman et al., 2012). A number of other naturally 
occurring molecules identified for having anti-biofilm activity include a number 
of plants and spices including turmeric, cinnamon oil, garlic, usnic acid and 
linalool (Hsu et al., 2012, Rukayadi and Hwang, 2012, Sardi et al., 2013). Further 
studies have investigated fulvic acids and showed in addition to a reduction of 
inflammation in vivo (Gandy et al., 2011, Sabi et al., 2012), these compounds 
also have broad-spectrum antimicrobial activity (van Rensburg et al., 2000).  
Ethanol is another natural antimicrobial agent that can either be used alone or 
in combinational therapy to control C. albicans biofilm formation (Blackwood et 
al., 2011, Pieroni et al., 2012). The broad-spectrum activity of ethanol has also 
allowed its use in catheter locks to inhibit bacterial biofilm development 
(Oliveira et al., 2012), with biofilms found within polymicrobial infections also 
being treated effectively with ethanol (Peters et al., 2013). Other mixed species 
biofilms including C. parapsilosis and MRSA have shown to be eradicated when 
ethanol and ethylenediaminetetraacetic acid (EDTA) are used in combination 
(Raad et al., 2007), however EDTA treatment alone can also be used in 
endodontic infections (Siqueira and Sen, 2004). 
Overall, these studies have shown the potential that natural antimicrobials 
possess when it comes to the treatment of biofilm infections. The main 
advantage of using these is their broad-spectrum antimicrobial activity as many 
of these infections consist of mixed bacterial-fungal biofilms.  
1.7 Aims and hypothesis 
It is clear by reviewing the current literature that C. albicans biofilms have a 
great impact on the clinical management of candidiasis. At present there are no 
definitive diagnostic tools to aid in identification of fungal biofilm infections, 
and antifungal therapies are increasingly failing.  
Given that these biofilm infections caused by C. albicans do not have consistent 
responses to clinical management, the overall hypothesis of this study was that 
standard antifungal therapies are ineffective and that these biofilms vary 
physically and transcriptionally, which therefore impacts their clinical 
management. 
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The aims of this study were therefore to, 1) investigate the variation of biofilm 
development within clinical isolates, 2) identify a potential mechanism 
responsible for differential biofilm formation and to 3) explore the potential of a 
natural broad-spectrum antimicrobial agent against C. albicans and 
polymicrobial biofilms.  
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Chapter 2: 
Candida albicans biofilm 
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2.1 Introduction 
Candida species are frequently isolated commensals of the human skin and 
mucosal membranes, but if these barriers become compromised in any way then 
there can be an increase in Candida colonisation leading to invasive forms of 
candidiasis (Eggimann et al., 2011). Candida is the most common fungal 
pathogen of bloodstream infections (BSI) where it is the fourth most prevalent 
causative organism of these infections and the third most commonly isolated 
species within the ICU in the USA (Wisplinghoff et al., 2004). Candidaemia is 
often associated with the ability of Candida to adhere to and form biofilms on 
indwelling medical devices, such as CVC and prostheses (Kojic and Darouiche, 
2004, Lynch and Robertson, 2008).  
Biofilms are a population of microorganisms attached to one another and/or a 
surface, surrounded by an ECM (Ramage et al., 2012c). A defining feature of 
these is their resistance to antimicrobial therapy, with higher drug 
concentrations required to kill biofilms and their dispersed cells when compared 
to equivalent free-floating planktonic cells (Ramage et al., 2012c, Taff et al., 
2012b, Uppuluri et al., 2010). Another feature of C. albicans biofilms is their 
enhanced pathogenicity. For example, cells detaching from biofilms have been 
shown to be more cytotoxic in vivo than their planktonic counterparts and 
significantly increase mortality within a murine model of infection (Uppuluri et 
al., 2010). These observations have been demonstrated clinically, where a 
significant association was observed between C. albicans biofilm formation and 
mortality rates in candidaemia patients (Tumbarello et al., 2007).  
Whilst there is growing evidence of the importance of Candida biofilms in 
clinical medicine, not all clinical isolates are able to form biofilms (Tumbarello 
et al., 2012). There is, therefore, a fundamental gap in understanding exactly 
what drives biofilm formation and its clinical implications. Establishing methods 
to differentiate these isolates is challenging, as many studies rely on either 
metabolic assays or biomass, and these frequently use a variety of different 
substrates and media (Daniels et al., 2013, Kucharikova et al., 2011, Pierce et 
al., 2008, Samaranayake et al., 2009b). Therefore, comparison between these 
studies is not possible, and further interpretation of the data to improve clinical 
management both for diagnostics and antifungal therapy is limited.  
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2.2 Aims 
The aim of this chapter was to investigate and characterise biofilm formation by 
clinical isolates of C. albicans using standard methodologies and subsequently 
analyse biofilm subsets at a phenotypic level. Next, the antifungal susceptibility 
profiles of these clinical isolates were established using amphotericin B, with the 
impact of C. albicans strain variation assessed in vivo using a Galleria mellonella 
model. Finally, a number of C. albicans biological markers were used to assess 
biofilm variation at a transcriptional level and to determine if these could 
potentially be used as a diagnostic tool for identifying C. albicans biofilm 
formation. 
The data represented in this chapter has been accepted for publication in: 
Sherry L, Rajendran R, Lappin D, Borghi E, Perdoni F, Falleni M, Tosi D, Williams 
C, Jones, Nile C, Smith K and Ramage G. Biofilms formed by Candida albicans 
bloodstream isolates display phenotypic and transcriptional heterogeneity that 
are associated with resistance and pathogenicity. BMC Micro, epub ahead of 
print. 
Work from this chapter has been presented at the following conferences: 
Sherry L, Rai M, Murray C, Nile C, Jones B, Williams C and Ramage G. 
‘Evaluating the incidience of biofilm formation from candidaemia isolates and 
the effects of Ambisome®.’ ASM Candida and Candidiasis. March 2012. 
Sherry L, Rajendran R, Jones B, Williams C, Nile C and Ramage G. ‘Biofilm 
phenotypic and transcriptional heterogeneity amongst Candida albicans 
bloodstream isolates differentially affect amphotericin B tolerance.’ ECCMID, 
Barcelona, Spain. May 2014. 
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2.3 Materials and Methods 
To investigate the biofilm forming ability of clinical C. albicans isolates, an 
established method used for evaluating and quantifying biofilm biomass was 
employed. Based on this initial screening, three distinct groups of isolates were 
identified based upon their ability to form a biofilm; low biofilm formation 
(LBF), intermediate biofilm formation (IBF) and high biofilm formation (HBF). 
Minimum inhibitory concentrations (MIC) of these selected isolates were 
determined and the clinical significance of biofilm formation by C. albicans in 
relation to antifungal therapy and pathogenicity was assessed.  
2.3.1 Culture conditions and standardisation 
2.3.1.1 C. albicans strain collection 
A collection of C. albicans clinical bloodstream isolates (n=42) was obtained 
from the Royal Hospital of Sick Children (Yorkhill Division, Glasgow, UK) between 
January 2009 to July 2011 (Appendix 1). The laboratory strains SC5314 and 3153A 
were also included as appropriate control isolates. All Candida isolates obtained 
during this period of time were independently identified using Colorex Candida 
chromogenic plates (E&O Laboratories Ltd, Bonnybridge, UK) and purity plates 
made for each isolate. All isolates were stored in Microbank® vials (Pro-Lab 
Diagnostics, Cheshire, UK) at -80°C until further use.  
2.3.1.2 Optimisation of C. albicans biofilm formation 
C. albicans SC5314 and 3153A biofilm formation was optimised as described 
previously (Ramage et al., 2001a). Initially, isolates were retrieved from 
Microbank® vials and sub-cultured on to Sabouraud’s dextrose agar (SAB [Sigma-
Aldrich, Dorset, UK]). Plates were incubated at 30°C for 48 h and maintained at 
4°C. A loopful of each isolate was inoculated in to 10 mL of yeast peptone 
dextrose (YPD) medium (1% w/v yeast extract, 2% w/v peptone, 2% w/v dextrose 
[Sigma-Aldrich, Dorset, UK]) contained in a 25 mL universal (Sterilin® Limited, 
Cambridge, UK) and placed in the orbital shaking incubator at 150 rpm and 30°C 
for 18 h. Cells were centrifuged at 3,000 rpm for 5 min and the resultant 
supernatant containing cellular debris was discarded. The remaining pellet was 
washed with 10 mL of phosphate buffered saline (PBS [Sigma-Aldrich, Dorset, 
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UK]) and centrifuged for 5 min at 3,000 rpm. The supernatant was discarded 
once more, the pellet was resuspended in PBS, and cells were counted using a 
Naeuber haemocytometer. C. albicans cells were standardised to the desired 
cellular density of 1 × 106 cells/mL in either RPMI-1640 (Sigma-Aldrich), YPD + 
10% foetal calf serum (FCS), yeast nitrogen base (YNB [Sigma-Aldrich]) + 100 mM 
glucose or Spider media (2% nutrient broth [Oxoid], 2% mannitol, 0.4% K2HPO4 
and 2.7% agar, pH adjusted to 7.2). The selection of media was based upon a 
range of growth conditions currently used in various laboratories (Ferreira et al., 
2013, Ramage et al., 2001a, Midkiff et al., 2011). Standardised cells (200 μL) 
within each medium were dispensed into defined wells of a pre-sterilised, 
polystyrene, 96 well flat-bottom microtitre plate (Corning Incorporated, NY, 
USA), which were incubated for 24, 48 and 72 h at 37°C. Following incubation, 
biofilms were carefully washed twice with PBS to remove planktonic cells and 
biofilm biomass was determined using the crystal violet (CV) assay (Jose et al., 
2010), described in detail in 2.3.2.1. Negative controls containing no organisms 
were also included. Testing was carried out in triplicate for each isolate, on two 
separate occasions.  
2.3.2 Characterisation of Candida albicans biofilm formation by clinical 
isolates 
Based on this initial optimisation experiment above, all other clinical C. albicans 
isolates (n=42) were assessed for their biofilm forming ability in RPMI (Roswell 
Park Memorial Institute) 1640 media (Sigma-Aldrich, Dorset, UK). C. albicans 
cells were standardised to 1 × 106 cells/mL in RPMI and 200 μL dispensed into 
each well of pre-sterilised, polystyrene, 96 well flat-bottom microtitre plate 
(Corning Incorporated, NY, USA). Plates were incubated for 24 h at 37°C. 
Following incubation, the culture media was discarded and biofilms were 
carefully washed twice with PBS to remove planktonic cells. Biofilm biomass was 
quantified using the CV assay.  
2.3.2.1 Biomass quantification by crystal violet 
Biofilms were grown as previously described in 2.3.1. Biofilms were carefully 
washed with PBS and allowed to air dry. One hundred microlitres of 0.05% w/v 
CV solution was added to each biofilm and incubated at room temperature for 20 
min to allow uptake of the dye. Following incubation, the CV solution was 
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discarded and the biofilms were washed with running tap water to remove any 
unbound dye, and 100 μL of 100% ethanol applied to destain each biofilm. The 
contents of the wells were mixed thoroughly by pipetting and transferred to a 
new 96 well flat-bottom microtitre plate for measurement. The biomass was 
quantified spectrophotometrically by reading absorbance at 570 nm in a 
microtitre plate reader (FluoStar Omega, BMG Labtech). All absorbance values 
were blank corrected based upon the negative control where no biofilms were 
formed. Isolates were grouped based on their level of biomass distribution 
(OD570nm values). Isolates that fell below the 1st quartile (Q1) were classed as 
having LBF, strains with a biomass greater than the 3rd quartile (Q3) were 
deemed isolates with HBF, and those that lay in between were classified as IBF 
(Q2). Each isolate had eight replicates and biomass measured on two separate 
occasions. Biofilms were also formed in 12 well flat-bottom microtitre plate 
(Corning Incorporated, NY, USA) for 24 h before carefully washing with PBS and 
stained with 0.05% CV solution. Macroscopic images were digitally taken (Canon 
IXUS 220 HS) to show biomass after 24 h of biofilm development. 
2.3.2.2  Biomass quantification by dry weight 
C. albicans biomass was further assessed using dry weight measurements. 
Selected isolates with LBF (n=3) and HBF (n=3) were grown as biofilms in 12 well 
plates for 24 h, as previously described, and the resulting biomass collected in 1 
mL of PBS using a cell scraper (STARLAB, Milton Keynes, UK). This was then 
passed through a 0.22 μm filter disc (Satorius Stedim, Surrey, UK) using a 
vacuum, and the filters subsequently dried at 40°C overnight before measuring 
each isolates dry weight. Un-inoculated controls were used for background 
correction.  
2.3.3 Scanning electron microscopy 
For biofilm visualisation, sessile cells of isolates with proven high (n=2 [28158, 
34106]) and low (n=2 [27915, 74174]) biofilm forming ability were grown directly 
on Thermanox coverslips (Nunc, Roskilde, Denmark) for 4 and 24 h at 37°C. 
Following incubation, biofilms were carefully washed with PBS and then fixed 
with a fixative solution containing 2% para-formaldehyde, 2% gluteraldehyde and 
0.15 M sodium cacodylate, and 0.15% w/v alcian blue (pH 7.4) and left in 
solution for 18 h. The fixative was carefully discarded and replaced with 0.15 M 
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sodium cacodylate buffer and stored at 4°C until processing. Samples were then 
prepared for SEM as previously described (Erlandsen et al., 2004). Samples were 
washed 3 × 5 min with 0.15 M cacodylate to ensure all gluteraldehyde had been 
removed. Samples were then treated with 1% osmium tetroxide solution 
containing 0.15 M sodium cacodylate (1:1) and incubated in the fume hood for 1 
h. Samples were rinsed 3 × 10 min with distilled water and then treated with 
0.5% uranyl acetate and incubated in the dark for 1 h. Uranyl acetate was 
removed from the samples and quickly rinsed with water before a series of 
dehydration steps were carried out. Two 5 min rinses of 30, 50, 70 and 90% 
alcohol were followed by 4 × 10 min rinses of absolute and dried absolute 
alcohol. Hexamethyldisilazane (HMDS) was used to dry the specimens by soaking 
the samples for 5 min before transferring to a plate containing fresh HMDS. All 
samples were then placed in a dessicator overnight to allow evaporation of any 
residue and drying. The specimens were then mounted and sputter-coated with 
gold in an argon filled chamber, and then viewed under a JEOL JSM-6400 
scanning electron microscope. Images were assembled using Photoshop software 
(Adobe, San Jose, CA, USA). 
2.3.4 Growth kinetics 
The growth kinetics of C. albicans clinical isolates with LBF (n=10) and HBF 
(n=10) were assessed to determine if growth rate played a role in their ability to 
form biofilms. Each isolate was standardised to 1 × 104 cells/mL in YPD, with 200 
μL added to each well of a 96 well round-bottomed plate. The plate was 
incubated at 37°C for 24 h with absorbance measured at 530 nm every 1 h, 
following shaking at 100 rpm for 30 s. Each isolate was tested in duplicate and 
this experiment was repeated on three independent occasions. Negative controls 
containing no C. albicans were included for background correction.  
2.3.5 Cellular surface hydrophobicity assay 
Cellular surface hydrophobicity (CSH) was determined for selected C. albicans 
clinical isolates with LBF (n=10) and HBF (n=10). CSH was assessed using the 
microbial adhesion to hydrocarbon test, with a few modifications (Yoshijima et 
al., 2010, Rosenberg et al., 1980). Isolates were standardised to 1 × 106 
cells/mL in RPMI-1640 and grown as biofilms for 4 and 24 h in 75 cm2 flasks 
(Nunc, Rochester, NY) at 37°C. These were then carefully washed with PBS and 
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the resultant biomass scraped off using a cell scraper and homogenised in YPD. 
Cells were standardised (OD590nm 1.0) and cells transferred into a glass tube and 
overlaid with 1/5th volume of xylene. Contents were vortexed for 1 min and 
phases allowed to separate over 30 min. The aqueous phase was carefully 
removed and OD590nm measured again. The percentage of hydrophobicity was 
calculated as ([OD590nm before xylene overlay - OD590nm after xylene overlay]/ 
OD590nm before xylene overlay) × 100%. Controls containing no C. albicans were 
used for background correction. Each isolate was tested on three separate 
occasions.  
2.3.6 Antifungal susceptibility testing 
The following antifungal agents were used in the course of this study: 
AmBisome®(AmBi, Gilead, UK), amphotericin b (AMB, Sigma-Aldrich, Gillingham 
UK), caspofungin (CSP, Merck Sharp & Dohme, Hertfordshire, UK) and micafungin 
(MFG, Astellas, UK). All antifungals were prepared at a stock concentration of 2 
mg/mL in sterile water and stored at -20°C until required. 
2.3.6.1 Planktonic and sessile inhibitory testing 
Antifungal testing to determine minimum inhibitory concentrations (MICs) of 
planktonic cells was performed using the CLSI M-27A broth microdilution method 
(CLSI, 2008). Two hundred microlitres of each drug was added to the appropriate 
wells of a 96 well round-bottom plate (Corning Incorporated, NY, USA) and serial 
2-fold dilutions were made in RPMI-1640. Next, 100 μL of standardised C. 
albicans cells (1 × 104 cells/mL) was added to each well containing the drug, 
giving a final volume of 200 μL, before incubation at 37°C for 24 h. Appropriate 
positive and negative controls were also included. Biofilms were grown for 24 h 
at 37°C, washed with PBS and sessile susceptibility testing was performed, as 
previously described, in commercially available pre-sterilised, polystyrene, flat-
bottomed, 96 well microtitre plates (Corning Incorporated, NY, USA) (Ramage et 
al., 2001a). Two-fold serial dilutions were prepared as described for planktonic 
susceptibility testing with a final 100 μL of RPMI-1640 added to each well to take 
the final volume to 200 μL in each well. Biofilms were incubated at 37°C for 24 
h. Sessile minimum inhibitory concentrations (SMIC) were determined at 90% 
inhibition using an XTT metabolic reduction assay, as described in 2.3.6.2 
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(Pierce et al., 2008). Testing of all planktonic and sessile isolates was performed 
in triplicate. 
Further sessile susceptibility testing was carried out using AMB against selected 
C. albicans isolates with LBF (n=10) and HBF (n=10) to determine if biofilm 
phenotype impacts antifungal treatment, see appendix 1 for highlighted strains. 
Testing of each isolate was carried out in duplicate on three separate occasions.  
2.3.6.2 Quantification of biofilm metabolic activity 
A semi-quantitative measure of each biofilm was calculated using a formazan 
salt-based XTT reduction assay (Pierce et al., 2008). Briefly, XTT (Sigma-Aldrich, 
Dorset, UK) was prepared as a solution of 0.25 g/L in ddH2O. The solution was 
then filtered through a 0.22 μm filter, aliquoted and stored at -80°C. Prior to 
use, XTT was thawed and menadione ([Sigma-Aldrich, Dorset, UK], 10 mM 
prepared in acetone) added to a final concentration of 1 μM. A 100 μL aliquot of 
the XTT/menadione solution was subsequently added to each pre-washed 
biofilm, and to control wells (for measurement of background XTT-reduction 
levels). Plates were then incubated in the dark for 2 h at 37°C. A colorimetric 
change in the XTT reduction assay, representing a direct correlation of 
metabolic activity of the biofilm, was then measured at 492 nm in a microtitre 
plate reader (FluoStar Omega, BMG Labtech, Aylesbury, Buckinghamshire, UK). 
Negative controls containing no biofilms were used for background correction. 
Testing of all planktonic and sessile isolates (n=42) was performed in duplicate. 
2.3.7 Investigating pathogenicity of two biofilm sub-sets 
2.3.7.1 Galleria mellonella pathogenicity assay 
The pathogenicity of C. albicans isolates pre-defined as LBF (n=3), HBF (n=3) and 
SC5314 were assessed using the G. mellonella killing assay, as described 
previously (Cotter et al., 2000). This biological model has been shown previously 
to be useful in the study of fungal virulence (Gago et al., 2014, Cirasola et al., 
2013, Fallon et al., 2012). Sixth-instar G. mellonella larvae (Livefoods Direct 
Ltd, UK) were stored in the dark and used within 7 days of shipment. Ten 
random larvae with a bodyweight of between 200 to 300 mg were used for each 
group. Overnight YPD cultures of each isolate were washed and standardised to 1 
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x 107 cells/mL in PBS. Larvae were inoculated using a 50 μL Hamilton syringe 
with 26 g needle by injecting 10 μL aliquots (1 x 105 cells/larva) into the 
haemocoel, through the hindmost proleg. In addition, mock inoculated larvae 
pierced on the proleg with a sterile needle and a PBS inoculated control group 
were also included in each experiment. Each group contained ten replicates for 
each condition. The infected larvae were placed in sterile petri dishes, 
incubated at 37°C and the number of dead larvae were scored daily. Larva was 
considered dead when it displayed no movement in response to touch together 
with a dark discolouration of the cuticle. Pathogenicity of C. albicans isolates 
with LBF and HBF was assessed using a Kaplan-Meier plot with percentage 
survival monitored over 7 days. 
2.3.7.2 Histology analysis of infected G. mellonella 
These experiments were performed with the help and assistance from Elisa 
Bourghi from the University of Milan. 
The morphology of the larvae infected with two isolates of C. albicans LBF and 
HBF was examined. Larvae were infected with the respective strains as 
described previously, and after post-infection (24, 48 and 72 h) larvae were 
fixed by a direct injection of formalin into the haemocoel and by formalin 
immersion at room temperature for 24 h. Paraffin embedded samples were then 
transversally sectioned into four-micron thickness using a microtome (microm 
HM 3335H, Thermoscientific). Sections were then stained with Periodic Acid-
Schiff (PAS) to evaluate C. albicans infected cells. Whole larvae sections were 
examined for characterisation and localisation of nodules by light optical 
microscope visualisation (Leica microscope, model 020-519.502). Two larvae 
were processed for each isolate, carried out on three separate occasions. 
2.3.8 Optimisation of PCR conditions for transcriptional analysis 
Before the transcriptional profiles of C. albicans could be determined, a series 
of primer and PCR optimisation stages were required. All future PCR studies 
were carried out in a laminar flow hood (Bioquell UK Ltd, Hampshire, UK) with 
UV-radiated equipment and filter tips to ensure no contamination occurred 
within the samples. Specific genes related to adhesion, cell wall structure, 
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morphology, pathogenicity and antimicrobial resistance were selected and used 
for analysis in gene expression studies. 
2.3.8.1 DNA extraction for PCR optimisation 
C. albicans SC5314 was used as a template for all subsequent PCR optimisation 
studies. An overnight culture of C. albicans SC5314 in 10 mL of YPD broth, 
incubated at 30°C at 150 rpm, was used from the DNA extraction. The 
MasterPure™ Yeast DNA purification kit from Epicentre® Biotechnologies 
(Cambio, Cambridge UK) was used, following the manufacturer’s instructions. 
One and a half millilitres of the overnight culture was transferred into a 
microfuge tube and centrifuged at 10,000 rpm for 5 min to pellet the cells.  The 
supernatant was discarded and the remaining pellet resuspended in 300 μL of 
yeast cell lysis solution. The cells were incubated at 65°C for 15 min and then 
cooled on ice for 5 min. Following incubation, 150 μL of MPC protein 
precipitation reagent was added to the solution and mixed by vortexing.  
Samples were centrifuged for 10 min at 13,000 rpm to ensure all cellular debris 
had been pelleted before transferring the supernatant to a fresh microfuge tube. 
Five hundred microlitres of isopropanol was mixed with the solution by inversion 
and centrifuged for a final 10 min at 10,000 rpm. The supernatant was discarded 
and the remaining genomic DNA was washed with 500 μL of 70% ethanol before 
being resuspended in 35 μL of TE buffer (10 mM Tris-HCl [pH 7.5], 1 mM EDTA). 
DNA was quantified using the NanoDrop™ ND-1000 spectrophotometer (Labtech) 
as described in 2.3.8.2.  
2.3.8.2 Nucleic acid quantification 
Nucleic acid was quantified using the NanoDrop™ ND-1000 spectrophotometer 
(Labtech International, Ringmer, East Sussex, UK). TE buffer was used as a 
reference before the DNA was quantified and concentrations were recorded in 
ng/μL. Samples with a 260/280 nm ratio of 1.8 to 2.2 were deemed to be of high 
quality and were used for subsequent PCR reactions. DNA was stored at -20°C 
until required. 
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2.3.8.3 Primer designing 
All primers used for qPCR throughout this study were either taken from peer-
reviewed papers or designed based upon their sequence, obtained from the 
Candida Genome Database (CGD) web site (http://www.Candidagenome.org). 
For primer sets being designed in house, the web-based primer design software 
program, Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/) was used. Primers 
were designed with a PCR product size of 70-120 base pairs. The National 
Institute of Health’s Basic Local Alignment Search Tool (NIH-BLAST) was used to 
check the specificity of designed primers to C. albicans 
(http://www.nlm.nih.gov/BLAST). Oligonucleotides matching the resulting 
primer sequences were synthesised (Invitrogen, Paisley, UK) for the C. albicans 
genes listed in Table 2.1. 
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Table 2.1 C. albicans primers used for real time qPCR 
Gene Sequence (5' - 3') Reference 
ALS1 F - TTCTCATGAATCAGCATCCACAA 
R - CAGAATTTTCACCCATACTTGGTTTC 
(Nailis et al., 2010a) 
ALS3 F - CAACTTGGGTTATTGAAACAAAAACA 
R - AGAAACAGAAACCCAAGAACAACCT 
(Nailis et al., 2006) 
ALS5 F - CTGCCGGTTATCGTCCATTTA 
R - ATTGATACTGGTTATTATCTGAGGGAGAAA 
(Green et al., 2005) 
EAP1 F - ACCACCACCGGGTATACAAA 
R - GCCATCACATTTGGTGACAG 
In house 
HWP1 F - GCTCAACTTATTGCTATCGCTTATTACA 
R - GACCGTCTACCTGTGGGACAGT 
(Nailis et al., 2010a) 
BCR1 F - ATTGCCACCAATACCTGCTC 
R - GGCTGTCCATGTTGTTGTTG 
In house 
CPH1 F - ACGCAGCCACAAGCTCTACT 
R - GTTGTGTGTGGAGGTTGCAC 
In house 
EFG1 F - CCAGTGGTGGCAGTAATGTG 
R - CAGTGGCAGCCTTGGTATTT 
In house 
TUP1 F - GCTTCAGGTAACCCATTGTTGAT 
R - CTTCGGTTCCCTTTGAGTTTAGG 
(Uppuluri et al., 2009a) 
OCH1 F - TCATCCAATGTTGCGTGAAT 
R - TCATGATATCGCCACCTTCA 
In house 
PMR1 F - GAATCCCCGCAGACATTAGA 
R - GGGCCTGTTTTCACCAGTTA  
In house 
MNN4 F - TGAGCAATCGTCAAAACCAG 
R - GGCGGTTGTCATTTGTTGAT 
In house 
MNT2 F - CGTCAAGGTGCCTGAAGAAT 
R - GAGGAGGAGGAGGATTTTGG 
In house 
SAP1 F – ACAAGCCCTCCCAGTTACTTTAAA  
R - AACCAATAGTGATGTCAGCAGCAT 
(Nailis et al., 2010a) 
SAP2 F-GAATTAAGAATTAGTTTGGGTTCAGTTGA 
R - CCACAAGAACATCGACATTATCAGT 
(Nailis et al., 2010a) 
SAP3 F - CAGCTTCTGAATTTACTGCTCCATT  
R - TCCAAAAAGAAGTTGACATTGATCA 
(Nailis et al., 2010a) 
SAP4 F -CAAAAACTTAGCGTTATTGTTGACACT  
R - AAACGGCATTTGAATCTGGAA  
(Nailis et al., 2010a) 
SAP5 F - CCAGCATCTTCCCGCACTT  
R - GCGTAAGAACCGTCACCATATTTAA 
(Nailis et al., 2010a) 
Ch.2 C. albicans biofilm heterogeneity is associated with resistance and pathogenicity 
55 
 
SAP6 F - GCTAACGTTTGGTCTACTAGTGCTCATA  
R - TGGTAGCTTCGTTGGCTTGGA 
(Nailis et al., 2010a) 
PLB1 F - GGTGGAGAAGATGGCCAAAA  
R - AGCACTTACGTTACGATGCAACA 
(Nailis et al., 2010a) 
CDR1 F - GTACTATCCATCAACCATCAGCACTT  
R - GCCGTTCTTCCACCTTTTTGTA  
(Watamoto et al., 2011) 
MDR1 F - TCAGTCCGATGTCAGAAAATGC 
R - GCAGTGGGAATTTGTAGTATGACAA 
(Watamoto et al., 2011) 
ZAP1 F - CGACTACAAACCACCAGCTTCATC 
R - CCCCTGTTGCTCATGTTTTGTT 
(Nobile et al., 2009) 
ACT1 F - AAGAATTGATTTGGCTGGTAGAGA 
R - TGGCAGAAGATTGAGAAGAAGTTT 
(Ricardo et al., 2009) 
 
2.3.8.4 Primer optimisation by gradient PCR 
Gradient PCR was used to optimise the primers designed in-house, as illustrated 
in section 2.3.8.3, to obtain the most appropriate annealing temperature. All 
other primer sets used in the gene expression studies had already being 
optimised by other groups. 
Primers were diluted to a working concentration of 100 μM in sterile water. A 
mastermix was prepared consisting of 22.5 μL of ReddyMix (Abgene, 
ThermoFisher, Epsom, Surrey, UK), 1 μL of forward and reverse primers and 0.5 
μL of DNA at 200 ng/μL, previously extracted from C. albicans SC5314. Eight 
replicates for each gene of interest were carried out in 200 μL PCR tubes. A 
negative control containing no DNA template was also included. The tubes were 
placed in a temperature gradient heat block with PCR cycling capability (MJ 
Research, Waltham, MA, USA), where annealing temperatures ranged from 
56.0°C to 63.0°C.  The thermal profile included a 2 min initial denaturation step 
at 95°C, followed by an amplification cycle of 40 cycles of 95°C for 25 s, the 
appropriate annealing temperature (56.0°C to 63.0°C) for 35 s, and a 65 s 
extension at 72°C. A final 5 min extension step at 72°C was followed by a 4°C 
holding stage. Amplified samples were then visualised using gel electrophoresis 
to assess to most appropriate annealing temperature. 
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2.3.8.5 Gel electrophoresis 
A 2% (w/v) agarose (Life Technologies, Paisley, UK) gel was prepared in 100 mL 
of 0.5× TBE buffer and melted in a microwave, with frequent stirring until the 
agarose had dissolved. This solution was allowed to cool before 5 μL of 10 
mg/mL ethidium bromide was added. The gel apparatus was assembled 
according to the manufacturer’s instructions (Advance Mupid EX, Japan) and a 
13-lane comb and was inserted into the tray. The agarose solution was initially 
used to seal the tray at both ends to ensure a tight fit was achieved before the 
remainder was poured into the tray, ensuring any air bubbles were removed. The 
agarose was allowed to set for 20 min before the tray was placed inside the 
electrophoresis tank and covered with 0.5 × TBE buffer. The comb was carefully 
removed and 10 μL of each PCR product was added to an individual well. In 
addition, 10 μL of a 1000 base pair hyperladder (1 in 10 dilution) and a water 
control were also included on the gel. The gel tank was connected to the power 
supply and run for 2 h at 60 v. Upon completion, the gel was observed under UV 
light and photographed (BioRad Gel Doc 2000, Hemel Hempstead, Hertfordshire 
UK). 
2.3.8.6 Optimisation of quantitative PCR 
The efficiencies of each primer set designed in 2.3.8.3 were assessed using a 
standard curve to confirm linear PCR kinetics independent of the genomic DNA 
concentration. The simplest method to determine the amplification efficiencies 
was to use the DNA extracted from C. albicans SC5314 in 2.3.8.1 as a template 
and to serially dilute the DNA using 1 in 10 dilutions, from 400 ng to 0.04 ng/μL. 
For each dilution, 1 μL of each concentration of genomic DNA was added to a 
mastermix containing 12.5 μL of SYBR® GreenER™ (Life Technologies, Paisley, 
UK), 0.5 μL of forward and reverse primers and 10.5 μL of sterile distilled water. 
All reactions were carried out in 96 well plates and sealed using caps (Agilent 
Technologies, Cambridge, UK). The thermal profile cycle was carried out on a 
Strategene MX5300x Pro (Agilent Technologies) and consisted of a UDG 
incubation of 2 min at 50°C, an UDG inactivation and DNA polymerase activation 
of 10 min at 95°C followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. A melt 
curve was also carried out after the end of the PCR thermal profile to confirm 
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only one product had been amplified. Reactions were carried out in duplicate, 
on one occasion and included no template controls (NTC). 
The cycle threshold (Ct) values for each sample were plotted against the log10 of 
the DNA concentration and the efficiency of the PCR reaction was calculated 
from the formulas; 
Efficiency = -1+10 (-1/slope); Slope =  (y2-y1) / (x2-x1) 
Efficiencies that fell between 90-110% are deemed acceptable for subsequent 
transcriptional analysis of C. albicans clinical biofilms by qPCR. 
2.3.9 Transcriptional analysis of biofilm related genes 
Based upon the initial screening of the C. albicans bloodstream isolates, those 
categorised as LBF (n=10) and HBF (n=10) were used in the transcriptional 
analysis studies. 
2.3.9.1 RNA extraction from in vitro biofilms 
Biofilms were grown as described in 2.3.2 in 24 well flat-bottom plates for 4 h 
(early phase) and 24 h (mature phase) at 37°C. Following incubation, the 
supernatant was discarded and biofilms carefully washed with PBS. One millilitre 
of TRIzol™ solution (Invitrogen, Paisley, UK) was added to the wells containing 
pre-formed biofilms and a CytoOne™ cell scraper (STARLAB, Milton Keynes, UK) 
was used to remove the adherent biofilm from the plate. The resulting biomass 
was transferred to an O-ring screw-cap microcentrifuge tube (Stratech, 
Newmarket, UK) and approximately 250 μL of 0.5 mm diameter sterile glass 
microbeads (BioSpec, Bartlesville, Oklahoma, USA) were added to each tube and 
placed on ice. Cells within the TRIzol™ solution were mechanically disrupted in a 
Mini-Beadbeater (BioSpec, Bartlesville, Oklahoma, USA) for 3 cycles of 30 s. 
Samples were placed kept on ice in between each cycle and 100 μL of 1-bromo-3-
chloropropane (Sigma-Aldrich, Dorset, UK) was added to each sample before they 
were vortexed for 30 s. Samples were left at room temperature for 5 min, with 
occasional inversion, before centrifuged at 13,000 rpm for 15 min at 4°C 
(Heraeus,) and then placed on ice. The upper aqueous layer of each sample was 
transferred to a sterile microfuge tube and 500 μL of ice-cold isopropanol was 
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added in order to precipitate the RNA. The solution was placed at -20°C 
overnight to maximise the precipitation of RNA. 
Following overnight precipitation, all samples were centrifuged for 10 min at 
10,000 rpm at 4°C. The supernatant was discarded and the remaining pellet 
washed with 500 µL of ice cold 70% ethanol. Samples were inverted 40 times 
then centrifuged at 10,000 rpm for 5 min at 4°C. The ethanol was carefully 
removed and samples were air dried for 5 min.  The RNA was finally resuspended 
in 25 µL of RNase free distilled water and incubated at 65°C in a heat block 
(Techne, Staffordshire, UK) for 5 min to aid the recovery of RNA. 
2.3.9.2 DNase digestion of total RNA 
To ensure the extracted RNA was free from DNA contamination, a DNase 
digestion kit was used, as per manufacturer’s instructions (Qiagen Ltd, Crawley, 
West Sussex, UK).  Briefly, 10 μL of RDD buffer was mixed with 2.5 μL of DNase 
before being added to the extracted RNA. Finally 62.5 μL of RNase-free distilled 
water was added to the reaction to make a final volume of 100 μL and samples 
were incubated at room temperature for 10 min. 
2.3.9.3 RNA cleanup 
After the DNA digestion stage, RNA was then purified using the RNeasy MinElute 
CleanUp kit as per manufacturer’s instructions (Qiagen Ltd., Crawley, West 
Sussex, UK).  A solution containing 350 μL of RLT buffer and 250 μL of 100% 
ethanol were added to the RNA extract and mixed thoroughly by pipetting. The 
700 μL sample was then transferred to the RNeasy MinElute spin column within a 
2 mL collection tube and centrifuged for 15 s at 10,000 rpm. The flow-through 
was discarded and 500 μL of RPE buffer was added directly on to the column. 
Samples were centrifuged at 10,000 rpm for 15 s and the flow-through 
discarded.  To ensure there was no carry over, the column containing the RNA 
was transferred to a new 2 mL collection tube and centrifuged for 1 min at 
10,000 rpm. Finally, the column was then placed into a 1.5 mL microfuge tube 
and 50 μL of RNase free water was added directly onto the membrane before 
being centrifuged at 10,000 rpm for 1 min in order to release the RNA. To ensure 
the maximum RNA concentration was achieved, the eluted RNA was then passed 
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through the membrane once more at 10,000 rpm for a further minute. The 
purified RNA was now ready for quantification, as described in 2.3.8.2.  
2.3.9.4 cDNA synthesis from total RNA  
Two hundred nanograms of purified RNA was added to 4 μL of High-Capacity 
RNA-to-cDNA™ reverse transcription (RT) mastermix (Applied Biosystems, UK) 
within 0.2 mL dome-capped PCR microtubes (Abgene, ThermoFisher, Epsom, 
Surrey, UK), with a final volume of 20 μL made up using RNase free water. No RT 
controls were also included using a mastermix which did not contain the reverse 
transcriptase enzyme. Samples were briefly centrifuged to remove any air 
bubbles and loaded on to the thermal cycler (Bio-Rad, Hertfordshire, UK). The 
cycle conditions consisted of 5 min at 25°C, 30 min at 42°C, 5 min at 85°C and a 
final hold stage at 4°C. cDNA was then stored at -20°C until used in subsequent 
PCR. 
2.3.9.5 Analysis of real time PCR gene expression 
The Ct concept is the basis of quantification of real-time PCR using fluorescence-
based indicators, such as SYBR® GreenER™ (Invitrogen, Paisley, UK).  The total 
amount of product amplified gives a fluorescence value that is recordable 
throughout the cycled reaction. An inverse relationship exists between the 
amount of DNA template and the cycle number. A higher amount of template 
present at the beginning of the reaction, correlates to a lower number of cycles 
required to reach the threshold where the fluorescence measured is statistically 
greater than background readings (Gibson et al., 1996). This is defined as the 
cycle threshold (Ct) and is found during the exponential phase of amplification 
(Higuchi et al., 1993).  
2.3.9.6 Assessing gene expression using real time PCR 
The selected C. albicans clinical isolates with LBF and HBF were used in gene 
expression studies to determine any transcriptional differences between the 
biofilm subsets. Regulation of the genes of interest within the clinical samples, 
were all relative to the standard housekeeping gene ACT1. The same SYBR® 
GreenER™ mastermix and thermal profile described in 2.3.8.6 was used for all 
gene expression studies, with the addition of 1 μL of 200 ng/μL of cDNA. No RT 
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and no template controls (NTC) were also included. Each parameter (LBF n=10, 
HBF n=10 at 4 and 24 h) was analysed in duplicate. Expression of the genes of 
interest were normalised to the housekeeping ACT1 and relative expression 
quantified using the 2−ΔCt method (Livak and Schmittgen, 2001). 
2.3.9.7 Clustering and heat map analysis 
Differential expression of the selected genes from isolates with LBF and HBF 
were assessed by clustering and heat map analysis using GenEx software (Exiqon, 
Vedbaek, Denmark). The Ct values from qPCR experiments were pre-processed 
to obtain the percentage gene expression relative to the housekeeping gene 
ACT1 by ΔCt method. Percentage expression data was then log transformed and 
the mean values were used for heat map production. Each coloured cell in the 
heat map represents the variable expression of genes in LBF and HBF at 4 and 24 
h time points. An increase in gene expression is represented by red and a down-
regulation by green. Clustering techniques were used to show genes with similar 
expression patterns (co-regulated genes) in each set of isolates. The clustering 
was performed independently by average linkage and Euclidean distances used 
as a distance measure for both dimensions in the data. 
2.3.10 Statistical analysis 
Graph production, data distribution and statistical analysis were performed using 
GraphPad Prism (version 4; La Jolla, CA, USA). After assessing whether data 
conformed to a normal distribution data were transformed where necessary and 
One Way Analysis of Variance (ANOVA) was used to investigate significant 
differences between independent groups. A Bonferroni post-test was used to 
determine statistically significant differences between groups. The G. 
mellonella survival curve was analysed using log rank test. Student t-tests were 
used to measure statistical differences between the two independent groups 
assessed in gene expression studies. Statistical significance was achieved if 
p<0.05. IBM SPSS® (version 20) statistical analysis software was used for 
correlation analysis. Two-tailed Spearman rho correlation coefficient was 
determined separately for all 4 and 24 h selected genes expression versus 24 h 
biomass data. Genes that had a significant correlation with biomass were tested 
for correlations with the other genes as described above.  
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2.4 Results 
2.4.1 Growth conditions impact C. albicans biofilm formation 
First, to determine the most appropriate medium for biofilm evaluation, an 
initial optimisation study was undertaken using biomass quantification using two 
laboratory strains, SC5314 and 3153A (Figure 2.1).  
 
Figure 2.1 - Optimisation of C. albicans biofilms. 
C. albicans SC5314 and 3153A biofilms were grown for 24, 48 and 72 h in RPMI-1640, 
YPD + 10% FCS, YNB + 100mM glucose and Spider media. Three replicates for each 
isolate were used and carried out on two separate occasions. Data represents mean ± 
SEM. Significant differences were observed when comparing RPMI-1640 to all other 
growth media at 24 h (§§P<0.005, §§§P<0.0001), 48 h (#P<0.005, ###P<0.0001) and 72 h 
(†P<0.05, †††P<0.0001). Significant differences were also found between periods of 
biofilm development within each growth media, except RPMI-1640 (*P<0.05, **P<0.01). 
C. albicans biofilms were shown to differ greatly in their biomass depending on 
the media used. YNB + 100mM glucose was the least effective medium for 
biofilm growth, as biomass was 5.5 – 7-fold reduced at all time points when 
compared to biofilms grown in RPMI-1640 (p<0.0001). YPD + 10% FCS was the 
second poorest medium for developing biofilms as biomass was 2.7, 2 and 2.3-
fold less at 24, 48 and 72 h, respectively, than those developed in RPMI-1640 
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(p<0.0001). Finally, despite Spider medium being able to develop moderate 
biofilms, it was the only growth media where the age of biofilm development 
played a significant role in biomass. Biofilms grown in Spider medium for 48 h 
had 30% greater biomass than those grown for 24 h (p<0.05). Based on this data, 
RPMI-1640 was identified as the most appropriate growth medium for the 
development of C. albicans biofilms and was therefore used throughout the 
remainder of this study. 
2.4.2 C. albicans clinical isolates exhibit heterogeneous biofilm 
formation 
C. albicans bloodstream isolates displayed heterogeneity with respect to their 
biofilm biomass when grown in RPMI-1640 (Figure 2.2), the medium shown to 
support the optimal growth of C. albicans over various stages of biofilm 
development and allowed for hyphae development. 
 
Figure 2.2 - C. albicans clinical isolates form differential biofilms. 
Forty-two C. albicans bloodstream isolates were used to evaluate biofilm formation of 
strains derived from a clinical setting. Eight replicates were used for each isolate, which 
was carried out on two separate occasions, with the mean of each represented. C. 
albicans isolates with LBF (square), HBF (triangle) and IBF (circle) were defined by the 
upper and lower quartiles, as shown by CV stained biofilms. 
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Isolates were categorised with LBF or HBF if their biomass absorbance were less 
than the first quartile (Q1 OD570 = 0.565) or greater than the third quartile (Q3 
OD570 = 1.682), respectively. Those isolates in between the first and third 
quartile (Q1-Q3) were defined with intermediate biofilm formation (IBF). When 
HBF were stained with CV, the extent of the biofilm formation was observed 
macroscopically, where the bottom of the well was clearly covered with cellular 
biomass (Figure 2.2). In contrast, minimal staining was retained on isolates 
classed as LBF, as demonstrated by the well remaining almost colourless. 
Further confirmation of differences in biofilm biomass was then confirmed using 
dry weight measurements (Figure 2.3).   
     
Figure 2.3 – Dry weight is greater in C. albicans isolates with HBF. 
Biofilms were grown for 24 h and dry weight was measured for three C. albicans isolates 
with LBF and HBF, in triplicate on three separate occasions.  Data represents mean ± SD 
with significance **p<0.005. 
The dry weight of the C. albicans subsets were shown to differ significantly, 
where isolates with HBF had 2-fold greater compared to strains with LBF 
(p=0.0023), confirming our previous biomass observations. These differences are 
clearly evident when viewed under SEM (Figure 2.4).  
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Figure 2.4 – C. albicans clinical isolates have differences in morphology. 
A panel of C. albicans LBF (i, ii) and HBF (iii, iv) were grown on Thermanox coverslips 
for 24 h at 37°C. Note the abundance of hyphae in HBF as denoted by arrows, which is 
lacking in LBF. Scale bars represent 20 μm and 5 μm for 1000 × (i, iii) and 3000 × (ii, iv) 
magnifications, respectively. Representative images were taken from 10 independent 
fields and of three isolates with LBF and HBF. 
One obvious observation under microscopic viewing was the lack of hyphal cells 
in isolates with LBF (Figure 2.4i and ii), with biofilms mainly consisting of yeast 
cells. In contrast, C. albicans isolates with HBF were highly filamentous with a 
multi-dimensional structure with very few yeast cells (Figure 2.4iii and iv), 
illustrating a definite difference microscopically between these two biofilm 
subsets. These images confirmed our initial studies that identified differential 
biofilm formation existed between C. albicans clinical isolates at a phenotypic 
level. The next stage was to determine whether biofilm heterogeneity was 
simply related to defective growth (Figure 2.5).  
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Figure 2.5 – Variation in C. albicans biofilm formation is independent of 
growth kinetics. 
The growth kinetics of C. albicans isolates with LBF (grey circle) and HBF (black square) 
was assessed over 24 h, with absorbance read at 530 nm every hour. Isolates with LBF 
(n=10) and HBF (n=10) were grown in duplicate, on three separate occasions. Data 
represents mean ± SEM. 
Figure 2.5 shows no significant differences exist between C. albicans isolates 
with LBF and HBF at each time point (p>0.05). Therefore, variation in biofilm 
biomass in clinical strains is independent of their growth kinetics.  
2.4.3 Biofilm phenotype is affected by cell surface hydrophobicity 
The CSH of LBF and HBF isolates was quantified to determine whether it played 
a role in biofilm forming ability (Galan-Ladero et al., 2013). Figure 2.6 illustrates 
that hydrophobicity of an isolate significantly alters its ability to form a biofilm. 
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Figure 2.6 – CSH influences C. albicans biofilm formation. 
Ten C. albicans isolates with LBF and HBF were assessed for their CSH at various stages 
of biofilm development (i). A visual representation CSH was shown for planktonic LBF 
(ii) and HBF (iii), 4 h LBF (iv) and HBF (v) and 24 h LBF (vi) and HBF (vii). Note the 
cloudy upper layer denoted by arrows showing hydrophobic cells. Each isolate was 
measured on two independent occasions. Data represented mean ± SD. Significant 
differences between LBF and HBF were observed when 4 and 24 h biofilms were 
compared to their planktonic counterparts (*P<0.05, ***P<0.0001, ###P<0.0001). 
Furthermore, significant differences were found between 4 and 24 h in HBF 
(†††P<0.0001) and between LBF and HBF at 24 h (§§§P<0.0001). 
Figure 2.6i shows the cellular state of C. albicans significantly alters the 
hydrophobicity, as CSH increased in isolates with LBF by ~30% in 4 (p<0.05) and 
24 h (p<0.0005) biofilms, when compared to planktonic counterparts. This trend 
was also found in isolates with HBF where CSH increased by 50% in 4 h 
(p<0.0001) biofilms and 81% in 24 h (p<0.0001) biofilms, when compared to 
planktonic equivalents. Furthermore, CSH was significantly increased by 31% in 
isolates with HBF, when comparing 4 and 24 h biofilms (P<0.001). Of greater 
importance, differences in CSH between isolates with LBF and HBF were 
compared to determine if hydrophobicity influenced biofilm formation. Here it 
was shown that CSH increased significantly by 41% in isolates with HBF compared 
to those with LBF at 24 h (p<0.0001). However, no differences were observed at 
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planktonic (p=0.2162) or early biofilm stages (p=0.683) between isolates with 
LBF and HBF.  
Figure 2.6 ii-vii shows a visual representation of CSH in C. albicans isolates with 
LBF and HBF. Planktonic cells of LBF (ii) and HBF (iii) both had a relatively 
transparent upper layer, similar to 4 h biofilms in the LBF group (iv). However, it 
was shown at 4 h that isolates with HBF (v) had an opaque layer on top of the 
mixture, as indicated by arrows. Furthermore, 24 h biofilms of LBF (vi) and HBF 
(vii) both had a turbid opaque upper layer, which was more apparent in the HBF 
and corresponded to the level of CSH previously measured in Figure 2.6i.  
2.4.4 Antifungal activity is impacted by biofilm phenotype 
Planktonic and sessile antifungal susceptibility testing was undertaken on all C. 
albicans clinical isolates (n=42) using two polyenes (AmBi, AMB) and two 
echinocandins (CSP, MFG) to initially understand how active these agents were 
against clinical strains. Table 2.2 summarises these findings. 
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Table 2.2– Susceptibility of C. albicans clinical isolates to four antifungal agents 
Minimum Inhibitory Concentrations (MICs) 
 
 
n = 42 
AmBi (mg/L)
 
AMB (mg/L)
 
CSP (mg/L) MFG (mg/L) 
PMIC* SMIC 
80% 
PMIC SMIC 
80% 
PMIC SMIC 
80% 
PMIC SMIC 
80% 
Range** 0.125 – 
1 
0.5 –  
32 
0.25 –  
0.5 
0.25 – 
 32 
0.25 – 
 0.5 
0.125 – 
 >16 
<0.0156 – 
 0.0625 
1 –  
>16 
MIC50 0.5 8 0.5 4 0.25 >16 0.0313 >16 
MIC90 1 32 0.5 16 0.5 >16 0.0313 >16 
*PMIC = Planktonic minimum inhibitory concentration, SMIC = Sessile minimum inhibitory concentration 
**MIC range of all isolates  
SMIC80 = 80% inhibition of isolate 
MIC50/90 = % of isolates susceptible to the antifungal concentration 
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All planktonic C. albicans isolates tested were susceptible to all four antifungal 
agents where MFG was the most sensitive compound with MIC90 of 0.0313 mg/L 
for MFG, followed by CSP and AMB at 0.5 mg/L and AmBi at 1 mg/L (Table 2.2). 
When the sessile activity of each compound was compared only AmBi and AMB 
were effective at killing all C. albicans biofilms giving a MIC90 of 32 and 16 mg/L, 
respectively. In contrast, the echinocandin agents showed inferior activity 
against biofilms as the MIC50 for both compounds was >16 mg/L, a concentration 
substantially greater than what has been documented in the literature 
previously. Next, time kill analysis of sessile cells was performed on C. albicans 
isolates with LBF and HBF to determine if one group were more susceptible to 
treatment, using AMB which was the most effective antifungal overall (Figure 
2.7).  
 
 
Figure 2.7 – Amphotericin B sensitivity is significantly impacted by biofilm 
formation. 
Biofilms of ten isolates with LBF (circle) and HBF (square) were grown for 24 h and 
tested against AMB Each isolate was tested in duplicate, on three separate occasions 
with data represented by mean ± SEM. Viability as determined using the XTT assay. 
*p<0.05, **p<0.01, ***p<0.001. 
A dose-dependent effect was evident in all isolates tested with AMB (Figure 2.7). 
Moreover, a significant difference was observed between LBF and HBF treated 
with 0.25 – 32 mg/L AMB (p<0.05). LBF and HBF isolates both had a MIC50 of 0.25 
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mg/L AMB, yet isolates with LBF were significantly less viable than those with 
HBF at this concentration (p=0.0307). In addition, LBF isolates suffered an ~80% 
kill at a concentration of 4 mg/L, whereas HBF required 32 mg/L to reach the 
same kill.  
2.4.5 In vivo pathogenicity is affected by biofilm phenotype 
Next, the impact of the isolates ability to form biofilms based upon the severity 
of infection was analysed using a previously described G. mellonella model 
(Figure 2.8). Here isolates with LBF (n=3) and HBF (n=3) were compared to the 
reference strain SC5314.  
 
Figure 2.8– C. albicans with HBF significantly impacts mortality. 
Larvae of G. mellonella were infected with C. albicans isolates with LBF (n=3), HBF 
(n=3) or SC5314 and pathogenicity assessed using a Kaplan-Meier plot, with percentage 
survival monitored over 7 days. Three strains with LBF and HBF contained 10 larvae and 
was repeated on two independent occasions, with the mean of each group represented 
in the survival plot.  
The average rate of killing by HBF (n=3), LBF (n=3) and a reference strain 
(SC5314) of C. albicans were calculated to plot a survival curve (Figure 2.8). 
Survival data showed a significant difference in the killing of larvae between HBF 
and LBF (p<0.0001). After 2 and 6 days, respectively, >50% and 100% larval death 
was recorded for HBF isolates, whereas larvae infected with LBF only achieved 
20% killing after 7 days challenge. The reference strain SC5314 achieved 50% and 
100% larval death by day 4 and 7, respectively. Similar kill rates to that of HBF 
were observed in SC5314, however, when compared to LBF there was a 
significant difference in larval mortality (p=0.0005). Next, host-pathogen 
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interactions in this model were investigated by microscopically observing the 
morphology of the infected larvae at 24, 48 and 72 h post-infection with C. 
albicans HBF and LBF (Figure 2.9). 
 
Figure 2.9– C. albicans phenotype differentially impacts morbidity in vivo.  
Infected larvae were formalin fixed and sectioned for histology analysis. At 24 h, LBF 
(Feulgen staining, 20× original magnification (o.m.); inset: 4× o.m.) (i) and HBF (20× 
o.m.; inset: 10× o.m) (iv) were stained using Feulgen, whereas  48 h LBF (20× o.m.; 
inset: 10× o.m.) (ii) and HBF (40× o.m.; inset: 10× o.m.) (v) and 72 h LBF (20× o.m.; 
inset: 10× o.m.) (iii) and HBF (40× o.m.; inset: 10× o.m.) (vi) were stained using PAS. 
Images are representative of two isolates with LBF and HBF, repeated on two 
independent occasions. 
At 24 h in both the LBF (Figure 2.9i) and HBF (Figure 2.9iv) groups, the nodule 
formation and melanin deposition were mainly observed under the cuticle and in 
the fat body, with mild to strong melanisation observed in the centre of the 
nodules, together with the presence of yeast cells and/or hyphae. The LBF 
nodules were smaller in dimension and dispersed mainly in the sub-cuticle area 
(Figure 2.9i), whereas the HBF nodules had a stronger melanisation with the 
tendency to converge in large aggregates, and were localised more deeply within 
the fat body (Figure 2.9iv). At 48 h, the LBF were confined to the external part 
of the visceral organs, with a spot-like distribution (Figure 2.9ii), whereas the 
HBF were found to display a pronounced filamentation all around the intestinal 
wall, with a PAS positive matrix visible surrounding the hyphae (Figure 2.9v). 
Furthermore at 72 h, there was a substantial invasion of both the 
Ch.2 C. albicans biofilm heterogeneity is associated with resistance and pathogenicity 
 72 
gastrointestinal tract and the tracheal system with damaged gut epithelium, 
where yeast and hyphal cells both observed in the HBF infection (Figure 2.9vi). 
In contrast, a segmental invasion of the intestinal wall (Figure 2.9iii) was 
observed with LBF infection and the progression of the infection was to a lesser 
extent than that by the HBF. Moreover, Table 2.3 summarises the localisation 
and characterisation of the nodules with LBF and HBF infected larvae. Changes 
in the fat body morphology and composition including vacuolisation and 
haemocyte recruitment were detected during the course of the infection and 
were more evident in the HBF group. 
Table 2.3– Characteristics and localisation of nodules found in infected G. 
mellonella larvae 
 
 Nodules 
  
Size 
 
Melanisation 
 
Encapsulation 
 
Confluence 
Fungal 
morphology 
 
Localisation 
 Yeast Hyphae SC FB PI PT 
 
LBF 
 
 
Small 
 
+ 
 
+ 
 
- 
 
+++ 
 
+ 
 
+ 
 
+ 
 
++ 
 
- 
 
HBF 
 
 
Large 
 
++, +++ 
 
+++ 
 
+ 
 
+ 
 
+++ 
 
++ 
 
++ 
 
++
+ 
 
+ 
SC: subcuticle, FB: fat body, PI: paraintestinal, PT: paratracheal 
+ low, ++ medium, +++ high 
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2.4.6 Transcriptional heterogeneity is associated with biofilm 
phenotype 
Before C. albicans clinical isolates could be assessed at a transcriptional level for 
their expression differences of genes associated with biofilm formation, a range 
of primer sets designed in house had to be validated. 
2.4.6.1 C. albicans qPCR primer optimisation 
The primer sets designed in this study were shown to amplify the genes of 
interest at similar annealing temperatures, with a range of annealing 
temperatures for each primer set shown in Figure 2.10.  
 
Figure 2.10– Optimisation of C. albicans qPCR primers using gradient PCR.  
DNA extracted from C. albicans SC5314 was used to identify the most appropriate 
annealing temperature for each set of designed primers. Lane 1 contains 1000 bp 
hyperladder. Lanes 2-9 show the PCR products for annealing temperatures 63.0, 62.3, 
61.2, 59.4, 57.3, 55.7, 54.6 and 54°C, respectively. 
The aim was to identify an annealing temperature that was able to amplify all 
genes of interest equally. All PCR products were amplified at 60°C and therefore 
this was the annealing temperature selected for used in the remainder of the 
transcriptional studies.  In addition to optimising the annealing temperature for 
the genes of interest, amplification efficiencies for each primer set were 
calculated for qPCR (Table 2.4).  
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Table 2.4– Amplification efficiencies of primers designed for qPCR 
MNN4 Average 
Ct 
Log 
(dilution) 
 PMR1 Average 
Ct 
Log 
(dilution) 
400 ng/μL 19.96 2.6  400 ng/μL 18.18 2.6 
40 ng/μL 22.79 1.6  40 ng/μL 21.63 1.6 
4 ng/μL 26.19 0.6  4 ng/μL 25.46 0.6 
0.4 ng/μL 30.11 -0.4  0.4 ng/μL 29.18 -0.4 
0.04 ng/μL 33.58 -1.4  0.04 ng/μL 32.33 -1.4 
Slope  -3.457  Slope  -3.585 
% 
Efficiency 
 95%  % 
Efficiency 
 90% 
 
OCH1 Average 
Ct 
Log 
(dilution) 
 EFG1 Average 
Ct 
Log 
(dilution) 
    400 ng/μL 18.91 2.6 
40 ng/μL 24.56 1.6  40 ng/μL 22.08 1.6 
4 ng/μL 27.84 0.6  4 ng/μL 26.35 0.6 
0.4 ng/μL 34.12 -0.4  0.4 ng/μL 28.80 -0.4 
Slope  -3.211  Slope  -3.394 
% 
Efficiency 
 105%  % 
Efficiency 
 97% 
       
MNT2 Average 
Ct 
Log 
(dilution) 
 CPH1 Average 
Ct 
Log 
(dilution) 
400 ng/μL 18.16 2.6  400 ng/μL 18.57 2.6 
40 ng/μL 21.27 1.6  40 ng/μL 21.71 1.6 
4 ng/μL 25.50 0.6  4 ng/μL 25.49 0.6 
0.4 ng/μL 28.20 -0.4  0.4 ng/μL 28.47 -0.4 
Slope  -3.465  Slope  -3.348 
% 
Efficiency 
 94%  % 
Efficiency 
 99% 
       
EAP1 Average 
Ct 
Log 
(dilution) 
 BCR1 Average 
Ct 
Log 
(dilution) 
400 ng/μL 17.94 2.6  400 ng/μL 20.91 2.6 
40 ng/μL 20.95 1.6  40 ng/μL 23.56 1.6 
4 ng/μL 24.78 0.6  4 ng/μL 26.62 0.6 
0.4 ng/μL 27.54 -0.4  0.4 ng/μL 29.51 -0.4 
Slope  -3.262  Slope  -2.886 
% 
Efficiency 
 103%  % 
Efficiency 
 122% 
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Each DNA template was then amplified to determine the efficiency of the 
primers. Table 2.4 shows the average Ct and log Ct of each DNA template, which 
was used to calculate the slope of the line, and in turn the efficiency of each 
primer set. The lowest concentration of 0.04 ng/µL was not amplified for most 
of the primer sets including OCH1, EFG1, CPH1, EAP1, BCR1 and MNT2. In 
addition, the template did not amplify for OCH1 at the highest concentration 
(400 ng/µL). Therefore these samples were excluded from the efficiency 
analysis.  
2.4.6.2 Differential expression of genes associated with C. albicans biofilm 
formation  
C. albicans clinical isolates defined with LBF and HBF were further assessed at a 
transcriptional level and the expression of genes related to biofilm formation 
was investigated using 4 and 24 h biofilms. Percentage expression of all genes of 
interest normalised to ACT1 are shown in Figure 2.11 and Table 2.5. ACT1 was 
used as the housekeeping gene and was shown to be stably expressed throughout 
all biofilm conditions. 
 
Figure 2.11– Genes associated with C. albicans biofilm development are up-
regulated in HBF.  
Ten C. albicans isolates with LBF and HBF were grown as biofilms for 4 (i) and 24 h (ii). 
Percentage of gene expression is shown as log10 mean ± SD, relative to housekeeping 
gene ACT1. All strains were assessed in duplicate and included appropriate no RT and 
non-template controls. *p<0.05, **p<0.005. 
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Figure 2.11 illustrates the levels of gene expression of LBF versus HBF at both (i) 
4 and (ii) 24 h. Overall, the majority of the genes tested followed a trend of up-
regulation in HBF compared to LBF. However, statistically significant differences 
were only observed in the glycosylated mannoproteins MNN4 (p=0.0313) and 
MNT2 (p=0.0044) at 4 h, where expression was increased by ~2 fold.  
Furthermore, the resistance gene CDR1 was significantly increased in HBF by 4- 
and 6-fold at 4 h (p=0.0113) and 24 h (p=0.0239), respectively. Clustering the 
expression of 23 selected genes from 5 different functional groups in a heat map 
showed their relationship with one another and their variable expression in LBF 
and HBF over time (Figure 2.12).  
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Figure 2.12– Clustering analysis identified the transcriptional relationship of 
biofilm specific genes.  
Percentage expression of each gene was also assessed by clustering and heat map 
analysis using GenEx software. Data was log transformed and mean values were used for 
heat map construction. Increased expression of genes is shown by red and a decrease is 
represented by green. 
Here, it was found that the expression of the adhesion genes ALS3 and HWP1 
were closely related, particularly in HBF isolates at 4 and 24 h. Furthermore, 
genes from different functional groups were closely related to one another 
irrespective of whether LBF or HBF, such as the proteinase SAP5 and the 
adhesion genes ALS5 and EAP1. The remaining SAP genes were all closely related 
to one another, and interestingly the resistance gene MDR1 and the cell wall 
mannoprotein OCH1. Further analysis of SAP3 showed an increase in 
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transcription within LBF at 24 h, despite no differences being observed at 4 h. In 
contrast, SAP5 expression was consistently high at 4 and 24 h within HBF. 
Analysis of Spearman rho coefficients identified that out of 23 selected genes, 7 
genes, including those related to adhesion (ALS3, EAP1), filamentation (CPH1), 
hydrolytic enzymes (SAP5, PLB1) and resistance (CDR1, ZAP1) showed a 
significant positive correlation (p<0.05) with biomass data at 4 h (Table 2.6). 
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Table 2.5- C. albicans biomass correlates with biofilm gene expression at 4 h 
 
 
 
4h Correlationsa ALS3 EAP1 CPH1 SAP5 PLB1 CDR1 ZAP1 
CV Rho= .529* .608** .534* .539* .483* .647** .515* 
  p = 
.029 .010 .027 .026 .050 .005 .035 
ALS1 Rho= .240 .529* .542* .336 .608** .382 .250 
  p = .353 .029 .025 .188 .010 .130 .333 
ALS3 Rho= 1.000 .385 .708** .544* .593* .779** .365 
  p =   .127 .001 .024 .012 .000 .149 
ALS5 Rho= .229 .538* .644** .607** .681** .145 .214 
  p = .378 .026 .005 .010 .003 .579 .410 
EAP1 Rho= .385 1.000 .544* .490* .860** .537* .279 
  p = .127   .024 .046 .000 .026 .277 
HWP1 Rho= .868** .338 .821** .571* .532* .615** .201 
  p = .000 .184 .000 .017 .028 .009 .439 
MNN4 Rho= .350 .554* .645** .537* .672** .493* .309 
  p = .168 .021 .005 .026 .003 .045 .228 
PMR1 Rho= .333 .635** .527* .534* .784** .233 .377 
  p = .191 .006 .030 .027 .000 .368 .135 
BCR1 Rho= .262 .250 .539* .566* .485* .306 .522* 
  p = .309 .333 .026 .018 .048 .232 .032 
CPH1 Rho= .708** .544* 1.000 .833** .748** .547* .321 
  p = .001 .024   .000 .001 .023 .209 
EFG1 Rho= .257 .520* .576* .645** .605* .409 .392 
  p = .319 .033 .016 .005 .010 .103 .119 
TUP1 Rho= .713** .397 .397 .463 .544* .684** .444 
  p = .001 .115 .115 .061 .024 .002 .074 
SAP1 Rho= .356 .523* .794** .744** .730** .251 .413 
  p = .160 .031 .000 .001 .001 .332 .100 
SAP2 Rho= .091 .554* .478 .417 .654** .172 .292 
  p = .729 .021 .052 .096 .004 .510 .256 
SAP5 Rho= .544* .490* .833** 1.000 .676** .395 .539* 
  p = .024 .046 .000   .003 .117 .026 
SAP6 Rho= .371 .772** .637** .627** .869** .320 .284 
  p = .143 .000 .006 .007 .000 .211 .269 
PLB1 Rho= .593* .860** .748** .676** 1.000 .532* .434 
  p = .012 .000 .001 .003   .028 .082 
CDR1 Rho= .779** .537* .547* .395 .532* 1.000 .262 
  p = .000 .026 .023 .117 .028   .309 
ZAP1 Rho= .365 .279 .321 .539* .434 .262 1.000 
  p = .149 .277 .209 .026 .082 .309   
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*Correlation is significant at the 0.05 level (2-tailed),  
** Correlation is significant at the 0.01 level (2-tailed).     
a. List wise N = 17 
Further analysis of the relationship between these seven genes and all the other 
genes tested presented various correlations (marked bold in Table 2.6). For 
example, PLB1 was significantly correlated with all other genes tested (94.11%) 
except ZAP1, followed by CPH1 (76.47%), SAP5 (76.47%), EAP1 (64.71%), CDR1 
(41.17%), ALS3 (35.29%) and ZAP1 (11.76%).  Correlation of individual genes with 
one another at the 4 h time point showed that PLB1, CPH1, MNN4 and HWP1 all 
correlated with 5 of the 7 key genes defined above. Notably, 24 h gene 
expression revealed very few significant correlations other than CV (Table 2.7). 
In fact, a significant negative correlation was found between SAP3 and the 
biomass data (Rho = -0.465, p=0.045). Furthermore, SAP3 was positively 
correlated with MNT2 (Rho = 0.468, p=0.043) and Sap4 (Rho = 0.460, p=0.048). 
Table 2.6- C. albicans biomass correlates with biofilm gene expression at 24 
h  
     
24 h 
Correlationsb 
SAP3 
    
    
  
  
CV Rho= .465*      
  
  p = 0.045           
  
MNT2 Rho= .468*      
  
  p = 0.043           
  
SAP4 Rho= .460*      
  
  p = 0.048           
  
* Correlation is significant at the 0.05 level (2-tailed),  
** Correlation is significant at the 0.01 level (2-tailed).     
b. List wise N = 19 
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2.5 Discussion 
The presence of medical devices, such as central venous catheters (CVCs), are 
known to be important risk factors for developing candidaemia (Gamaletsou et 
al., 2014), suggesting that biofilm formation plays a critical role. The past 
decade has seen a significant leap in our knowledge and understanding of the 
biology of C. albicans biofilms, particularly with respect to the molecular basis 
of their development and homeostasis (Blankenship and Mitchell, 2006). 
However, in the clinical setting it is generally assumed that all C. albicans 
isolates have the capacity to form biofilms, but often with little regard to 
individual differences within the species when managing the infection. Here it 
was demonstrated that C. albicans display heterogeneous biofilm characteristics, 
and these strain differences have important implications with respect to 
treatment and pathogenicity. 
Previous studies have reported very defined categories in their analysis of 
association with clinical outcomes, i.e. biofilm formers and non-biofilm formers 
(Tumbarello et al., 2012, Tumbarello et al., 2007). However, these important 
studies fail to take into account the heterogeneous nature of individual clinical 
isolates forming biofilms, which based on their metabolic XTT values can range 
from 0.125 to 1.358 (Tumbarello et al., 2012). When looking for clinical 
correlations with these phenotypes important information can be missed, as the 
isolates at either end of the biofilm forming spectrum may lead to different 
clinical outcomes. For example, use of the XTT metabolic assay as quantitative 
measure of biomass has been shown to have pitfalls (Alnuaimi et al., 2013, Kuhn 
et al., 2003, Kuhn et al., 2002a). Kuhn and colleagues explored the limitations of 
this assay and demonstrated that although it could be used for analysing and 
comparing parameters of an individual strain, Candida spp. clinical isolates can 
differentially metabolise XTT and therefore and it cannot be assumed that the 
colorimetric signal produced is correlated with cell number (Kuhn et al., 2003). 
Moreover, the authors previously demonstrated non-invasive Candida strains had 
increased XTT activity when compared to invasive isolates and that significant 
differences were observed between XTT activity and dry weight (DW) 
measurements, concluding techniques that measure direct biomass instead of 
metabolic activity are more appropriate for comparing strains to one another 
(Kuhn et al., 2002a). It was hypothesised that isolates could shift their 
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metabolism away from routine functions and those with LBF could in fact have 
increased metabolic activity. Therefore, careful consideration must be taken 
with the conclusions drawn from studies using reference strains, as these may 
not relate directly to the observations founds in vivo with regards to biofilm 
formation.  
Another technique that could potentially be used to determine biofilm biomass 
is SYTO® 9, a nucleic acid stain shown previously to quantify both bacterial and 
fungal cells (Honraet et al., 2005, Peeters et al., 2008, Jin et al., 2005), 
however, due to cost limitations this assay is not suitable for large scale 
screening of isolates. In this current study, CV was selected as the method to 
determine C. albicans biofilm formation, as this stain was shown to have high 
reproducibility and is relatively inexpensive and straightforward to use, as has 
been described elsewhere (Peeters et al., 2008). Although this assay was able to 
distinguish groups with LBF and HBF, its sensitivity between strains of similar 
biofilm forming ability is limited. 
Initially, biofilms were categorised grown in RPMI using a biomass stain (Jose et 
al., 2010) and confirmed by  dry weight analysis, which differentiated clinical 
isolates into defined groupings. This approach was used in preference to 
metabolic assays due to the highly variable nature of XTT from strain to strain 
(Tumbarello et al., 2012). Moreover, the usefulness of the XTT assay is limited to 
antifungal drug testing of biofilms (Nett et al., 2011a, Pierce et al., 2008). This 
classification made in this study, based initially on biomass, was supported by 
observations on a macro- and microscopic level where it was clear that 
numerous cells consisting of hyphae and yeasts were visible in HBF, whereas 
scant layers of yeast cells were observed for LBF. Growth kinetics was performed 
and excluded isolate growth rate from being responsible for variation in biofilm 
formation. CSH was also investigated as an additional biofilm promoting feature, 
as previous studies have also shown a link between biofilm biomass and CSH 
(Blanco et al., 2010, Galan-Ladero et al., 2013). This study confirms that CSH 
impacts different phases of biofilm development, which is in agreement with 
previous work where it was shown that cells dispersed from mature biofilms 
were more hydrophobic than those dispersed from earlier stages of biofilm 
development (Bujdáková et al., 2013). Furthermore, it has been shown 
hydrophobic cells are more adherent (Perez et al., 2011), and therefore it is 
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unsurprising that CSH was increased in HBF isolates. Based on this overall 
approach to biofilm categorisation there is confidence in the phenotypes 
selected for further detailed analysis. It is however conceded that there are 
caveats to defining levels of biofilm, and this requires further work and 
collaboration between groups to establish a standardised method.  
One of the key defining features of C. albicans biofilms is their insensitivity to 
sterol active antifungal agents (Ramage et al., 2012c). Notably, AMB was less 
effective against HBF biofilms than LBF, which was hypothesised due to the 
inability of the compound to permeate easily throughout the dense physical 
structure of the cells encased within ECM (Nett et al., 2010a). AZL were not 
used in the study due to their resistance towards C. albicans biofilms. Moreover, 
ECN were purposely excluded from this study as these have been shown to be an 
effective anti-biofilm antifungals, therefore quantifying differences in activity 
against the two populations would be difficult (Bachmann et al., 2002). 
Moreover, due to their paradoxical effect, then these would not be appropriate 
to identify subtle differences in antifungal activity (Stevens et al., 2005, 
Walraven et al., 2014). The observations from this study may have implications 
to whether a patient responds to antifungal therapy, as Tumbarello and 
colleagues (2012) demonstrated that inadequate antifungal therapy (azoles) and 
the presence of an indwelling venous catheter were key predictors of patient 
mortality and hospital length of stay in patients infected with biofilm forming 
isolates (Tumbarello et al., 2007). Guidelines have also suggested that removal 
of the catheter is an important factor in improving clinical outcomes, again 
supporting the notion that biofilm formation has a crucial role in clinical 
outcomes (Andes et al., 2012, Cornely et al., 2012). Given the importance of 
these infections, efficient and appropriate treatment in candidaemia cases has 
been highlighted (Almirante et al., 2005, Garey et al., 2006), as failure to treat 
quickly and effectively has profound consequences on mortality statistics (Kollef 
et al., 2012).  
To this end the pathogenicity of clinical isolates capable of forming robust 
biofilms was investigated in comparison to non-biofilm forming isolates, which 
was hypothesised as a potential reason for their apparent role in infections with 
increased mortality (Tumbarello et al., 2012). Previous experimental work has 
shown that cells dispersed from biofilms are more cytotoxic and more rapidly 
Ch. 2 C. albicans biofilm heterogeneity is associated with resistance and pathogenicity 
 100 
lethal in murine models than the equivalent planktonic cells (Uppuluri et al., 
2010). Using a G. mellonella model it was shown that HBF isolates caused 
significantly greater mortality rates than LBF isolates, a finding supported 
elsewhere (Cirasola et al., 2013). In addition, it was previously reported that the 
virulence of C. albicans isolates was shown to vary with the levels of biofilm 
formation, and that mice infected with a LBF had increased survival rates 
compared to isolates that were infected with HBF (Hasan et al., 2009). 
Furthermore, strains known to be more virulent have been shown to contribute 
to disease severity and induce greater inflammatory responses in vivo, thought 
to be more damaging towards the host than protective (MacCallum et al., 
2009a). Histological analysis of the infected larvae displayed similar cell 
morphology of yeast and filamentous hyphae as observed in SEM images of LBF 
and HBF, respectively. This is in agreement with a previous study that showed 
filamentation plays a role in killing G. mellonella larvae (Fuchs et al., 2010). A 
number of animal models are currently used to assess the virulence of Candida, 
with mouse and rat models being the most popular choice for both mucosal and 
invasive infections (Maccallum, 2012, Nett et al., 2010b, Rahman et al., 2007). 
Therefore, it would be ideal to utilise such models for assessing the impact of 
isolates with LBF and HBF in vivo.  
Filamentous growth is a characteristic feature of C. albicans biofilm formation. 
Defective hyphal formation through deletion of EFG1 has been shown to lead to 
low levels of biofilm growth (Ramage et al., 2002d). Given the growing 
knowledge of key biofilm related genes it was decided to investigate 
transcriptional changes to determine whether these are truly represented 
amongst clinical isolates, and therefore could be used as a more robust way to 
categorise biofilm formation and as potential diagnostic targets of HBF isolates. 
ACT1, the stably expressed housekeeping gene, as reported elsewhere (Lepak et 
al., 2006, Nailis et al., 2006, Nett et al., 2009), enabled these relative 
comparisons. Regulation of biofilm related genes were shown to influence an 
isolates biomass within clinical isolates, echoing work carried out by other 
groups (Nailis et al., 2010a, Uppuluri et al., 2009b). Cluster analysis of the 
selected biofilm related genes showed a good association with functional classes 
of genes, such as adhesins and proteinases, suggesting that both LBF and HBF 
had conserved pathways in the basic developmental phases of biofilm growth. 
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However, individual gene expression profiles were inconclusive, showing very 
few clear independent significant differences, though gene expression proved 
interesting at 4 h. The overall biomass at 24 h was investigated and examined 
how 4 h gene expression related to this. Overall HWP1 was the most highly 
regulated at this time point in both LBF and HBF, as has been shown elsewhere 
(Nailis et al., 2010a), though no significant differences between the populations 
were observed. Seven other genes were however shown to have significant 
positive correlations with biomass. The most significant was CDR1, which was 
unsurprising as it has been shown to be transiently expressed in different biofilm 
studies, though does not correspond directly to antifungal resistance (Mukherjee 
et al., 2003, Ramage et al., 2002a). PLB1 was shown to be significantly 
correlated with another 16 genes including biomass, though expression appeared 
constitutively low within the biofilm, which is agreement with previous studies 
(Nailis et al., 2010a), and may have an accessory role in the degradation of host 
tissue alongside SAPs. Of these, SAP5 was shown to be highly expressed in 
mature biofilms, and correlated with biomass and 13 other genes. It was 
previously reported that SAP5 was associated with higher levels of expression in 
in vitro biofilms formed from denture stomatitis C. albicans isolates (Ramage et 
al., 2012a). In addition, Nailis and colleagues (2010) demonstrated its crucial 
role both in a reconstituted human epithelial model and within in vivo biofilms 
(Nailis et al., 2010a). Furthermore, the role of SAP5 in biofilm formation has 
recently been demonstrated in BSI, where its expression was significantly 
increased when compared to planktonic counterparts (Joo et al., 2013). 
Adhesins, such as ALS3, were also up-regulated, which has previously been 
identified to be involved in biofilm formation, particularly at early stages of 
biofilm development (0-6 h) (Nailis et al., 2009, Zhao et al., 2006), where C. 
albicans mutants lacking this gene produce sparse biofilms on catheter material 
in vitro (Liu and Filler, 2011). EAP1, though showing no clear independent 
association with biofilm formation per se, did show a clear correlation with 
biomass and 11 other genes. Its importance in biofilm formation has been 
reported previously (Li et al., 2007). Of interest was the positive correlation 
with ZAP1 expression at 4 h, which is a negative regulator of matrix production 
(Nobile et al., 2009). It did positively correlate with BCR1, the global regulator 
of biofilm formation, suggesting that the early interaction between their 
proteins may be important for downstream construction of the biofilm. 
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Collectively the data highlighted the importance of looking at multiple genes 
simultaneously opposed to single gene targets. 
Overall, this study has categorised isolates based on biological properties 
relating to biofilm characteristics, and evaluated these in models of infection 
and treatment, where clear differences in virulence have been shown. In an 
attempt to create a molecular basis of categorising these strains, gene 
expression studies have shown that individual gene expression analysis of the 
biofilm related genes to differentiate and categorise biofilm-forming isolates 
might be futile. Instead, it has been shown here that taking a defined panel of 
genes during early biofilm growth may be more informative. In particular, the 
panel of genes such as SAP5, HWP1, EAP1, PLB1 and CDR1 investigated in tandem 
could constitute an important step towards diagnostics of C. albicans biofilm 
formation, though the use of transcriptomics, such as RNA-Seq, may prove useful 
in identifying novel diagnostic targets. Further work is required to determine 
why some patients succumb to C. albicans biofilms whereas others do not, as the 
HBF isolates do have an increased pathogenic potential and are more difficult to 
manage with antifungal agents. Understanding the mechanism underlying these 
differences would be an important step to improving the clinical management of 
these patients. 
 
CHAPTER FINDINGS 
The phenotype of C. albicans isolates varies greatly within the clinical setting.  
Isolates with HBF have increased pathogenicity and are less susceptible to 
antifungal therapy. 
Transcriptional analysis of individual biofilm-specific genes was inconclusive at 
grouping these organisms, though strong correlation with several of these was 
observed with respect to biomass. 
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3.1 Introduction 
The mechanism of biofilm formation by C. albicans is complex and 
multifactorial, yet is not fully understood. Previous studies have tended to focus 
primarily on molecular mechanisms through characterised laboratory strains. 
This, however, bears no resemblance to the clinical heterogeneity that exists in 
patient cohorts. One of the pivotal characteristics of fungal biofilms is the 
extracellular matrix (ECM), which provides a structural scaffold and protection 
for biofilm cells from hostile factors, including antifungal agents (Flemming and 
Wingender, 2010, Ramage et al., 2012c). Typically the ECM consists of 
exopolysaccharides, proteins, surfactants, lipids and water (Al-Fattani and 
Douglas, 2006, Martins et al., 2010). Recent studies showed another important 
component of a fungal biofilm matrix is extracellular DNA (eDNA) (Martins, et 
al., 2010, Rajendran et al., 2013). These studies demonstrated the role of eDNA 
in fungal biofilm formation and antifungal susceptibility. In both C. albicans and 
A. fumigatus it was shown that addition of eDNA significantly improved biofilm 
formation, and depletion of biofilm eDNA adversely affects the overall biomass. 
Moreover, bacterial biofilm studies have suggested that eDNA has a 
multifactorial purpose, as a nutrient source (Mulcahy et al., 2010), facilitator of 
genetic information exchange (Molin and Tolker-Nielsen, 2003), contributor to 
biofilm stability and dispersal (Whitchurch et al., 2002, Izano et al., 2008, 
Allesen-Holm et al., 2006, Berne et al., 2010), and as an antimicrobial resistance 
factor (Mulcahy et al., 2008, Tetz et al., 2009).  
The mechanism of eDNA release from biofilms is not yet fully understood. Work 
in bacterial cells has suggested various mechanisms potentially responsible for 
eDNA release, including cell lysis (Allesen-Holm et al., 2006, Qin et al., 2007). In 
a recent study by our group it was demonstrated that the chitinase regulated 
autolytic pathway was associated with eDNA release in A. fumigatus (Rajendran 
et al., 2013).  To date chitinase activity with respect to eDNA release in C. 
albicans biofilms has yet to be demonstrated.  
 
  
Ch. 3 Investigating mechanisms of C. albicans biofilm formation 
 105 
3.2 Aims 
It is hypothesised that variation in C. albicans biofilm formation is due to the 
release of eDNA through chitinase activity. Therefore the aim of this study was 
to evaluate and quantify eDNA within C. albicans isolates with variable biofilm 
formation. Chitinase activity was assessed to determine if these contribute to 
the presence of eDNA within C. albicans biofilms. Moreover, inhibitors of eDNA 
and chitinases were used to determine if these have an impact on antifungal 
therapy.   
 
Data presented in this chapter has been submitted and is under review for 
publication in: 
Rajendran R, Sherry L, Williams C, Munro C and Ramage G. 2014. Extracellular 
DNA confers variation to C. albicans biofilm formation. BMC Microbiology. 
 
Work from this chapter has been presented orally at the following conference: 
Rajendran R, Sherry L, Williams C, Munro C and Ramage G. ‘Strain dependent 
extracellular DNA release affects Candida albicans biofilm formation and 
antifungal sensitivity.’ OMIG, Gregynog, UK. April 2014. 
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3.3 Materials and Methods 
3.3.1 Culture conditions and standardisation 
A number of clinical BSI previously identified and characterised as LBF (n=3 
[27915, 50348, 74174]) and HBF (n=3 [9629, 28158, 34106]) were processed for 
biofilm assessment as described in section 2.3.2.1. These representative isolates 
were selected as those strains with the absolute lowest and highest biofilm 
formation of those tested. In addition, C. albicans SC5314 and chitinase mutants 
cht2Δ (DSY1768), cht3Δ (SPY24), cht2/3Δ (DSY1741), including the parental 
strain CAI4 (ura3::λimm434/ura3::λimm434) transformed with CIp10, (gifted by 
Dr Carol Munro, [Aberdeen Fungal Group]), were used throughout this study 
(Selvaggini et al., 2004). Isolates were sub-cultured on to SAB agar and 
incubated at 30°C for 48 h and stored at 4°C. Overnight broths of all C. albicans 
strains were prepared in YPD and incubated with orbital shaking at 30°C with 
150 rpm for 18 h, as described previously in 2.3.1.2. Cells were then 
standardised to the appropriate concentration in RPMI-1640 unless otherwise 
stated (Ramage et al, 2001).  
3.3.2 Growth kinetics  
The growth kinetics of C. albicans isolates with LBF (n=3) and HBF (n=3) were 
assessed to determine if growth rate played a role in eDNA release. Each isolate 
was standardised to 1 × 104 cells/mL in YPD with 200 μL added to each well of a 
96 well round-bottom plate. Plates were incubated at 37°C for 24 h and 
absorbance was measured at 530 nm every 1 h, as described in 2.3.4. Each 
isolate was tested in duplicate and repeated on three independent occasions. 
Negative controls containing no C. albicans were included for background 
correction.  
3.3.3 DNase treatment on preformed biofilms 
The role of eDNA in C. albicans biofilm formation was first investigated by 
depletion of eDNA within the biofilm using a hydrolytic enzyme DNase I.  DNase I 
from bovine pancreas (Sigma-Aldrich) was prepared in 0.15 M NaCl supplemented 
with 5 mM of MgCl2 to a final concentration of 256 μg/mL. Biofilms of HBF (n=3) 
and LBF (n=3) isolates were grown in RPMI-1640 as described previously. 
Following incubation, biofilms were washed with PBS and treated with 256 
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μg/mL of DNase I (Sigma-Aldrich) for 24 h at 37°C, a concentration previously 
shown to decrease fungal bioﬁlm biomass (Martins et al., 2010, Rajendran et al., 
2013). Untreated controls were also included for direct comparison. Biofilms 
were then washed twice with PBS and the biomass was scraped from the surface 
and passed through 0.22 μM membrane filters. Biofilms retained on the filters 
were dried overnight at 60°C and then dry weight measurements were taken for 
each isolate, as described previously (Richard et al., 2005). Measurement of 
each isolate was carried out in duplicate, on three independent occasions.  
3.3.4 Assessment of eDNA release 
C. albicans isolates with LBF (n=3), HBF (n=3), CAI4, and chitinase mutants 
cht2Δ, cht3Δ, cht2/3Δ biofilms were grown in RPMI-1640 for 4 and 24 h at 37°C 
as described previously in 2.3.2. The quantity of eDNA release was measured 
using a microplate fluorescence assay (MFA) using a DNA binding dye (SYBR® 
Green I), as previously described (Rajendran et al., 2013). Briefly, SYBR® Green I 
(Invitrogen) was added to biofilm supernatants in a black well microtitre plate 
(Costar3603; Corning) at a ratio of 1:4. Binding of this dye produces fluorescence 
directly proportional to DNA concentration. The levels of eDNA were quantified 
using a fluorescence plate reader (Fluostar Optima; BMG Labtech) at 485 and 
518 nm, respectively. The concentration of eDNA in the sample was quantified 
using the DNA standard curve as previously described (Leggate et al., 2006). In 
addition, optical density of the culture was measured at 530 nm simultaneously 
for normalising the relative fluorescence units (RFU) data.  Each isolate was 
tested in duplicate, on three separate occasions. 
3.3.5 Fluorescence microscopy 
C. albicans CAI4, cht2Δ, cht3Δ, cht2/3Δ, cells were standardised to 1 × 106 
cells/mL in RPMI-1640 medium and biofilms were grown on Thermanox™ 
coverslips within a 24 well plate at  37°C for 24 h. Following biofilm 
development, cells were gently washed with PBS and stained with 5 μM 
calcofluor white ([CFW] Invitrogen), which binds chitin of C. albcians cell walls, 
and with 20 μM propidium iodide (PI) (Sigma), which stains the DNA present 
within a biofilm, according to the manufacturer’s instructions. Biofilm growth 
and accumulation of eDNA was visualised under a fluorescence microscope 
(Motic BA400 Colorview system) at Ex350/Em400 for CFW and Ex540/Em525 for PI. 
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Representative images from 10 fields were taken and one from each group was 
digitally photographed.  
3.3.6 Quantification of chitinase activity 
Previously it has been shown that chitinase activity was an autolytic marker in 
the investigation behind the mechanism of eDNA release (Rajendran et al., 
2013). Therefore, C. albicans chitinase activity from isolates with LBF (n=3) and 
HBF (n=3) was assessed after 4 and 24 h of biofilm formation using a 
fluorometric chitinase assay kit (Sigma, United Kingdom), as per the 
manufacturer's instructions. Following biofilm development, supernatants were 
collected at 4 and 24 h, and an appropriate volume of each sample was 
incubated with a substrate working solution (4-methylumbelliferyl N-acetyl-β-d-
glucosaminide) at 37°C for 30 min. Fluorescence was then quantified at 
Ex360/Em450. Appropriate positive and negative controls included in the kit were 
added to each plate.  Chitinase activity was calculated and expressed as a ratio 
between chitinase units and optical density of culture (U/OD). Each isolate was 
measured in duplicate, on three separate occasions. 
3.3.7 Quantitative gene expression  
C. albicans isolates with LBF (n=3) and HBF (n=3) biofilms were grown in 24 well 
plates as described in 2.3.2 for 4 and 24 h at 37°C. Quantitative analysis of 
transcriptional changes within these biofilms was performed as previously 
described in 2.3.9.1 (Ramage et al., 2012a). Briefly, RNA was extracted by 
mechanical disruption in TRIzol (Invitrogen) and purified using an RNeasy 
MinElute cleanup kit (Qiagen, Crawley, United Kingdom) as per the 
manufacturer's instructions. RNA was quantified and its quality determined using 
a NanoDrop spectrophotometer (ND-1000; Thermo Scientific, Loughborough, 
United Kingdom). cDNA was synthesised with a High-Capacity RNA-to-cDNA kit 
(Applied Biosystems) using a MyCycler PCR machine (Bio-Rad, Hertfordshire, 
United Kingdom), and was stored at −20°C until required for transcriptional 
analysis. The expression of the chitinase genes CHT2 and CHT3 and hyphal cell 
markers HWP1 and ALS3 were then assessed using qPCR with SYBR® GreenER™ 
(Invitrogen), according to the manufacturer's instructions. Primer sequences for 
these genes are shown in Table 3.1 and PCR cycling conditions are described in 
2.3.8.6. The individual gene expression levels were then calculated using the 
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2−ΔCT method for different phases and normalised to the ACT1 housekeeping 
gene. All isolates were tested in duplicate for this experiment. 
Table 3.1 - C. albicans primers used for qPCR 
Gene Sequence (5' - 3') Function 
ALS3 F - CAACTTGGGTTATTGAAACAAAAACA 
R - AGAAACAGAAACCCAAGAACAACCT 
Adhesin 
HWP1 F - GCTCAACTTATTGCTATCGCTTATTACA 
R - GACCGTCTACCTGTGGGACAGT 
Hyphal wall protein 
CHT2 F – TGATTTATTATCCAAAGTCCCACTTG 
R – TTGAATTGGCCATTGATTGAA 
Chitinase 
CHT3 F - TGCTACTATTCCAGATGACAAAGAAATT 
R - TTCAGTGATGATAGCAGGTGGTTT 
Chitinase 
ACT1 F - AAGAATTGATTTGGCTGGTAGAGA 
R - TGGCAGAAGATTGAGAAGAAGTTT 
Housekeeping  
 
3.3.8 Scanning electron microscopy 
C. albicans single (cht2Δ, cht3Δ) and double knockout (cht2/3Δ) chitinase 
mutants and their parental strain CAI4 were standardised and grown as biofilm in 
RPMI-1640 directly onto Thermanox coverslips (Nunc, Roskilde, Denmark) for 
24 h. Following biofilm development, biofilms were carefully washed with PBS 
and prepared for SEM as described in 2.3.3. Images were assembled using 
Photoshop software (Adobe, San Jose, CA, USA) at magnification ×1000. 
3.3.9 Antifungal susceptibility testing  
The impact of eDNA and chitinases on AMB sensitivity was assessed using a 
hydrolytic enzyme DNase I and a chitinase inhibitor acetazolamide ([AZE] Sigma-
Aldrich). AMB was chosen C. albicans isolates with LBF (n=3), HBF (n=3) and the 
control strain SC5314 were standardised to 1 × 106 cells/mL in RPMI-1640 and 
biofilms grown in 96 well flat-bottom plates for 4 and 24 h. Preformed biofilms 
were washed with PBS and treated with serially diluted AMB ± DNase (256 
μg/mL) or AZE (256 μg/mL). Biofilms were incubated for a further 24 h at 37°C 
before metabolic activity assessed using the XTT assay, as previously described 
(Pierce et al., 2008). 
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3.3.10 RNA Seq 
One C. albicans clinical isolate with LBF and HBF were standardised to 1 × 106 
cells/mL in RPMI-1640 and biofilms grown in 75 cm2 tissue culture flasks for 24 h 
at 37°C. Following development, biofilms were gently washed with PBS before a 
cell scraper was used to dislodge the biomass and RNA extracted as previously 
described in 2.3.9.1. The integrity of the RNA was assessed using an agarose gel 
to visualise the two distinct rRNA bands. Each isolate was grown in triplicate and 
a minimum of 10 μg of total RNA was submitted for each sample and sent for 
sequencing to The GenePool (Edinburgh, UK). RNA integrity was assessed using a 
Bioanalyzer where an RIN value >7.0 was deemed acceptable for RNA Seq using 
Illumina 50 base sequencing.  
Bioinformatics analysis included the raw read alignment to version A21-s02-m01-
r27 of C. albicans SC5314 using version 2013-05-09 of a genomic mapping and 
alignment program (GMAP). Duplicate reads were removed using smatools 
version 0.1.18 and reads assigned to exons described in C. albicans SC5314 
version A21-s02-m08-r03 using htseq-count version 0.5.4. Differential expression 
analysis was performed using the bioconducter package EdgeR (version 2.6.12) 
and R (version 2.15.0) on LBF and HBF, carried out by Edinburgh Genomics 
(Edinburgh, UK). The output from the bioinformatics analysis represented the 
differential expression as log2 fold change and statistical significance. Genes 
with a positive log FC value were considered up-regulated in HBF whereas those 
with a negative value were up-regulated in LBF. All differentially expressed 
genes were classified based upon their functional groups using GO Slim Mapper 
(http://www.Candidagenome.org/cgi-bin/GO/goTermMapper). In addition, 11 
genes from different functional groups, previously investigated in Chapter 2 and 
3, were selected to validate the RNA-Seq data. These included ALS3, BCR1, 
HWP1, MNN4, PMR1, CPH1, SAP3, SAP4, SAP6 PLB1 and CHT2.  
3.3.11 Statistical analysis 
Analysis of variance (ANOVA) and t-tests were used to investigate independent 
sample data. A Bonferroni correction for multiple comparisons was applied to 
the data where appropriate. SPSS (Version 11, Chicago, USA) was used for these 
analysis and GraphPad Prism (Version 4, La Jolla, USA) for the production of the 
figures. The Spearman’s rho correlation coefficient was determined to 
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investigate the relationship between the parameters measured. A p value of less 
than 0.05 was considered significant.  
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3.4 Results 
3.4.1 eDNA contributes to C. albicans biofilm formation 
Initially, C. albicans biofilm formation was assessed in 6 BSI isolates defined as 
either LBF (n=3) or HBF (n=3) based on biomass quantification (Figure 3.1). 
 
Figure 3.1- Variation in C. albicans biofilm formation.  
C. albicans isolates with LBF (n=3) and HBF (n=3) were grown as biofilms in 96 well flat-
bottom microtitre plates at 37°C for 24 h. Biofilm biomass was assessed 
spectrophotometrically by reading CV absorbance at 570 nm. Each isolate was assessed 
in triplicate, on at least two independent occasions. Data represents mean ± SD. 
*p<0.05. 
A significant difference in biofilm formation was observed between isolates with 
LBF and HBF, where 11.6× more (p=0.0035) biomass was observed in the latter 
group (Figure 3.1). To determine the mechanism behind the variation of biofilm 
formation in C. albicans clinical isolates, the release of eDNA from isolates with 
LBF and HBF was evaluated by investigating their response to DNase treatment 
(Figure 3.2). 
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Figure 3.2– DNase treatment reduces C. albicans biofilm biomass.  
C. albicans isolates LBF (n=3) and HBF (n=3) were grown as biofilms at 37°C for 24 h. 
Biofilms were treated ± 256 μg/mL DNase for a further 24 h before being passed through 
0.22 μM membrane filter. Biomass retained on the filters were dried overnight at 60°C 
and dry weight measurements taken. In addition, biofilms ± DNase treatment were 
stained with CV and imaged to show the disruptive effect of DNase on the biofilms. Dry 
weight measurements were carried out in duplicate for each isolate, on three 
independent occasions. Photographs show representative images from three 
independent experiments. Data represents mean ± SEM. **p< 0.01.  
A significant reduction in dry weight was observed for isolates with HBF with a 5-
fold decrease (p<0.01) in biomass compared to untreated controls (Figure 3.2). 
However, despite isolates with LBF having 3× less biomass following DNase 
treatment, no significant differences were observed. To further investigate the 
hypothesis that eDNA preferentially supports biofilm growth, the release of 
eDNA from both LBF and HBF at 4 and 24 h was investigated using the SYBR® 
green I assay (Figure 3.3).   
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Figure 3.3– eDNA release is greater in isolates with HBF.  
C. albicans isolates with LBF (n=3) and HBF (n=3) were grown as biofilms for 4 and 24 h 
in the presence of the DNA binding dye SYBR® Green I. Fluorescence was measured after 
4 and 24 h at Ex485/Em518. Absorbance was measured simultaneously for normalising the 
fluorescence data. Each isolate was tested in duplicate, on three independent 
occasions. Data represents mean ± SD. *,# p<0.05, ** p<0.01. 
eDNA release was significantly greater in isolates with HBF compared to LBF at 
both 4 h (2.8-fold, p=0.0252) and 24 h (5.9-fold, p=0.0087), as shown in Figure 
3.3. Moreover, eDNA release increased significantly in isolates with HBF by a 
further 2.8-fold (p=0.0221) between 4 and 24 h. As eDNA has been shown to play 
a role in C. albicans biofilm formation in Figure 3.2 and 3.3, the impact this had 
on AMB sensitivity was investigated (Table 3.2).  
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Table 3.2 – AMB sensitivity ± DNase treatment against C. albicans biofilms  
MIC 
 
 
Strain 
4 h biofilm 24 h biofilm 
AMB MIC50 
(mg/L) 
+ DNase 
AMB MIC50 
(mg/L) 
+ DNase 
SC5314 <0.0313 <0.0313 0.5 2 
LBF 0.0313 0.0313 0.25 - 0.5 0.25 - 0.5 
HBF 0.125 - 0.25 0.125 - 0.25 0.25 - 1 1 - 8 
 
It was shown that isolates with LBF were up to 8-fold more susceptible to AMB 
than those with HBF at 4 h. However, when comparing these biofilm subsets at 
24 h there was only a 2-fold difference in MIC. The addition of DNase during AMB 
treatment did not have an impact on isolates with LBF at 4 h, with only a 2-fold 
difference observed at 24 h with DNase treatment. In contrast, isolates with HBF 
were most susceptible to AMB therapy at both time points, particularly 24 h 
where a 8-fold decrease in MIC was observed with the addition of DNase.  The 
addition of DNase during AMB treatment increased AMB sensitivity by up to 2 and 
8-fold in HBF isolates from 4 and 24 h biofilms, respectively, whereas, those LBF 
isolates showed no change at 4 h, and only a 2 fold change at 24 h. 
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3.4.2 Differential expression of chitinase activity is correlated with 
eDNA release and biofilm formation 
Previous studies demonstrated a positive correlation between chitinase activity 
in A. fumigatus biofilms and eDNA release (Rajendran et al., 2013). Therefore, 
this property was evaluated for C. albicans biofilms (Figure 3.4). No differences 
in chitinase activity were identified between isolates with LBF and HBF at 4 h, 
however at 24 h isolates with HBF had ~3-fold greater (p<0.05) chitinase activity 
than those with LBF (Figure 3.4).  
 
Figure 3.4 – Chitinase activity is increased in C. albicans biofilm formation.  
C. albicans isolates with LBF (n=3) and HBF (n=3) were grown as biofilms for 4 and 24 h 
at 37°C. Supernatants were retained and added to a chitinase substrate working 
solution for 30 min at 37°C. Fluorescence was measured at Ex360/Em450 and chitinase 
activity represented as U/OD, normalised to isolate biomass. Each isolate was measured 
in duplicate, on three independent occasions. Data represents mean ± SEM. *p<0.05. 
Two well characterised chitinase genes in C. albicans CHT2 and CHT3 (Selvaggini 
et al., 2004) were investigated to determine if their expression was related to 
the chitinase activity observed in Figure 3.4.  
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Figure 3.5 – Expression of chitinases at the mRNA level is up-regulated in C. 
albicans isolates with HBF.  
Biofilms with LBF (n=3) and HBF (n=3) were grown for 4 and 24 h before RNA extracted, 
cDNA synthesised and qPCR used to measure the expression of CHT2 (i) and CHT3 (ii). 
Each individual isolate was measured in duplicate. Percentage of gene expression was 
log10 transformed and represents mean ± SD relative to housekeeping gene ACT1. 
*p<0.05. 
Although no difference was observed in CHT2 expression at 4 h between the two 
biofilm subsets, a significant up-regulation by 23% (p<0.05) was found at 24 h in 
those with HBF compared to those with LBF (Figure 3.5i). Furthermore, despite 
CHT3 expression being increased by 4-fold and 3-fold in isolates with HBF than 
LBF at 4 and 24 h, respectively, no significant difference between the groups 
was observed (Figure 3.5ii).  
In chapter 2 the expression of biofilm-related genes in C. albicans biofilms was 
evaluated, where it was found that these were up-regulated in isolates with 
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HBF. Here, the expression of ALS3 and HWP1 were further investigated for a 
selective group of isolates with LBF and HBF (Figure 3.6). 
 
Figure 3.6 – Expression of biofilm related genes at mRNA level is up-regulated 
in C. albicans isolates with HBF.  
Biofilms with LBF (n=3) and HBF (n=3) were grown for 4 (i) and 24 h (ii) before RNA 
extracted, cDNA synthesised and qPCR used to measure the expression of ALS3 and 
HWP1. Each individual isolate was measured in duplicate. Percentage of gene 
expression is represented by mean ± SD relative to housekeeping gene ACT1. *p<0.05. 
Despite ALS3 and HWP1 expression being increased in HBF by 11× (p=0.1143) and 
18× (p=0.1447) at 4 h (Figure 3.6i) when compared to LBF respectively, the only 
significant difference in the transcriptional analysis was observed at 24 h where 
LBF had 18× less expression of ALS3 (p=0.0102) than HBF (Figure 3.6ii).  
To investigate the relationship between eDNA release, chitinase activity, biofilm 
biomass and genes related to biofilm formation (HWP1 and ALS3), a Spearman’s 
rho correlation analysis was performed (Table 3.3). 
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Table 3.3 - Spearman’s rho correlation analysis 
Spearman's rho Biomass Chitinase HWP1 ALS3 
eDNA 
Correlation 
Coefficient 
.943
**
 .886
**
 .771
*
 .829
*
 
Sig.  
.002 .009 .036 .021 
Chitinase 
Correlation 
Coefficient 
.943
**
   .771
*
 .714 
Sig.  
.002   .036 .055 
* Correlation is significant at the 0.05 level 
** Correlation is significant at the 0.01 level 
A significant correlation was observed between eDNA release and biomass 
(p<0.01), chitinase activity (p<0.01), and expression of HWP1 (p<0.05) and ALS3 
(p<0.05) at 24 h. A significant positive correlation was also found between 
chitinase activity and expression of HWP1 (p<0.05) in 24 h biofilms (Table 3.3). 
3.4.3 Compromising chitinase activity affects isolates biofilm formation 
and antifungal sensitivity 
C. albicans single and double knockout mutants CHT2Δ, CHT3Δ and CHT2/3Δ 
were assessed to confirm whether these chitinases played a role in biofilm 
formation and eDNA release (Figure 3.7). cht2Δ, cht3Δ and cht2/3Δ all showed a 
reduction in biofilm biomass by 1.5 to 2-fold when compared to the parental 
strain CAI4. However, a significant reduction was found only with cht3Δ (p<0.05) 
and cht2/3Δ (p<0.005) (Figure 3.7). To investigate whether this reduction in 
biomass was caused by presence of eDNA, the biofilms were treated with DNase. 
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Figure 3.7 – Chitinase mutants have less biomass and are unaffected by DNase 
treatment.  
C. albicans cht2Δ, cht3Δ, cht2/3Δ biofilms were grown for 24 h at 37°C then treated ± 
256 μg/mL DNase for a further 24 h. Biomass was assessed using CV absorbance at 570 
nm and stained biofilms were digitally imaged to show the difference in biofilm 
formation. Each isolate was measured in triplicate on three independent occasions. 
Data represents mean ± SD. **p<0.01,§p<0.05, §§p<0.01, compared to parental strain. 
Here a significant reduction in biofilm biomass by 2-fold was observed with 
DNase treatment in CAI4 compared to untreated controls (p<0.01). Conversely, 
no significant reduction was observed with either single or double knockout 
mutants. The reduction in biofilm formation by all the knockout mutants was 
confirmed by microscopy (Figure 3.8). SEM imaging showed reduced biomass in 
these isolates compared to CAI4, with cht3Δ showing the clearest visual 
difference, providing evidence that chitinases play a role in C. albicans biofilm 
formation. 
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Figure 3.8 – Chitinase mutants are defective in biofilm formation.  
C. albicans cht2Δ, cht3Δ, cht2/3Δ and wild type CAI4 (×1000) were grown on 
Thermanox coverslips for 24 h at 37°C. Biofilms were then processed and viewed on a 
JEOL JSM-6400 scanning electron microscope and images assembled using Photoshop 
software. Note the reduction in biofilm biomass in cht3Δ and cht2/3Δ.  
3.4.4 Chitinase deficient strains have reduced eDNA release 
Next, eDNA release was further quantified in these mutants by using the SYBR® 
green I assay (Figure 3.9). All knockout strains had significantly reduced eDNA 
release after 24 h. The greatest reduction was in cht2Δ, where eDNA was 
decreased by 53% (p=0.02) compared to the parental strain CAI4. This was 
followed by cht2/3Δ with a reduction of 50% (p=0.0061) and cht3Δ by 26% 
(p=0.0161). 
 
 
CA14 cht2 △ 
cht3 △ cht2/3 △ 
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Figure 3.9 – eDNA release is reduced in chitinase mutants.  
C. albicans cht2Δ, cht3Δ, cht2/3Δ and their parental strain CAI4 were grown in RPMI for 
24 h at 37°C. eDNA release was then assessed using SYBR green I assay, normalised to 
each isolates biomass. Each isolate was measured in duplicate, on three separate 
occasions. Data represents mean ± SD. * p<0.05, ** p<0.01. 
The level of eDNA present in these knockout mutants was confirmed visually 
using fluorescence imaging (Figure 3.10). The presence of eDNA in the parental 
strain CAI4 is shown by the abundance of red/pink fluorescence, which was 
notably reduced in the single knockouts cht2Δ and cht3Δ, and completely absent 
from the double knockout cht2/3Δ (Figure 3.10).  
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Figure 3.10 – eDNA is reduced in chitinase mutants.  
C. albicans chitinase mutants CHT2Δ, CHT3Δ, CHT2/3Δ and their parental strain CAI4 
were grown on Thermanox coverslips for 24 h at 37°C before staining with CFW and 
PI. The accumulation of eDNA was visualised under a fluorescence microscope 
(Motic BA400 Colorview system) at an Ex350/Em400 CFW and Ex540/Em525 for PI. One 
representative from each group was digitally photographed. 
3.4.5 Inhibition of chitinase activity improves antifungal sensitivity 
Next, to test whether pharmacological inhibition of chitinases impacted 
antifungal sensitivity, AZE was used in combination with AMB (Table 3.4). It was 
shown that the addition of AZE had little impact on AMB sensitivity in any C. 
albicans isolates with LBF and HBF biofilm at 4 h, as the MIC remained 
unchanged. Furthermore, only a minimal increase in AMB susceptibility was 
found in HBF isolates at 24 h where a 2-fold decrease in MIC50 was found.  
 
 
 
 
 
 
CA14 cht2Δ 
cht3Δ cht2/3Δ 
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Table 3.4 – AMB sensitivity ± AZE treatment against C. albicans biofilms 
MIC 
 
Strain 
4 h biofilm 24 h biofilm 
AMB MIC50 
(mg/L) 
+ AZE 
AMB MIC50 
(mg/L) 
+ AZE 
SC5314 <0.0313 <0.0313 0.5 1 
LBF 0.0313 0.0313 0.25 - 0.5 0.25 - 0.5 
HBF 0.125 - 0.25 0.125 - 0.25 0.25 - 1 0.5 - 2 
 
Although chitinases were shown to contribute to C. albicans biofilm formation 
through an increase in eDNA release, these were not shown to play a significant 
role with regards to antifungal therapy. Differential expression of genes 
associated LBF and HBF in C. albicans were further investigated.  
To understand mechanisms that play a role in C. albicans biofilm formation in 
greater detail, RNA Seq was undertaken in C. albicans isolates with LBF (n=1) 
and HBF (n=1). Genes with a positive log2 FC value were considered up-regulated 
in HBF whereas those with a negative value were up-regulated in LBF. Figure 
3.11 illustrates the up-regulation of genes by C. albicans isolates with LBF (i) and 
HBF (ii). All the differentially expressed genes were grouped into functional 
categories using the GO Slim Mapper genome database 
(http://www.Candidagenome.org/cgi-bin/GO/goTermapper). These functional 
categories included a range of processes including filamentous growth, biofilm 
formation, cellular transport, response to stress, pathogenesis, etc. 
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Figure 3.11 – Up-regulation of C. albicans functional groups based on RNA-
Seq analysis.  
C. albicans isolates with LBF (i) and HBF (ii) were grown as biofilms for 24 h before RNA 
extracted and used for RNA Seq. Up-regulation of each gene was grouped based upon its 
function. Each isolate was analysed in triplicate. 
Notably, the three largest functional groups identified in both LBF and HBF of C. 
albicans were transport, response to chemicals, and response to stress (Figure 
3.11), where they accounted for 54% and 50% of the total number of gene up-
regulated, respectively (Figure 3.11). A total of 1076 genes were up-regulated in 
LBF where the greatest increase in regulation was found in genes related to 
cellular responses to stress, (Figure 3.11i). Genes associated with cell transport 
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were the functional group mostly highly expressed in the C. albicans isolate with 
HBF, accounting for 22% of the 853 genes (Figure 3.11ii). Of interest, there was 
no difference in the percentage of genes associated with cell adhesion and 
hyphal growth in both LBF and HBF, which accounted for only 2% in total. 
Furthermore, the number of genes related to biofilm formation only represented 
4% and 3% in LBF and HBF, respectively. However, when the specific genes 
within this functional group were investigated, genes associated with a yeast 
state (YWP1 [9×], NRG1 [3.7×]) were up-regulated in LBF, whereas HBF had 
hyphae specific gene expression increased (HWP1 [6×], HYR1 [3.8×] and ALS3 
[2.8×]), which is consistent with their phenotypic presentation.  
Next, genes were selected from the RNA Seq data that had shown the greatest 
regulation within C. albicans isolates with HBF (Table 3.5) and LBF (Table 3.6) to 
determine if other processes were significant in biofilm variation.  
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Table 3.5 – Genes with greatest regulation in C. albicans isolates with HBF by RNA-Seq 
HBF 
Gene ID Function Functional group (Figure 3.11) 
Log2 
FC 
p value 
RHD2 orf19.2688 Retrotransposon Biological process 12.62 1.2E-26 
TLO4 orf19.7276.1 Telomere-proximal gene Biological process 9.85 2.21E-39 
LDG3 orf19.6486 Putative LDG family protein Biological process 8.23 7.69E-22 
ATO1 orf19.6169 Putative transmembrane 
protein 
Biological process 7.00 1.68E-9 
HWP1 orf19.1321 Hyphal cell wall protein Biofilm formation, cell adhesion, pathogenesis, cell wall 
organisation 
6.43 6.47E-15 
ECE1 orf19.3374 Hyphae specific protein Biofilm formation 6.41 8.41E-14 
SOD5 orf19.2060 Superoxidase dismutase Response to chemicals/stress, interspecies interactions 6.18 1.42E-9 
SAP8 orf19.242 Protease Other 5.98 2.03E-16 
EXG2 orf19.2952 Cell wall protein Carbohydrate metabolic process 5.79 7.07E-13 
HGT9 orf19.644 Glucose transporter Transport 5.66 4.57E-11 
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Table 3.6 - Genes with greatest regulation in C. albicans isolates with LBF by RNA-Seq 
LBF 
Gene ID Function Functional group (Figure 3.11) 
Log2 
FC 
p value 
POL93 orf19.6078 Retrotransposon DNA metabolic process -10.42 1.34E-26 
YWP1 orf19.3618 Yeast wall protein Biofilm formation, interspecies interactions -9.04 4.09E-20 
DAG7 orf19.4688 Secretory protein Response to chemicals/drugs -7.83 1.91E-19 
PHO87 orf19.2454 Putative phosphate 
permease 
Regulation of biological process, transport -7.38 6.43E-23 
PGA16 orf19.848 Putative GPI-anchored 
protein 
Biological process -6.98 3.28E-6 
RBR1 orf19.535 Cell wall anchored protein Filamentous growth -6.90 2.93E-11 
AQY1 orf19.2849 Aquaporin water channel Biofilm formation, cell development, transport, response to 
stress, cell cycle 
-6.85 3.52E-16 
FMA1 orf19.6837 Putative oxidioreductase Other -6.77 3.81E-23 
HSP70 orf19.4970 Chaperone into host cells Regulation of biological process, transport, protein folding, 
interspecies interactions, response to chemicals/stress 
-6.54 1.92E-10 
PCL1 orf19.2649 Cyclin homolog Response to stress/chemicals/drugs, cell cycle, filamentous 
growth 
-6.22 4.04E-17 
  
 
 
Although the ten genes with the highest regulation from RNA-Seq are shown in 
Table 3.5, a number of unknown genes were also shown to have high expression in 
LBF (n=7) and HBF (n=13). In the HBF group, HWP1 and ECE1 were shown to be 6.4 
fold greater than in LBF, both of which are known to be associated with hyphal 
cells. Other genes of interest that were up-regulated in HBF include a number of 
cell wall and membrane proteins (EXG2 and ATO1). YWP1 had the second greatest 
expression (>9×) of all genes up-regulated in C. albicans LBF, a gene associated with 
the presence of yeast cells. Other genes that had increased expression in LBF 
include a number of proteins, including PHO87 (7.38×) and PGA16 (6.98×), a 
phosphate permease also found in Saccharomyces cerevisiae and a predicted cell 
surface protein, respectively. 
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3.5 Discussion 
In the previous chapter it was shown that biofilms formed by different clinical 
isolates of C. albicans did not form biofilms in a homogenous fashion. Instead, there 
was significant variation in their ability to form and maintain biofilm structure, 
which was shown not only to impact biofilm formation, but also pathogenicity and 
antifungal sensitivity. Understanding why these isolates differ would be useful in 
developing better management strategies, both in terms of antifungal therapy, but 
potentially also for development of new molecular diagnostics. The data presented 
herein describes a novel role for eDNA release in conferring heterogeneity during 
biofilm formation by C. albicans, which is in part related to chitinase regulated 
autolytic events, and which contributes to biofilm associated antifungal resistance.  
There have been limited studies to date examining the presence and role of eDNA 
in C. albicans biofilms (Martins et al., 2010, Martins et al., 2012). These studies 
demonstrate that the quantity of eDNA in biofilms varied considerably with the 
growth media used, with RPMI-1640 showing a significantly higher accumulation of 
eDNA in ECM compared to other tested media (Martins et al., 2010).  In the previous 
chapter we showed that biofilm formation was intricately linked with the media in 
which it was grown, where RPMI-1640 was shown to support the greatest levels of 
biofilm, and these high biofilm-forming isolates released the greatest quantities of 
eDNA. Given that eDNA was associated with these high levels of biofilm formation it 
was hypothesised that this may explain the underlying mechanism for the 
heterogeneity, i.e. those isolates with the propensity to form biofilms may release 
more eDNA than isolates forming structurally simple biofilms. This is supported by 
the data showing that addition of exogenous DNA has been shown to significantly 
improve biofilm biomass (Rajendran et al., 2013, Shopova et al., 2013). In addition, 
a recent study by Sapaar and colleagues (2014) showed that addition of homologous 
eDNA favours yeast to hyphal transition, which in turn enhances biofilm formation 
by C. albicans (Sapaar et al., 2014). Moreover, there are studies highlighting the 
importance of eDNA within mixed C. albicans and bacterial biofilms (Pammi et al., 
2013b). Based on two biomass quantification assays in this study, the levels of eDNA 
observed were greater in isolates with HBF, which also increased with biofilm 
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maturity, a similar finding to that reported in studies of A. fumigatus biofilm 
development (Rajendran et al., 2013).  
The release of eDNA in fungal biofilms is hypothesised to be an end product of 
autolysis, a process controlled by various hydrolases, including chitinases 
(Rajendran et al., 2013, White et al., 2002). C. albicans has also been shown to 
possess complex chitinase families that hydrolyse chitin molecules in the fungal cell 
wall (Gooday et al., 1992). These enzymes are known to be involved in spore 
formation, hyphal growth, hyphal branching and septum formation (Gooday et al., 
1992). There are four chitinase genes known in C. albicans (CHT1-4), though their 
function remains unclear. CHT2 and CHT3 have been shown to be associated with 
yeast to hyphal morphogenesis and are more active in the hyphal form (Selvaggini 
et al., 2004). Here it was reported that these enzymes were transcriptionally 
expressed and biochemically active during the release of eDNA, which in turn 
contributes towards biofilm formation. Indeed, correlation analysis demonstrated 
the relationship between eDNA release, chitinase activity and biofilm formation. 
Furthermore, a positive correlation between chitinase activity and a hyphal cell 
marker HWP1 confirms the involvement of chitinases during hyphal growth, which in 
turn contributes to eDNA release. This may explain the morphological differences 
between the HBF and LBF, of which the former demonstrates more filamentous 
growth. It was also shown that compromising chitinase activity through gene 
deletion of cht2Δ, cht3Δ and cht2/3Δ significantly affects morphology, biofilm 
formation and eDNA release, which suggests a role for chitinases in the 
maintenance and architecture of C. albicans biofilms.  
Chitinases have also been shown to be involved in tolerance to cell wall stress 
following antifungal challenge (Kaneko et al., 2010b), and may also influence chitin 
synthesis. This has implications for the high levels of antifungal resistance in the 
HBF isolates, particularly in relation to azoles (data not shown). eDNA release was 
shown to improve AMB sensitivity, demonstrated through DNase combinational 
treatments, and also through pharmacological inhibition of chitinases that may 
regulate eDNA release, which was also previously demonstrated in A. fumigatus 
biofilms (Rajendran et al., 2013). Nevertheless, the difference was minimal and 
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therefore suggests that other mechanisms may also contribute to the variation in 
biofilms within C. albicans clinical isolates. 
Using RNA-Seq, a number of genes were identified as having being highly up-
regulated in either LBF or HBF, including a number of cell wall proteins. An obvious 
finding was the high expression of HWP1 as this is a hyphal specific gene known to 
be involved in biofilm formation (Staab et al., 2013, Nobile et al., 2006b). Recently, 
RNA-Seq was used to compare the differential expression of genes in C. albicans 
planktonic cells against those grown in a biofilm, where it was found 1,599 genes 
were up-regulated by at least 2-fold in the latter (Nobile et al., 2012). Amongst 
these was HWP1, which when knocked out resulted in a significant reduction of 
biomass, confirming its role in biofilm formation. This study has also identified SAP8 
as a gene highly expressed in C. albicans isolates with HBF, a protease previously 
identified to be highly expressed in mature biofilms of denture stomatitis patients 
(Ramage et al., 2012a). Another gene with increased expression in C. albicans HBF 
was HGT9, a known glucose transporter. The effect of glucose on C. albicans 
adhesion and biofilm formation has shown to be related (Nikawa et al., 1997, Jin et 
al., 2004, Santana et al., 2013), therefore the up-regulation of HGT9 expression in 
this study may be due to the increased utilisation of carbon sources in isolates with 
HBF.  
It was unsurprising that YWP1 expression was significantly expressed in C. albicans 
LBF as this gene is absent in hyphal cells, where cells lacking this gene are more 
adhesive and can form thicker biofilms (Granger, 2012). In addition, despite the 
function of the secretory protein DAG7 being unknown, the increased expression 
found in LBF here confirms a previous study that showed up-regulation of DAG7 in 
yeast cultures (Sorgo et al., 2010). Interestingly, PHO87 a gene associated with 
phosphate uptake was increased in isolates with LBF, with acid phosphatase levels 
previously shown to be associated with lower virulence in vivo (MacCallum et al., 
2009b). Furthermore, when C. albicans clinical isolates are exposed to phosphate 
limiting conditions there was a significant increase in biofilm formation 
(Romanowski et al., 2012). Therefore, the identification of increased gene 
expression of YWP1, DAG7 and PHO87 in clinical samples may indicate the presence 
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of an isolate with LBF, which has implications for more conservative approaches to 
antifungal therapy, i.e. azole use. 
Collectively, this data has provided a base for understanding the mechanisms that 
may lead to differences in biofilm variation within C. albicans isolates, which has 
been shown not to be reliant on one pathway. The main objective is to identify a 
potential marker of C. albicans biofilm formation that could be transferred into the 
clinical setting and used as a diagnostic marker, which in turn could help improve 
antifungal therapy and patient outcomes. Tumbarello and colleagues identified 
inadequate antifungal therapy as a predictor of patient mortality (Tumbarello et 
al., 2007), with other studies highlighting the importance of efficient and 
appropriate treatment of candidaemia cases (Almirante et al., 2005, Garey et al., 
2006). Mismanagement of antifungal therapy has important repercussions, as it has 
been shown that treatment with sub-MIC levels of antifungals causes an increase in 
chitin content within Candida species, which relates to decreased antifungal 
sensitivity (Walker et al., 2013, Walker et al., 2008). Moreover, a recent study has 
shown the use of sub-lethal concentrations of antibiotics leads to increased 
autolysis, eDNA release and biofilm formation in bacteria (Hsu et al., 2011).  
Therefore, it is of great interest to develop a molecular diagnostic for Candida 
biofilm infections, as this would be able to help direct more appropriate treatment, 
preventing an increase in antifungal resistance due to the misuse of antimicrobials 
and ultimately decrease hospital lengths of stay. Further pathway analysis of the 
RNA-Seq data may prove useful in identifying specific key pathways associated with 
the different biofilm groups. 
CHAPTER FINDINGS: 
eDNA is abundant in C. albicans isolates with HBF, where its release in biofilms is 
partly controlled by chitinases. 
The addition of DNase in combinational therapy increases the susceptibility of 
antifungals to isolates with HBF, including AMB. 
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A number of specific proteins associated with C. albicans cell structure were 
identified for having increased expression within these biofilm-subsets, and 
therefore could serve as potential diagnostic target. 
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4.1 Introduction 
Oral diseases such as oral candidosis, are characterised by microbial biofilms (Coco 
et al., 2008), which are difficult to control with standard chemotherapeutic 
approaches and host immune defences (Ramage et al., 2010). These biofilm 
consortia have a community structure, dominant metabolic processes and inter-
organism interactions. Antimicrobial resistance is a key characteristic of biofilms, 
which is associated with exopolymeric matrix, increased cell density, persister cells 
and up-regulation of efflux pumps (Ramage et al., 2009). Recent studies by our 
group demonstrated that C. albicans biofilms were refractory to prescription 
antifungal agents, mouthwashes and denture cleansers (Jose et al., 2010, Ramage 
et al., 2011a), which may explain why oral candidosis is a frequent problem within 
immunocompromised and elderly populations. Moreover, defined azole resistance 
mechanisms and the presence of Candida spp. that are inherently resistant to 
azoles (C. glabrata and C. krusei), complicate clinical management even further 
(Arendrup, 2013, Guinea et al., 2013). There is now a growing body of literature to 
demonstrate a key role for Candida biofilms in oral candidosis (Coco et al., 2008, 
Rautemaa and Ramage, 2011), which is associated with inflammation and symptoms 
such as pain, burning sensation and altered taste (Samaranayake et al., 2009a). 
Overall, these factors complicate clinical management, therefore alternative 
agents that elicit antifungal activity are of clinical interest.  
At a time where there is growing evidence of antifungal resistance, it is a high 
priority that alternative novel compounds, such as naturals, are assessed for their 
ability to prevent and treat fungal infections (Arendrup, 2014, Niimi et al., 2010, 
Ramage et al., 2012c). Natural compounds have previously been shown to be 
advantageous for use in the management of fungal infections, including tea tree oil 
(TTO) and polyphenols (Evensen and Braun, 2009, Ramage et al., 2012b). Fulvic 
acid is a novel antimicrobial molecule that is reported to have antibacterial and 
antifungal properties (van Rensburg et al., 2000).  It has recently been reported to 
be non-toxic in a rat wound model, in addition to having anti-inflammatory 
properties (Sabi et al., 2011). A randomized, double blind, controlled trial indicated 
that fulvic acid was well-tolerated, whereby side effects were limited and improved 
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some aspects of eczema (Gandy et al., 2011). This colloidal organic acid is a major 
constituent of humic acids and has been recognised for its biological significance for 
many years, yet there is minimal scientific understanding on which to support the 
claims of its biological properties. Fulvic acid can be isolated from the environment 
or produced from the oxidation of coal or lignite. However, such preparations 
contain high levels of heavy metals and potentially toxic elements, making their use 
in humans unsuitable. Recent innovation has seen the development of carbohydrate 
derived fulvic acid (CHD-FA), a pure form of fulvic acid produced by a patented 
process to GMP standards (PA107470/GB). It is characterised by a standard infrared 
spectrograph and is free of heavy metals and environmental pollutants normally 
found in fulvic acid from environmental sources. 
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4.2 Aims 
The aim of the chapter was to investigate the antifungal effects of the novel 
compound CHD-FA against clinically relevant isolates associated with different 
clinical manifestations of candidiasis growing as planktonic and sessile cells, and to 
compare this to conventional antifungal agents. Furthermore, the mode of action of 
CHD-FA was investigated, in addition to the impact of known Candida resistance 
mechanisms on CHD-FA sensitivity.  
The data represented in this chapter has been published in: 
Sherry L, Jose A, Murray C, Williams C, Jones B, Millington O, Bagg J and Ramage 
G. 2012. Carbohydrate Derived Fulvic Acid: An in vitro investigation of a novel 
membrane active antiseptic agent against Candida albicans biofilms. Front 
Microbiol, 3, 116. 
 
Work from this chapter has been presented orally at the following conferences and 
meetings: 
Sherry L, Murray C, Jones B, Williams C and Ramage G. ‘Carbohydrate-derived 
fulvic acid is a novel antifungal product.’ ECCMID, Milan, Italy. April 2011. 
Sherry L, Murray C, Jones B, Williams C and Ramage G. ‘Evaluation of 
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4.3 Materials and Methods 
To investigate the antimicrobial activity of CHD-FA, minimum inhibitory 
concentrations were determined against various C. albicans clinical isolates in 
planktonic and sessile states. The mode of action of CHD-FA was assessed using 
various membrane assays, including the release of intracellular ATP, selective 
fluorescent dyes and inhibition of fungal cell components. Efflux pump activity, 
extracellular matrix production and heat shock protein 90 (HSP90) were among the 
resistance mechanisms investigated to determine if CHD-FA sensitivity was 
impacted.  
4.3.1 Culture conditions and standardisation 
C. albicans type strains SC5314, 3153A, CAF2, ATCC 10231, ATCC 90028 and a range 
of clinical isolates (n=45) obtained from various oral and bloodstream samples, 
were used for planktonic and sessile sensitivity testing. All isolates were retrieved 
from Microbank vials (Pro-Lab Diagnostics, Cheshire, UK) stored at -80°C and sub-
cultured on to Sabouraud’s dextrose agar (SAB [Sigma-Aldrich, Dorset, UK]). Plates 
were incubated at 30°C for 24 h and maintained at 4°C. A loopful of each isolate 
was inoculated in to 10 mL of YPD and placed in the orbital shaking incubator at 
200 rpm and 30°C for 18 h, as described in 2.3.1.2. Cells were washed with PBS 
counted using a Neubauer haemocytometer. C. albicans cells were standardised to 
the desired cellular density in RPMI-1640 medium (Sigma-Aldrich, UK) (Ramage et 
al., 2001a).  
4.3.2 Biofilm formation 
C. albicans cells were standardised to 1 × 106 cells/mL in RPMI and 200 μL dispensed 
into each well of a 96 well flat-bottom microtitre plate to allow biofilm formation, 
as previously described in section 2.3.2. Plates were incubated for 24 h at 37°C. 
Following incubation, the culture medium was discarded and biofilms were 
carefully washed twice with PBS to remove planktonic cells. The metabolic activity 
of the biofilm was measured using the XTT metabolic reduction assay (Pierce et al., 
2008, Ramage et al., 2001a) and biofilm biomass quantified using the CV assay (Jose 
et al., 2010). 
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4.3.2.1 Quantification of biofilm metabolic activity 
A semi-quantitative measure of each biofilm was calculated using a formazan salt-
based XTT reduction assay (Hawser et al., 1998b), as described in 2.3.6.2. Briefly, a 
100 μL aliquot of the XTT/menadione solution was added to each pre-washed 
biofilm, and to control wells containing no organisms (for measurement of 
background XTT-reduction levels). Plates were then incubated in the dark for 2 h at 
37°C. A colorimetric change in the XTT reduction assay, representing a direct 
correlation of metabolic activity of the biofilm, was then measured at 492 nm in a 
microtitre plate reader (FluoStar Omega, BMG Labtech, Aylesbury, 
Buckinghamshire, UK). 
4.3.2.2 Quantification of biofilm formation 
Quantification of C. albicans biofilms was performed using the CV assay, as 
described in 2.3.2.1. Briefly, biofilms were grown as previously described in 2.3.2 
carefully washed with PBS before quantifying the biomass (Jose et al., 2010). 
Biofilms were air-dried before staining with 0.05% w/v CV solution and then de-
stained with 100% ethanol The contents of the wells were mixed thoroughly by 
pipetting and transferred to a new 96 well flat-bottom plate for measurement. The 
biomass was quantified spectrophotometrically by reading at 570 nm in a microtitre 
plate reader All absorbance values were blank corrected based upon the negative 
control where no biofilms were formed. 
4.3.3 Antifungal susceptibility testing 
The following antifungal agents were used in the course of this study: CHD-FA 
(Fulhold, Cape Town, South Africa), voriconazole (VRZ, Pfizer Pharmaceuticals, 
Sandwich, UK), caspofungin (CSP, Merck Sharp & Dohme, Hertfordshire, UK), 
amphotericin B (AMB, Sigma-Aldrich, Gillingham, UK). All antifungals were prepared 
at a stock concentration of 2 mg/mL in sterile water and stored at -20°C until 
required. 
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4.3.3.1 Planktonic and sessile inhibitory testing 
Antifungal testing to determine minimum inhibitory concentrations (MICs) of 
planktonic cells was performed using the CLSI M-27A broth microdilution method 
(CLSI, 2008), as described in 2.3.6.1. In brief, each antifungal was serially diluted 
two-fold in RPMI-1640 in 96 well round-bottom plate and 100 μL of 1 × 104 cells/mL 
C. albicans cells added to each well. Plates were incubated at 37°C for 24 h with 
appropriate positive and negative controls included. For sessile susceptibility 
testing, biofilms were grown for 24 h at 37°C and treated with two-fold serial 
dilutions of the appropriate agent (Ramage et al., 2001a). Biofilms were incubated 
at 37°C for a further 24 h. Sessile minimum inhibitory concentrations (SMICs) were 
determined at 90% inhibition using an XTT metabolic reduction assay (Pierce et al., 
2008). Testing of all planktonic and sessile isolates was performed in triplicate. 
4.3.3.2 Kill kinetics of antifungals against C. albicans 
For time-kill studies two type strains (3153A, SC5314) and 2 clinical bloodstream 
isolates were selected based on their superior and equivalent biofilm properties. 
Biofilms were grown for 24 h and treated with CHD-FA, VRZ, CSP and AMB at 1, 2 
and 4 × SMIC50. At 1, 2, 4, 6, 8 and 24 h the biofilms were carefully washed with PBS 
and the metabolic activity of the biofilms assessed using the XTT metabolic assay as 
described in 4.3.2.1. Testing of these four isolates for each drug and each time-
point was performed with six replicates and repeated on two separate occasions. 
4.3.3.3 Biomass disruption by CHD-FA 
C. albicans biofilms (n=40) were grown for 24 h and treated with 2 and 4 × SMIC50 
for a further 24 h as these concentrations of CHD-FA were highly effective in the 
time-kill study above. Following treatment the wells were washed carefully with 
PBS and the biomass of each biofilm quantified using the CV assay, as described in 
2.3.2.1. 
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4.3.4 Scanning electron microscopy 
For scanning electron microscopy (SEM) sessile cells were grown directly on 
Thermanox coverslips (Nunc, Roskilde, Denmark) prior to antifungal treatment as 
described in 2.3.2. Planktonic C. albicans cells were standardised (2.3.1.2) then 
pre-treated with CHD-FA prior to immobilisation on the coverslip. Treatment was 
performed for 24 h at 1 × SMIC90 for both planktonic and sessile cells. Following 
treatment, C. albicans cells were washed with PBS and then fixed with 2% para-
formaldehyde, 2% gluteraldehyde and 0.15 M sodium cacodylate, and 0.15% w/v 
alcian blue, pH 7.4 for 18 h. The fixative was carefully discarded and samples were 
then prepared for SEM processing as previously described in 2.3.3 (Erlandsen et al., 
2004). The specimens were then mounted and sputter-coated with gold in an argon 
filled chamber and viewed under a JEOL JSM-6400 scanning electron microscope. 
Images were assembled using Photoshop software (Adobe, San Jose, CA, USA).  
4.3.5 Membrane permeabilisation assays 
To investigate whether CHD-FA interacted with the membrane a PI uptake and ATP 
release assay were used. C. albicans (SC5314) was grown in an overnight broth as 
described previously (2.3.1.2), standardised to 5 × 107 cells/mL in RPMI-1640 and 
treated with CHD-FA at 4% for 10, 20, 30, 40, 50 and 60 min.  
4.3.5.1 PI uptake 
Following treatment, cells were centrifuged at 10,000 rpm to remove CHD-FA, 
washed twice with PBS, stained with 20 µM of PI (Sigma-Aldrich) and incubated at 
37˚C for 15 min shielded from light to allow the dye to bind to DNA. One hundred 
microliters of each sample was transferred to a black microtitre plate (Corning 
Incorporated, NY, USA) and fluorescence measured using a microtitre plate reader 
at excitation and emission wavelengths 535/617 nm, respectively. Raw data was 
corrected for background fluorescence and the assay was carried out in triplicate, 
on two separate occasions. Alternatively, planktonic cells were standardised in 
RPMI-1640 and plated onto an Ibidi µSlide VI (Thistle Scientific, Glasgow, UK) and 
allowed to settle for 30 min. Cells were grown at 37˚C and imaged on an inverted 
Nikon Eclipse TE300 using a ×20 objective lens for 1 h. Following incubation, 20 µM 
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PI was added to the cells and imaged for 10 min to confirm cell viability. A 4% CHD-
FA was added next and cells imaged every 20 s for 1 h to visualise the uptake of PI. 
These experiments were performed with the help and assistance from Dr Owain 
Millington from the University of Strathclyde, Glasgow, UK. 
4.3.5.2 Measurement of ATP release 
Supernatants were retained from cells treated in the PI studies in order to measure 
ATP release. The supernatants were buffered to pH 7.0 using 10 mM sodium 
hydroxide and equal volumes of supernatant were added to ATP assay mix (Sigma-
Aldrich, UK) which allowed for the measurement of 2.0 × 10-6 – 2.0 ×10-12 moles/L of 
ATP. The ATP assay mix (lyophilised powder containing MgSO4, DDT, EDTA, BSA and 
tricine buffers salts) was reconstituted in 5 mL of sterile water to generate a stock 
solution at pH 7.8. One hundred microlitres of the ATP assay mix was added to a 1.5 
mL tube and incubated at room temperature for 3 min, which would allow any 
endogenous ATP to be hydrolysed, thereby decreasing background levels. Next, 100 
µL of the sample or standard was added to the ATP assay mix, vortexed briskly and 
the amount of luminescence measured in a white 96 well plate (Corning 
Incorporated, NY, USA) using a microtitre plate reader. Standards were prepared in 
ten-fold dilutions starting at 2.0 × 10-6 moles/L and used for the production of an 
ATP calibration curve. Background light was calculated using sterile water as a 
blank and subtracting this from all samples tested. This assay was carried out in 
triplicate and repeated on two separate occasions.  
4.3.5.3 Chitin synthase inhibition 
To further elucidate the mechanism of action of CHD-FA the role of the cell wall 
was investigated, specifically the role of chitin. To do so a specific inhibitor of the 
chitin synthesis pathway, nikkomycin Z ([NKZ] Sigma, Gillingham, UK) was used  
CHD-FA to delineate mechanisms of action. For planktonic cells CLSI methodologies 
were employed, with CHD-FA (0.0625 and 0.125%)  NKZ (0.4 µg/mL) (Kaneko et 
al., 2010a), which was incubated for 24 h at 37°C. Sessile cells were grown in the 
presence of NKZ for 24 h at 37°C then treated with CHD-FA for further 24 h. This 
was to allow the formation of biofilms with reduced chitin, in turn allow the cell 
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membrane to be more accessible. Following incubation of both planktonic cells and 
biofilms the metabolic activity was quantified using the XTT reduction assay (Pierce 
et al., 2008). This assay was carried out on two individual occasions, using two type 
and two clinical strains tested in quadruplicate. 
4.3.6 Resistance mechanisms  
We next investigated whether well-characterised resistance mechanisms in C. 
albicans biofilms impacted the activity of CHD-FA.  
4.3.6.1 Stress response 
The first resistance mechanism investigated was heat shock protein 90 (HSP90) as it 
has been shown to be involved in antifungal resistance (Singh et al., 2009). To do 
so, a specific inhibitor of the Hsp90p, 17-allylamino-17-demethoxygeldanamycin 
(geldanamycin [Invivogen, San Diego, CA, USA])  CHD-FA was used. Planktonic cells 
and 24 h biofilms were treated with CHD-FA (0.0625 and 0.125%)  geldanamycin 
(12.5 µg/mL) and incubated for 24 h at 37°C. The concentration of geldanamycin 
(GDM) used in this study was adapted from a previous investigation by Robbins and 
colleagues where they used a checkerboard assay to show the impact of various 
concentrations of GDM on C. albicans biofilms. The highest non-toxic concentration 
of GDM that retained its activity was 12.5 µg/mL (Robbins et al., 2011). Following 
incubation the metabolic activity of the cells was quantified using the XTT 
reduction assay, as previously described. This assay was carried out on two 
individual occasions, using two type and two clinical strains tested in quadruplicate. 
4.3.6.2 Matrix regulation by FKS1 
The role of the extracellular matrix in C. albicans biofilm resistance was also 
investigated using strains previously described with altered expression of fks1 (Nett 
et al., 2010c). Reference strain (DAY185), FKS1/fks1∆ defective in ECM production 
and TDH3-FKS1 a strain overexpressing β-glucans and matrix were gifted by Prof 
David Andes (University of Wisconsin-Madison, WI, USA) (Nett et al., 2010c). These 
strains were standardised to 1 × 106 cells/mL in RPMI-1640 and inoculated in to 96 
well flat-bottom plates as described in 2.3.1.2, and biofilms grown for 8 h at 37°C. 
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After incubation, biofilms were carefully washed three times with PBS and treated 
with 0.05 and 0.1% CHD-FA for 24 h. Biofilms were then carefully washed with PBS 
and metabolic activity was measured using the XTT assay, previously described in 
4.3.2.1. This assay was carried out on two separate occasions, in triplicate.  
4.3.6.3 Efflux pump activity 
A further aim was to evaluate whether CHD-FA treatment of C. albicans affected 
efflux pump expression, as it had been shown to be the case for azoles (White, 
1997). Efflux pump activity of planktonic and sessile cells was initially assessed 
using an alanine β-naphthylamine [MC-005,556 (Ala-Nap)] fluorescent assay, as 
previously described (Rajendran et al., 2010). Ala-Nap is enzymatically cleaved 
inside the cells to produce highly fluorescent β-naphthylamine. Higher levels of 
fluorescence reflect low efflux pump activity and vice versa. C. albicans SC5314 
was prepared as standardised planktonic cells (5 × 107 cells/mL) in buffer solution 
(K2HPO4 [50 mM], MgSO2 [1 mM], and glucose [0.4%]) at pH 7.0. Planktonic cells 
were treated with 0.0313% and 0.0625% CHD-FA for 4 and 24 h before being washed 
with PBS, resuspended in assay buffer and 100 μL transferred to a black flat 
bottomed microtitre plate. For sessile cells, these were grown directly as biofilms 
for 24 h within the plates and treated with 0.0313% and 0.0625% CHD-FA for 4 and 
24 h. Following incubation, biofilms were washed with assay buffer and 100 μL of 
the buffer solution was added to the biofilms. The reaction was initiated by the 
addition of Ala-Nap at a final concentration of 100 µg/mL. Fluorescence was 
quantified at 30 s intervals for 1 h at 37˚C using a fluorescence plate reader at an 
excitation and emission wavelengths 355/460nm, respectively. Testing was carried 
out in triplicate, on three separate occasions.   
To determine whether efflux pump activity was detrimental to the effects of CHD-
FA, an efflux pump inhibitor (EPI) was used, as previously described (Ramage et al., 
2011b). EPI (L-Phe-L-Arg-β-naphthylamide [MC-207,110], Sigma-Aldrich, Gillingham, 
UK) was freshly prepared at a working concentration of 1 mg/mL in distilled water. 
To determine the effects of MC-207,110 on the MIC of CHD-FA, a checkerboard 
titration assay was performed (Rajendran et al., 2011). CHD-FA was then tested 
against 24 h biofilms at a range of 0.002 to 1% in combination with MC-207,110 at a 
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concentration of 64 µg/mL and incubated overnight at 37˚C. Biofilms were washed 
with PBS and viability was assessed using the XTT reduction assay as previously 
described. Testing was carried out in triplicate, on three separate occasions.   
4.3.7 Statistical analysis 
Data distribution and statistical analysis was performed using GraphPad Prism 
(version 4; La Jolla, CA, USA). Time kill kinetics were log transformed and analysed 
using a one-way analysis of variance (ANOVA) with Bonferroni correction to 
determine significant differences between CHD-FA concentrations at each specific 
time point and between other antifungals. When comparing CHD-FA to the other 
classes of antifungals, a one-way ANOVA was used with a Dunnett post-test to 
compare all antifungals to CHD-FA. Non-parametric data from the membrane assays 
were analysed using the Kruskal-Wallis test with a Dunn’s post-test for comparing 
all time points to one another. Non-parametric data was also analysed using the 
Mann-Whitney U test to assess differences between two independent sample 
groups. Statistical significance was achieved if P<0.05.  
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4.4 Results 
4.4.1 CHD-FA exhibits potent antifungal activity 
4.4.1.1 Susceptibility of all classes of antifungals against C. albicans 
All planktonic C. albicans isolates tested were susceptible to all four antifungal 
drugs, with MIC90 for CHD-FA of 0.125% and VRZ, AMB and CSP of 0.125 mg/L (Table 
4.1). For sessile cells the most effective antifungal compound in ascending order 
based on MIC90 was CHD-FA (0.25%), CSP (0.5 mg/L) and AMB (8 mg/L). VRZ was 
unable to kill any of the biofilms tested, even at a concentration of 256 mg/L. 
Furthermore, the sessile activity of each compound was compared to planktonic 
cells in terms of MIC90 fold-change to calculate how much greater concentration of 
each drug was required to kill sessile communities. CHD-FA was the most effective 
compound as only 2 × greater concentration was required to kill biofilms than their 
planktonic counterpart. This was followed by CSP and AMB where 4 × and 64 × 
higher concentration was required to achieved the same kill potential. As VRZ was 
unable to reduce the metabolic activity of C. albicans biofilms, the fold change was 
>2048 × as no MIC could be defined for this drug. Both planktonic and sessile cells 
showed comparable MICs for all fifty strains tested.   
In addition, C. albicans clinical isolates with LBF (n=10) and HBF (n=10) were 
assessed for their susceptibility to CHD-FA. This was to determine if one biofilm 
subset was more sensitive to treatment by a novel agent (Figure 4.1). 
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Table 4.1 - Susceptibility of C. albicans to four antifungal agents 
*MIC = range of all isolates  
SMIC90 = 90% inhibition of isolate 
MIC50/90 = % of isolates susceptible to the antifungal concentration 
Fold change = difference between planktonic and sessile MIC  
 
 
MIC 
 
 
n = 50 
VRZ (mg/L) AMB (mg/L) CSP (mg/L) CHD-FA (%) 
PMIC SMIC90 
(fold change) 
PMIC SMIC90 
(fold change) 
PMIC SMIC90  
(fold change) 
PMIC SMIC90  
(fold change) 
Range* 0.0625 –  
2 
>256  
(>128-4096) 
0.0625 –  
0.25 
2 - 256 
(32 – 1024) 
0.0625 –  
0.25 
0.0625-8  
(1 – 32) 
0.125 0.25  
(2) 
MIC50 0.125 >256  
(>2048) 
0.0625 4  
(64) 
0.0625 0.25  
(4) 
0.125 0.125  
(1) 
MIC90 0.125 >256  
(>2048) 
0.125 8 
 (64) 
0.125 0.5  
(4) 
0.125 0.25  
(2) 
  
 
 
Figure 4.1 – CHD-FA sensitivity is not significantly impacted by biofilm 
formation. 
Biofilms of ten isolates with LBF (n=10) and HBF (n=10) were grown for 24 h and tested 
against CHD-FA. Each isolate was tested in duplicate, with data represented the 
average of each isolate mean + SEM.  
A dose-dependent effect was evident in both biofilm subsets tested with CHD-FA 
(Figure 4.1). LBF and HBF isolates both had a MIC50 of 0.0625% CHD-FA, yet 
isolates with LBF were less viable than those with HBF at this concentration by 
16%. In addition, LBF isolates also had and a MIC50 of 0.0625%, whereas isolates 
with HBF required 0.125% CHD-FA to reach the same kill. Despite these findings, 
no significant differences in viability were found between isolates with LBF and 
HBF at all CHD-FA concentrations. The PMIC and minimum fungicidal 
concentrations (MFC) was 0.25% for all isolates with LBF (n=10) and HBF (n=10) 
tested. 
4.4.1.2 Kill kinetics of CHD-FA and other antifungals 
The biofilm rate of kill of CHD-FA was assessed and dose and time dependent 
killing was observed (Figure 4.2i). Greater killing was observed after 1, 2 and 4 h 
at 4 × SMIC50 in comparison to 1 and 2 × SMIC50, where a decrease in viability of 
65% and 89% was observed (p<0.0001). Significant differences in cellular viability 
were observed between all CHD-FA concentrations at each time point except 
when 2 × and 4 × SMIC50 were compared at 6, 8 and 24 h and 1 × and 4 × SMIC50 at 
24 h. Furthermore, following a 24 h treatment with 2 × SMIC50, C. albicans 
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viability was significantly reduced to 7% compared to 10% achieved by 1 × SMIC50  
(p<0.05). 
When each antifungal was compared at 4 × SMIC50 then CHD-FA displayed the 
quickest killing compared in ascending order to AMB, VRZ and CSP, which after 2 
h was 89%, 61%, 18% and -5% (p<0.0001), respectively (Figure 4.2ii). In fact, 
CHD-FA was significantly more effective than any other antifungal agent up to 8 
h treatment (p<0.0001). However, after 24 h CSP elicited the most potent effect 
by reducing cell viability by 97% when compared to the 91% reduction achieved 
by CHD-FA (p<0.05). After 24 h treatment, AMB and VRZ reduced C. albicans 
viability by 88% and 43%, respectively.  
 
Figure 4.2 - C. albicans biofilm killing by CHD-FA is time and concentration 
dependent.  
Biofilm time-kill kinetics of CHD-FA at 1, 2 and 4 × SMIC50 (i). Biofilm time-kill kinetics 
of VRZ, CSP, AMB and CHD-FA at 4 × SMIC50 (ii). Standardised C. albicans (1×10
6 
cells/mL) were grown in flat bottom 96 well plates for 24 h, washed in PBS and treated 
with antifungal agents at defined concentrations for 1, 2, 4, 6, 8 and 24 h. Metabolic 
activity of treated biofilms was then quantified using the XTT assay. Four isolates were 
used for each assay, and this was performed on two independent occasions in triplicate.  
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4.4.1.3 CHD-FA does not disrupt biofilms 
The anti-biofilm activity of CHD-FA has been shown to be superior to other 
classes of antifungals when compared to planktonic cells. Therefore, the 
disruptive properties of CHD-FA were next investigated using 2 and 4 × SMIC50 as 
these concentrations showed greater activity in the time kill study. Despite the 
highly fungicidal activity of CHD-FA in the earlier part of this study, there was no 
significant reduction in biofilm biomass when 2 and 4 × SMIC50 were used (Figure 
4.3), compared to a PBS control (p=0.2318 and 0.1069, respectively). 
 
Figure 4.3 - CHD-FA does not disrupt C. albicans biofilms.  
Standardised C. albicans (1×106 cells/mL) were grown in flat bottomed 96 well plates for 
24 h, washed in PBS and treated with 0.25 and 0.5% CHD-FA for 24 h. The biomass was 
stained with 0.05% w/v crystal violet solution and quantified spectrophotometrically by 
reading at 570 nm. Forty isolates were tested during this assay, which was performed in 
triplicate.  
4.4.1.4 CHD-FA causes ultrastructural changes in C. albicans cells 
Planktonic and sessile C. albicans cells were treated with CHD-FA and imaged 
using a scanning electron microscope to visualise any ultrastructural changes in 
the cells. Deterioration of the general cell structure of both planktonic (Figure 
4.4i) and sessile cells (Figure 4.4ii) was observed, of which the latter appear to 
be crenated.  
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Figure 4.4 - CHD-FA causes crenation of C. albicans planktonic and sessile 
cells. 
Planktonic (i) and sessile (ii) cells were treated at their respective MIC90 for 24 h either 
in solution or on Thermanox coverslips, respectively. These were then processed and 
viewed on a JEOL JSM-6400 scanning electron microscope. Note the apparent disruption 
of the cell wall denoted by arrows on both the planktonic and sessile cells. Scale bars 
represent 5 μm.   
4.4.2 CHD-FA permeabilises C. albicans cell membranes 
Based on microscopy images it was hypothesised that the cell membrane may 
have been destabilised, so membrane permeability assays were performed 
including the measurement of ATP release and uptake of PI. 
 
Figure 4.5 - CHD-FA permeabilises cell membranes.  
C. albicans (SC5314) planktonic cells were treated with 4% CHD-FA for 0 to 60 min. For 
PI experiments the cells were washed and resuspended in 20 M PI and fluorescence 
measured at Ex485/Em620. For ATP release the cells were quantified using a luminescent 
plate reader. Each assay was performed on at least two independent occasions in 
triplicate.  
Ch. 4 Assessing the activity of a novel antifungal agent 
 152 
ATP was released in a time dependent manner, with a significant increase 
(p=0.0012) after 40 min exposure to CHD-FA (Figure 4.5). These observations 
were confirmed through quantification of PI, where uptake was shown to be 
rapid over the first 10 min (p<0.0001), after which this plateaued and no further 
significant increase in PI fluorescence was seen at later time points. The uptake 
of PI by the cells was also confirmed visually using time-lapse microscopy. 
 
Figure 4.6 - C. albicans cell membranes become rapidly compromised with 
CHD-FA treatment.  
C. albicans cells were allowed to grow on an Ibidi µSlide VI for 60 min before 20 µM PI 
and 2% CHD-FA was added. PI uptake was measured over 60 min using time-lapse 
microscopy, with images taken every 20 sec (i). Note the sudden uptake of PI into C. 
albicans cells after exposure to CHD-FA for 10 min. Fluorescence was also quantified 
during CHD-FA treatment (ii). 
Using time-lapse microscopy, uptake of PI was shown to occur rapidly following 
addition of CHD-FA, with detectable membrane permeability within 10 min of 
exposure to CHD-FA, with all cells becoming PI-positive and cell growth 
attenuated (Figure 4.6i, ii). 
To further elucidate the mechanisms of action, the impact of chitin was 
investigated using its inhibitor NKZ. It was hypothesised that by weakening the 
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chitin layer this would enable CHD-FA to have greater activity, if indeed the cell 
membrane was the target.  
 
Figure 4.7 - C. albicans has increased sensitivity to CHD-FA when the cell 
membrane is accessible.  
C. albicans was grown as planktonic and biofilm cells  NKZ (0.4 µg/mL) for 24 h and 
treated with 0.0625% and 0.125% CHD-FA for 24 h. Metabolic activity of treated biofilms 
was then quantified using the XTT assay. Four isolates were used for each assay, and 
this was performed on two independent occasions in quadruplicate. Data represents 
mean ± SD. **p<0.01. 
C. albicans planktonic cells treated with 0.0625% CHD-FA in the presence of NKZ 
were found to be significantly more sensitive to CHD-FA (p=0.0022) than NKZ 
free cells (Figure 4.7), which is demonstrated by a 21% reduction in cell 
viability. Treatment of C. albicans biofilm treatment showed a ~34% reduction in 
cell viability, however, this was not statistically significant (p=0.1057). In both 
planktonic and sessile states, NKZ showed no effect on cell viability (data not 
shown). 
4.4.3 The impact of C. albicans resistance mechanisms on CHD-FA 
4.4.3.1 C. albicans stress responses 
The roles of key resistance mechanisms utilised by C. albicans were next 
investigated to determine whether they were likely to impact the effectiveness 
of CHD-FA. A Hsp90 inhibitor was used to determine if C. albicans stress 
responses were responsible for reduced CHD-FA sensitivity. 
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Figure 4.8 – C. albicans stress responses play a limited role in CHD-FA 
activity.  
C. albicans was grown as biofilm  GDM (12.5 µg/mL) for 24 h and treated alongside 
planktonic cells with 0.0625 and 0.125% CHD-FA for 24 h. Metabolic activity of treated 
biofilms was then quantified using the XTT assay. Four isolates were used for each 
assay, and this was performed on two independent occasions in quadruplicate. *p<0.05, 
**p<0.01. 
C. albicans susceptibility to 0.0625% CHD-FA (sub-MIC) in the presence of the 
Hsp90 inhibitor GDM was significantly increased in planktonic (p=0.0009) and 
sessile (p=0.0133) cells (Figure 4.8), reducing the cell viability by 49% and 7%, 
respectively. No significant differences were observed for both planktonic and 
sessile cells treated at MIC levels (0.125%) in the presence of GDM. In both cell 
states, GDM showed no effect on cell viability. 
4.4.3.2 The impact of extracellular matrix 
The role of FKS1 expression in C. albicans biofilm resistance was assessed to 
determine if CHD-FA was sequestered by extracellular matrix β-1, 3 glucan 
(Figure 4.9). 
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Figure 4.9 - Extracellular matrix does not sequester CHD-FA.  
C. albicans DAY185, FKS1/fks1∆ and TDH3-FKS1 were grown as biofilms for 8 h and 
treated with 0.05 and 0.1% CHD-FA for 24 h. Metabolic activity of treated biofilms was 
then quantified using the XTT assay. This was performed on two independent occasions 
in triplicate. Statistical significance represents the comparison of FKS1/fks1Δ to the 
reference strain DAY185. Data represents mean + SD. *p<0.05, **p<0.005. 
Figure 4.9 shows that FKS1/fks1∆ biofilms were significantly more susceptible to 
CHD-FA at sub-MIC levels (0.05%) compared to the treated parental strain 
DAY185 (p=0.0126), with cellular metabolic activity being reduced by 40%. In 
comparison, the over-expressing strain, TDH3-FKS1, was less sensitive to 0.05% 
CHD-FA, with cell survival 10% greater than the reference strain (p=0.3095).  
4.4.3.3 Efflux pump activity 
Finally, the role of efflux pumps in CHD-FA sensitivity was investigated using a 
fluorescent dye (Ala-Nap) and an efflux pump inhibitor (Figure 4.10). 
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Figure 4.10 - Efflux pumps have a limited role in CHD-FA sensitivity.  
C. albicans SC5314 was grown as planktonic (i) and sessile (ii) cells and treated with 
0.0313 and 0.0625% CHD-FA for 4 and 24 h. Cells were resuspended 100 µg/mL of Ala-
Nap fluorescence read at 30 s intervals over 60 min (Ex355/Em460). For biofilms the 
relative fluorescence is presented, which is normalised to dry weight of biofilms 
(RFU/mg). High fluorescence values indicate low efflux activity and vice versa. 
**p<0.01, ***p<0.001. 
CHD-FA treated planktonic cells exhibited a time and dose dependent up-
regulation of efflux pump activity compared to untreated cells (Figure 4.10i). As 
the CHD-FA concentration increased from 0% to 0.0313% and 0.0625% there was 
significant up-regulation of efflux pump activity, indicated by low fluorescence, 
after treatment for 4 h (p<0.0001), but not after 24 h (p=0.2581 and 0.0625, 
respectively). For sessile cells a general increase in efflux pump activity was 
observed compared to planktonic cells. However, no significant increase in 
efflux pump activity was reported when the biofilms were exposed for 4 h to 
0.0313% and 0.0625% CHD-FA (p=0.3401 and 0.0503 respectively). Conversely, 24 
h treated biofilms showed a minor down-regulation of efflux pumps compared to 
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the untreated control at these concentrations (p=0.0003 and 0.0019, 
respectively) (Figure 4.10ii).  
Due to differential activity of efflux pumps in C. albicans cells treated with CHD-
FA, an efflux pump inhibitor (L-Phe-L-Arg-β-naphthylamide [MC-207,110],  
combined with CHD-FA was used to determine if cells became more sensitive to 
CHD-FA when efflux pumps were inhibited.  
 
Figure 4.11 – An efflux pump inhibitor does not increase the sensitivity of 
CHD-FA to C. albicans cells.  
C. albicans was grown as biofilms for 24 h and treated with 0.0625% CHD-FA  EPI for a 
further 24 h. Metabolic activity measured using XTT assay. Testing was carried out in 
triplicate and was performed on three independent occasions.  
There was no significant reduction in cell activity when 0.0625% CHD-FA and EPI 
were used in combination (p=0.0569), despite a 10% reduction in viability (Figure 
4.11).   
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4.5 Discussion 
C. albicans biofilm-related diseases are generally refractory to prescription 
antibiotics and antifungal agents (Ramage et al., 2012c). Studies from our group 
recently reported that commercial mouthwashes were superior to antifungals 
and a more favourable chemotherapeutic option for treating oral candidal 
biofilm infections (Ramage et al., 2011a). However, even with chlorhexidine 
containing products, residual viable biofilm cells are retained, so novel 
compounds are still urgently required. For the first time it is reported that a 
potential novel antifungal agent, CHD-FA, has potent antifungal activity against 
C. albicans biofilms. Furthermore, it is proposed that this compound is effective 
through disruption of the cellular membrane and is unaffected by biofilm 
resistance mechanisms.  
Initial studies aimed to evaluate the activity of CHD-FA and the three major 
classes of antifungal agent, namely azoles, polyenes and echinocandins, using a 
panel of clinical C. albicans strains. This was primarily to assess the anti-biofilm 
activity of each drug compared to planktonic cells rather than direct antifungal 
drug comparison. CHD-FA was shown to kill rapidly and be similarly effective 
against both planktonic and sessile cells for all strains, whereas the existing 
antifungal agents exhibited increased resistance in the biofilm phenotype. This is 
in agreement with earlier studies by our group, and others, who reported high 
level azole resistance and decreasing sensitivity of polyenes and echinocandins 
(Kuhn et al., 2002b). Furthermore, CHD-FA sensitivity was not impacted by the 
presence of an isolate with LBF or HBF. This is in contrast to AMB where a 
significant difference in MIC was observed in Chapter 2 between these biofilm 
subets. 
Disruption of the biofilm was also assessed, but despite CHD-FA being highly 
fungicidal no significant reduction of the biofilm biomass was observed. 
Nevertheless, given the effectiveness of this compound then it would be possible 
to combine CHD-FA with a known C. albicans biofilm disrupting compound, such 
as lauroyl glucose (Dusane et al., 2008). Lauroyl glucose is a sugar ester that 
exhibits antimicrobial and emulsification properties (Ferrer et al., 2005), which 
contribute to the disruption of pre-formed C. albicans biofilms by up to 45% 
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(Dusane et al., 2008). Therefore, these and other novel biofilm disruption agents 
could possibly be used to augment the activity of CHD-FA. 
The use of SEM demonstrated the appearance of crenated cells, both 
planktonically and in biofilms. Visually, these appear similar to polyene treated 
cells, which integrates into and actively disrupts cell membranes, lysing their 
cytoplasmic contents (Gale, 1963). It was therefore hypothesised that CHD-FA 
activity was potentially based on interaction with the cell membrane; an idea 
supported from the activity of CHD-FA against bacteria (van Rensburg et al., 
2000). Membrane permeabilisation assays were therefore used to confirm our 
hypotheses.  
The measurement of intracellular ATP release has been previously described as 
an appropriate method to measure membrane permeability, as ATP leakage is 
not observed in viable cells (Smelt et al., 1994). It was shown that ATP release 
occurred in a steady manner with maximum release being observed after 40 min 
CHD-FA exposure, with a slight reduction observed thereafter; a similar 
phenomenon to a previous report (Smelt et al., 1994). PI uptake was in 
agreement with ATP release, again showing a time dependent disruption of the 
cell membrane. It was demonstrated that C. albicans membrane integrity is 
compromised rapidly after exposure to CHD-FA, data supported visually from our 
fluorescent images showing PI uptake in as little as 1 min post-exposure (Ahmad 
et al., 2011).  
To further test this cell membrane hypothesis the cell wall was weakened by 
inhibiting chitin biosynthesis using the chitin synthase inhibitor NKZ, which has 
been shown to inhibit all three Chs isoenzymes in C. albicans, and in turn results 
in a lack of chitin in fungal cells (Kim et al., 2002). It was reasoned that if the 
membrane were the active target then the weakened cell would become hyper-
susceptible to CHD-FA. It was shown that NKZ in combination with CHD-FA made 
both planktonic and sessile cells more susceptible to CHD-FA, which is similar to 
previous work showing that NKZ in combination with azoles increased C. albicans 
biofilm susceptibility (Kaneko et al., 2010a).  
Our group, amongst others, have shown the importance of biofilms in 
antimicrobial resistance, a multifactorial process (Ramage et al., 2009). A 
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further aim was therefore to evaluate the potential effects of key biofilm 
resistance mechanisms on CHD-FA. The major regulator of stress in C. albicans is 
Hsp90, which has been shown to potentiate the emergence and maintenance of 
resistance to azoles and echinocandins in C. albicans biofilms, at least in part via 
calcineurin (Robbins et al., 2011). This study has shown that Hsp90 plays a role 
in stress induced resistance, as planktonic and sessile C. albicans cells were 
more susceptible to CHD-FA at a sub-MIC level when GDM, the Hsp90 inhibitor, is 
used in combination. Therefore, stress induced resistance mechanisms appear to 
play a role in C. albicans response to CHD-FA, however, this is more apparent in 
planktonic cells. 
Next, the role of biofilm ECM was investigated, a key component and defining 
characteristic of fungal biofilms (Baillie and Douglas, 2000). Recent work by the 
Andes group has shown that ECM -1,3 glucan, synthesised from Fks1p, is 
responsible for sequestering antifungal drugs and acting as a ‘drug sponge’ (Nett 
et al., 2010c), therefore conferring resistance on C. albicans biofilms. This was 
used as the basis to determine whether CHD-FA was sequestered by ECM -1,3 
glucan in the same way as other classes of antifungal agents. For this, strains 
used in the previous investigations were used (Nett et al., 2010c), where it was 
shown that FKS1/fks1∆ biofilms sensitivity to fluconazole was exquisite in 
comparison to the biofilm resistant parental strain and the ECM -1,3 glucan 
over-expressing strain TDH3-FKS1, which were highly resistant to fluconazole. 
These investigations showed that the FKS1/fks1∆, TDH3-FKS1 and the reference 
strain, DAY185, were equally sensitive at 1 × MIC50 to CHD-FA. This is surprising 
given that Nett et al (2010) had shown other classes of antifungals were 
impacted by ECM. This suggests that ECM -1,3 glucan does not sequester CHD-
FA, unlike azoles, polyenes and echinocandins (Nett et al., 2010c).  
Finally, investigation of whether efflux pumps were affected by CHD-FA was 
performed, as these have previously been shown to be expressed in C. albicans 
biofilms (Ramage et al., 2002a). In this study it was shown that efflux pump 
activity in both planktonic and sessile C. albicans cells was increased, but only 
significant up-regulation after 4 h treatment in planktonic cells at sub-MIC levels 
of CHD-FA. However, overall efflux pump activity in C. albicans biofilms was 
found to be higher when compared to planktonic cells, which was predicted 
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based on previous literature (Ramage et al., 2002a). In order to determine their 
contribution to potential resistance to CHD-FA efflux pump activity was inhibited 
using a competitive substrate. Efflux pump inhibitor studies have previously 
shown, with the use of mutants with single and double deletion mutations, that 
C. albicans have reduced mRNA expression for various multidrug resistant efflux 
pumps (Ramage et al., 2002a). Here it was demonstrated that this compound did 
not alter the MIC. This data indicates that CHD-FA is not impacted by efflux 
pump activity, despite these pumps being induced by treatment. This is 
unsurprising given that CHD-FA acts on the cell membrane and not through an 
internal cellular mechanism. 
CHD-FA is a fungicidal compound that acts non-specifically on the cell 
membrane. In the context of oral and systemic health, individuals suffer from a 
range of candidal biofilm diseases that cause high levels of morbidity and 
therefore, CHD-FA may serve as a potential novel antiseptic agent for the 
treatment of oral candidiasis and other candidal biofilm infections. Moreover, 
there are many other oral diseases of microbial biofilm origin, such as caries and 
periodontitis, which would benefit from novel antiseptic molecules, assuming 
these meet appropriate safety standards. Whilst CHD-FA appears to have 
appropriate biological properties of an antiseptic, further cellular and in vivo 
studies are required. 
 
CHAPTER FINDINGS 
CHD-FA is fungicidal against biofilms, but does not disrupt biomass. 
CHD-FA elicits its effects by non-specifically targeting the cell membrane. 
Known C. albicans resistance mechanisms do not play a role in CHD-FA sensitivity 
towards biofilms.
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5.1 Introduction 
Inflammation of the oral cavity in candidal associated biofilm diseases such as 
denture stomatitis is not strictly only caused by Candida spp (Pereira et al., 
2013, Chopde et al., 2012). Many manifestations of oral candidosis are 
polymicrobial, in which consortia of different species of bacteria coaggregate 
with yeasts and hyphal elements, which helps support the physical infrastructure 
of these complex biofilms. In addition to oral candidosis, dental caries, gingivitis 
and periodontitis are amongst the most common polymicrobial diseases of the 
oral cavity (Peyyala et al., 2013, Yamakami et al., 2013).  
Antimicrobial mouthwashes are one of the main therapeutic and preventative 
strategies currently used in the management of complex oral biofilm diseases, of 
which chlorhexidine (CHX) is widely accepted as the ‘gold standard’ (Herrera, 
2013). This antiseptic agent has superior activity to its comparators, and is both 
cidal and static against microorganisms present in oral biofilms with roles in the 
pathogenesis of oral disease. CHX has been shown to have a broad-spectrum of 
activity against bacteria, fungi and viruses, highlighting its usefulness in a 
number of diseases, particularly polymicrobial infections (Lim and Kam, 2008, 
Salim et al., 2013, Machado et al., 2011). Moreover, its substantivity provides 
prolonged activity through its ability to adsorb onto the pellicle found on enamel 
surfaces of teeth (Najafi et al., 2012). Despite this, various studies have shown 
long-term use of CHX may not be practical as it is associated with staining of the 
teeth and taste alterations (Quirynen et al., 2001, Jones, 1997). Furthermore, 
recent reports of adverse events, including anaphylactic reactions, to this 
compound have been described (Pemberton and Gibson, 2012). It has also been 
shown recently to be ineffective against biofilms grown from clinical isolates 
(Smith et al., 2013). 
The prevention and treatment of oral biofilm diseases, such as periodontal 
disease and mucosal infections, may benefit from a compound that has the 
potency of CHX with minimal side effects, but also elicits adjunctive biological 
properties, such as alteration of inflammatory pathways, which are clearly 
important in the pathogenesis of oral biofilm disease (Turkoglu et al., 2009, Liu 
et al., 2013). A previous study has shown CHX is able to down-regulate 
bacterially induced expression of proinflammatory mediators (Houri-Haddad et 
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al., 2008), although the toxicological aspects of CHX may have been the reason 
for this observation.  
Recent studies have shown the benefit of using natural agents in the 
management of oral infections. Tea tree oil (TTO) was shown to be non-toxic 
and effectively dampened the host immune response to a fungal stimulus 
(Ramage et al., 2012b). Furthermore, as outlined in the previous chapter, the 
antiseptic activity of CHD-FA was evaluated, where it was shown that the 
compound was equally effective against C. albicans planktonic and biofilm cells 
(Sherry et al., 2012). Mechanistically this was identified as a membrane 
disruption process that was not impacted by defined biofilm adaptive resistance 
mechanisms (Sherry et al., 2012). A purified form of CHD-FA has recently been 
produced by a patented process, which has been shown to be non-toxic in a rat 
wound model, with suggestions of anti-inflammatory activity (Sabi et al., 2012). 
Moreover, a recent randomized, double blind, controlled trial indicated that it 
was well-tolerated in a clinical study of eczema (Gandy et al., 2011). 
Collectively, these studies suggest that CHD-FA could have broader implications 
for oral healthcare applications. 
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5.2 Aims 
The aims of this chapter were to investigate whether CHD-FA has a broad-
spectrum of activity against microbial biofilms of oral relevance and to 
determine whether it could be used as an alternative to CHX based 
mouthwashes, which are known to have side effects from prolonged use. In 
addition, to determine whether CHD-FA had any adjunctive immunomodulatory 
properties, as reported elsewhere (Gandy et al., 2011, Sabi et al., 2011). 
 
The data represented in this chapter has been published in: 
Sherry L, Millhouse E, Lappin DF, Murray C, Culshaw S, Nile CJ and Ramage G. 
2013. Investigating the biological properties of carbohydrate derived fulvic acid 
(CHD-FA) as a potential novel therapy for the management of oral biofilm 
infections. BMC Oral Health, 13, 47. 
 
Work from this chapter has been presented orally at the following conferences 
and meetings: 
Sherry L, Murray C and Ramage G. ‘The potential use of carbohydrate-derived 
fulvic acid as a broad-spectrum antimicrobial.’ Scottish and Northern 
Periodontal Research Group, Newcastle, UK. April 2011. 
Sherry L, Murray C, Jones B, Williams C and Ramage G. ‘Evaluation of 
Carbohydrate-derived fulvic acid as a novel oral hygiene product.’ BSODR, 
Sheffield, UK. September 2011. 
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5.3 Methods 
5.3.1 Culture conditions and standardisation 
A selection of laboratory strains of commensal and pathogenic bacteria 
associated with oral biofilm disease were used in this study, including 
Porphyromonas gingivalis ATCC 33277 and Fusobacterium nucleatum ATCC 
10596, which were maintained at 37°C on fastidious anaerobic agar (FAA [Lab M, 
Lancashire, UK]) under anaerobic conditions (85% N2, 10% CO2 and 5% H2, [Don 
Whitley Scientific Limited, Shipley, UK]). Streptococcus mutans 10449, 
Streptococcus mitis NCTC 12261, Aggregatibacter actinomycetemcomitans OSM 
1123 and Enterococcus faecalis NCTC 5957 were grown and maintained at 37°C 
on colombia blood agar (CBA [Oxoid, Hampshire, UK] in 5% CO2. All isolates were 
stored in Microbank® vials (Pro-Lab Diagnostics, Cheshire, UK) at -80°C until 
required.  
P. gingivalis and F. nucleatum were propagated in 10 mL Schaedler’s anaerobic 
broth (Oxoid), S. mitis and A. actinomycetemcomitans were grown in 10 mL 
tryptic soy broth  (TSB [Sigma-Aldrich, Dorset, UK]) supplemented with 0.6% 
yeast extract and 0.8% glucose. E. faecalis was grown in TSB with 0.25% glucose, 
and S. mutans was grown in 10 mL brain heart infusion (BHI [Sigma-Aldrich]), all 
at 37°C and at appropriate atmospheric conditions. Overnight cultures were 
washed by centrifugation (3,000 rpm) and resuspended in 10 mL PBS. All 
bacteria were then standardised and adjusted to a final working concentration 
of 5 × 104 cells/mL and 1 × 107 cells/mL for planktonic and sessile susceptibility 
testing, respectively. 
5.3.2 Antibacterial susceptibility testing of planktonic and biofilm cells 
During the course of this study two active compounds from the oral hygiene 
products Dentradent (Fulhold Ltd, Cape Town, South Africa) and Corsodyl 
(GlaxoSmithKline Consumer Health Care, UK) were tested; CHD-FA and CHX, 
respectively.  
Antimicrobial testing to determine minimum inhibitory concentrations (MICs) of 
planktonic cells (PMIC) was performed using the CLSI M11-A8 broth microdilution 
method for anaerobic bacteria (CLSI, 2012) and CLSI M7-A9 for bacteria grown 
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in 5% CO2 (CLSI, 2011). Minimum bactericidal concentrations (MBC) were also 
determined by standard plating methods. From each well of the PMIC plates that 
contained no growth, 20 μL was plated out in duplicate on the appropriate 
medium and incubated for 24 h at the relevant atmospheric conditions. The 
lowest concentration with no growth was deemed the MBC.  
For biofilm testing standardised P. gingivalis, F. nucleatum, S. mitis and A. 
actinomycetemcomitans were grown for 72 h and E. faecalis for 24 h in their 
respective media and atmospheric conditions, with the exception of S. mutans 
which was grown in BHI supplemented with 2% sucrose for 48 h. Biofilms were 
grown statically in commercially available 96-well flat bottomed microtitre 
plates (Corning Incorporated, NY, USA) and sessile susceptibility testing was 
performed as described elsewhere (Pierce et al., 2008). Following antimicrobial 
treatment, biofilms were washed twice with PBS and 10% alamarBlue® 
(Invitrogen, Paisley, UK) was added to the biofilms prior to incubation for 4 h in 
the dark (Kirchner et al., 2012). The alamarBlue® is a colorimetric assay whereby 
an oxidation/reduction reaction occurs resulting in a colour change based upon 
cellular metabolic activity. Resazurin is the active ingredient of alamarBlue® that 
is reduced in the mitochondria of viable cells to produce resorufin, seen by a 
blue to pink colour change. Sessile minimum inhibitory concentrations (SMIC) 
were read visually and no change in colour was defined as the SMIC. Testing of 
all planktonic and sessile isolates was performed in quadruplicate on two 
separate occasions. 
5.3.3 Antibacterial susceptibility testing of a multi-species periodontal 
biofilm 
A multi-species periodontal biofilm model consisting of P. gingivalis, F. 
nucleatum, S. mitis and A. actinomycetemcomitans was previously developed 
(Jose, 2012) for antimicrobial testing. All bacterial species were standardised to 
1  107 cfu/mL in artificial saliva (AS) as previously described (Pratten et al., 
1998). This was comprised of porcine stomach mucins (0.25% w/v), sodium 
chloride (0.35 w/v), potassium chloride (0.02 w/v), calcium chloride dihydrate 
(0.02 w/v), yeast extract (0.2 w/v), lab lemco powder (0.1 w/v) and proteose 
peptone (0.5 w/v) in ddH2O. Urea was diluted in PBS (40% w/v) and added to a 
final concentration of 0.05% (v/v) in AS.  Biofilms were prepared in 24 well 
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plates (Corning, NY, USA) containing customised Thermanox™ coverslips (13 mm 
diameter, Fisher Scientific). For the addition of each bacterial species to the 
biofilm a standardised bacterial suspension was prepared in 500 µL of AS. 
Initially, S. mitis biofilms were grown for 24 h. Media was then removed and 
standardised F. nucleatum was then added and biofilms incubated anaerobically 
for a further 24 h. The supernatant was again removed and standardised P. 
gingivalis and A. actinomycetemcomitans in AS added to the biofilm. This was 
then incubated at 37°C in an anaerobic chamber for a further 4 days; each day 
supernatants were replaced with fresh AS. CHD-FA was shown to be active at 
0.5% v/v against all bacterial biofilms tested in this study, therefore this 
concentration was used in this study. In addition, ‘the gold standard’ 0.2% v/v 
CHX was also used to treat multispecies biofilms.  Biofilms were treated for 30 
min, before being carefully washed with PBS, and biofilm viability determined 
using alamarBlue®. The absorbance was read at 570 nm and the reference 
wavelength at 600 nm. The percentage reduction in biofilm viability was 
calculated according to the manufacturer’s instructions. To calculate the 
percentage reduced by the untreated and treated cells the following calculation 
was used; 
[(εOX)λ2Aλ1 - (εOX)λ1Aλ2 / (εRED)λ1A’λ2 - (εRED)λ2A’λ1] × 100  
λ1 = 570 nm, λ2 = 600 nm 
(εOX)λ2 = 117,216, (εOX)λ1 = 80,586, (εRED)λ1 = 155,677, (εRED)λ2 = 14,652 
Aλ1 = OD reading for test well, Aλ2 = OD reading for test well 
A’λ2 = OD reading for negative control, A’λ1 = OD reading for negative control 
 
This study was performed in triplicate on three separate occasions. 
5.3.3.1 DNA extraction of periodontal biofilms 
Following the antimicrobial treatment, biofilms were retained and used to 
quantify the number of each bacterial species found after CHD-FA and CHX 
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treatment compared to the untreated control. Once biofilms were treated with 
CHD-FA or CHX and washed with PBS, samples were sonicated in 1 mL of PBS for 
10 min and the supernatant transferred to a 1.5 mL microfuge tube and 
centrifuged at 13,000 rpm for 10 min to pellet each sample. DNA was 
subsequently extracted using the MasterPure Gram Positive DNA Purification Kit 
(Epicentre®, Cambridge, UK). The supernatant was discarded and 150 μL of TE 
Buffer was added to each sample to resuspend the pellet and 1 μL of lysozyme 
was added to break down the bacterial cells. Samples were incubated at 37°C 
for 2.5 h. Next, a mixture containing 1 μL proteinase K (50 μg/mL) and 150 μL 
Gram positive cell lysis solution was added to each sample, mixed thoroughly 
and incubated at 65°C for 15 min. Samples were allowed to cool to 37°C and 
then stored on ice for 5 min before the DNA precipitation stage. To each lysed 
sample, 175 μL of MPC protein precipitation reagent was and added and 
vortexed for 10 s. Samples were then centrifuged at 13,000 rpm for 10 min at 
4°C with the resultant supernantant transferred to a clean microfuge tube with 
1 μL of RNase A (5 μg/mL). All samples were incubated at 37°C for 30 min and 
500 μL of isopropanol added to each supernatant, which were then mixed by 
inverting each tube 40 times. The DNA was pelleted by centrifugation at 13,000 
rpm for 10 min at 4°C. The pellet was washed with 70% ethanol and the DNA 
pellet was resuspended in 35 μL of TE buffer. 
5.3.3.2 Quantification of periodontal bacteria following treatment 
One microlitre of extracted DNA, as outlined in section 5.3.3.1, was added to a 
mastermix containing 12.5 μL SYBR® GreenER™, 9.5 μL of UV-treated RNase-free 
water and 1 μL of 10 μM forward/reverse primers for S. mitis (Periasamy et al., 
2009), F. nucleatum (Sanchez et al., 2014b), P. gingivalis (Boutaga et al., 2003) 
and A. actinomycetemcomitans (van der Reijden et al., 2010). The sequences for 
each primer set used are shown in Table 5.1. 
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Table 5.1 – Primer sequences used for PCR 
Target Primer sequence (5’-3’) 
A. actinomycetemcomitans 
F - GAACCTTACCTACTCTTGACATCCGAA 
R - TGCAGCACCTGTCTCAAAGC 
F. nucleatum 
F - GGATTTATTGGGCGTAAAGC 
R - GGCATTCCTACAAATATCTACGAA 
P. gingivalis 
F - GCGCTCAACGTTCAGCC 
R - CACGAATTCGCCTGC 
S. mitis 
F - GATACATAGCCGACCTGAG 
R - CCATTGCCGAAGATTCC 
  
Three independent replicates were analysed in triplicate using a MxProP 
Quantitative PCR machine and MxProP 3000 software (Stratagene, Amsterdam, 
Netherlands). The thermal profile consisted of 95°C for 10 min for DNA 
polymerase activation and 40 amplification cycles of 95°C denaturation for 30 s, 
55°C annealing for 60 s and 72°C extension for 60 s. A dissociation curve was 
performed following the final amplification cycle for confirmation of only one 
product. This cycle consisted of 95°C for 60 s, 55°C for 30 s and 92°C for 30 s. A 
non-template control (NTC) replacing DNA with sterile water was included to 
rule out the presence of contamination. The cycle threshold (Ct) was set 
automatically and Ct values for all samples of interest were used for the 
quantification of bacteria. Quantification was carried out by standardising each 
bacterial species to 1 × 108 CFU/mL, DNA extracted as described in 5.3.3.1, ten-
fold dilutions prepared ranging from 1 × 103 to 1 × 108 CFU/mL and qPCR 
performed as described previously in this section. Standard curves were 
constructed by plotting the Ct value against the equivalent DNA dilution allowing 
unknown bacterial counts to be quantified. Each dilution of DNA was assessed in 
duplicate for each primer set.  
5.3.4 Ultrastructural changes of bacterial biofilms 
Scanning electron microscopy (SEM) was performed on S. mutans, E. faecalis, 
and the multispecies biofilms. Cells were standardised in appropriate media, as 
described above and biofilms grown directly onto Thermanox coverslips (Nunc, 
Roskilde, Denmark). Following maturation biofilms were carefully washed with 
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PBS before their respective treatments. Biofilms were then carefully washed 
twice with PBS and then fixed in 2% paraformaldehyde, 2% gluteraldehyde and 
0.15 M sodium cacodylate, and 0.15% w/v alcian blue, pH 7.4, and prepared for 
SEM as previously described (Erlandsen et al., 2004). The specimens were 
sputter-coated with gold and viewed under a JEOL JSM-6400 scanning electron 
microscope. Images were assembled using Photoshop software (Adobe, San Jose, 
CA, USA). 
5.3.5 Cytotoxicity of CHD-FA  
5.3.5.1 Growth and maintenance of OKF6/TERT2 
OKF6/TERT2 cells (gift of the Rheinwald laboratory, Brigham and Woman’s 
Hospital, Boston, USA) are an immortalised human oral keratinocyte cell line 
developed through the forced expression of telomerase (Dongari-Bagtzoglou and 
Kashleva, 2003). OKF6/TERT2 cells were maintained in keratinocyte serum-free 
medium (KSFM) [37010-022 Invitrogen, Paisley, UK] supplemented with 100 U/mL 
penicillin, 100 µg/mL streptomycin, 25 µg/mL bovine pituitary extract (BPE), 0.2 
ng/mL epidermal growth factor (EGF) and 0.4 mM CaCl2. BPE and EGF were filter 
sterilised (0.2 µm) in to KSFM. Cells were seeded at 5 x 104 cells/mL in a 75 cm2 
cell culture flask (Corning, NY, USA) and passaged when 90% confluence was 
reached. The adherent monolayer of cells was detached using 0.05% trypsin 
EDTA which was then neutralised with 15 mL of Dulbecco’s modified Eagle’s 
media ([DMEM] Sigma, Poole, UK) containing 10% FCS (Sigma, Poole, UK). Next, 
cells were washed in Hanks balanced salt solution (Sigma, Poole, UK) and 
resuspended in 4 mL KSFM before counted using a haemocytometer with 20 µL of 
cells mixed with 10 µL trypan blue (Sigma, Poole, UK) to give a dilution factor of 
1.5. Cells were viewed under the microscope and round, clear healthy cells 
counted using the appropriate grid. Trypan blue is able to stain dead cells blue 
due to the loss of cell wall integrity and were therefore omitted during the 
counting process. Cells were finally re-seeded at 1 x 105 cells/flask in KSFM. 
Frozen stocks of OKF6/TERT2 epithelial cells were prepared for long-term 
storage in liquid nitrogen. OKF6/TERT2 cell suspension were standardised to 2 x 
106 cells/mL in DMEM supplemented with 20% FCS. Equal volumes of 20% DMSO 
and the OKF6-TERT2 cells were transferred to a cryo-tube and stored in an 
insulated box at -80°C, overnight. This was to ensure the cells were cooled 
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slowly before finally being stored in liquid nitrogen. Frozen stocks of these cells 
were then revived by thawing the cells at 37°C before transferring them into a 
cell culture flask containing KSFM, pre-heated to 37°C. OKF6/TERT2 cells were 
maintained until the fourth passage by which point they could be used in 
experiments.  
For toxicity and immunomodulatory studies, OKF6/TERT2 cells were seeded in 
defined-KSFM (D-KSFM) where BPE is replaced with defined growth-promoting 
additives. This was due to BPE only being stable within media for 4 weeks, 
compared to the 3 months associated with D-KSFM and to also reduce the 
influence on the results of the variability found between batches of BPE. 
5.3.5.2 Toxicity of CHD-FA against the OKF6/TERT2 oral epithelial cell line 
OKF6/TERT2 cells were used for determining the cytotoxicity of CHD-FA. Cells 
were grown to 90% confluence in KSFM at 37°C in 5% CO2 and seeded at a density 
of 1 × 105 cells/mL in D-KSFM in a 24 well plate, as described in 5.3.5. Once the 
cells reached 80-90% confluence, the cells were carefully washed with PBS 
before treatment with 0.5% (v/v) CHD-FA at the native pH 2.0 and a neutral pH 
of 7.0 and with 0.2% (v/v) CHX for 30 min. After 30 min, the compounds were 
removed and the cells carefully washed with PBS to remove any residual actives. 
Cells were incubated in KSFM for 4 and 24 h before cell viability was assessed 
using the alamarBlue® assay, as described in 5.3.3. Viability studies were carried 
out in triplicate, on three separate occasions.  
5.3.6 Assessing immunomodulatory properties of CHD-FA 
5.3.6.1 Stimulation of epithelial cells with periodontal biofilms 
OKF6/TERT2 cells were grown to 90% confluence in 24 well plates in D-KSFM 
then pre-treated with 0.5% CHD-FA (pH 7.0) for 30 min before washed with PBS 
to remove residual CHD-FA. CHD-FA at pH 2.0 was toxic against the OKF6/TERT2 
cell line used in this study and therefore could not allow us to analyse any 
potential immunomodulatory properties of this compound. In addition, 0.2% CHX 
was also shown to be toxic to the epithelial cells and therefore these compounds 
were not further investigated. The multispecies periodontal biofilm was 
attached to the underside of a hanging cell culture insert (Millipore, 
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Massachusetts, USA) using Vaseline®, then laid adjacent to the OKF6/TERT2 
monolayer. Figure 5.1 displays a schematic of the co-culture system. 
 
 
Figure 5.1 – Epithelial biofilm co-culture model system.  
Hanging inserts with the Thermanox coverslips containing multispecies biofilms were 
introduced into each well of a 24 well plate. The inverted coverslip was secured to the 
hanging insert using sterile Vaseline® with a 0.5 mm space between the biofilm and the 
monolayer of epithelial monolayer. 
Epithelial cells were incubated with the periodontal biofilm for 4 and 24 h at 
37°C in 5% CO2. Epithelial cells not pre-treated with CHD-FA, or not challenged 
with biofilms, served as appropriate controls. Following stimulation, 
supernatants and cell lysates were retained to assess changes in the expression 
and release of a panel of pro-inflammatory mediators. 
5.3.6.2 Extraction of RNA from OKF6/TERT2 cells 
Following stimulation, RNA was extracted using the RNeasy Mini Kit (Qiagen, 
Crawley, UK), in accordance with the manufacturers’ instructions. Epithelial 
monolayers were lysed with the addition of 350 μL of buffer RLT to each well of 
the 24 well plate. The resultant lysate was transferred into an RNase free 
microfuge tube and mixed with 350 μL of 70% ethanol. Each 700 μL sample was 
then transferred to a RNeasy spin column placed within a 2 mL collection tube 
and centrifuged at 13,000 rpm for 15 s, with the flow-through discarded.  
DNA contamination of isolated total RNA was addressed using a DNase kit, as per 
manufacturer’s instructions (Qiagen Ltd, Crawley, West Sussex, UK). For DNase 
Ch. 5 Evaluating CHD-FA for the management of oral biofilm infections 
 174 
digestion, DNase I stock solution (Qiagen, Crawley, UK) was initially prepared by 
injecting 550 μL of RNase free water into the DNase I vial using a needle and 
syringe and mixed with gentle inversion. Aliquots of the stock solution were 
made and stored at -20°C for no longer than 9 months. Firstly, 350 μL of buffer 
RW1 was added to the spin column and centrifuged at 13,000 rpm for 15 s and 
flow-through discarded. Ten microlitres of DNase I was gently mixed with 70 μL 
of buffer RDD and added directly on to the RNeasy column membrane and 
incubated at room temperature for 15 min. Buffer RW1 was then added to the 
column and centrifuged at 13, 000 rpm for 15 s and flow-through discarded. 
Following the DNase digestion stage, 700 μL of buffer RW1 was added to the spin 
column, centrifuged at 13,000 rpm for 15 s and flow-through discarded. Next, 
two wash stages of the membrane occurred with 500 μL of buffer RPE with 
centrifugation at 13,000 rpm for 15 s. The spin column was then placed in a new 
2 mL collection tube and centrifuged at 13,000 rpm for 1 min to dry the 
membrane. The column was finally placed in a 1.5 mL microfuge tube and 30 μL 
of RNase free water added directly to the membrane and centrifuged at 13,000 
rpm for 1 min to elute the RNA. The resultant RNA can then be placed back on 
membrane and centrifuged one final time to ensure maximum release of the 
RNA from the column. RNA was collected and quantified using a 
spectrophotometer.  
To assess the concentration and quality of the RNA extracted from OKF6/TERT2 
cells or DNA from bacterial biofilms, a NanoDrop 1000 spectrophotometer 
(Thermo Scientific, DE, USA) was used. Before RNA was measured, the pedestal 
was wiped clean and background corrected with 1.5 μL of RNase free water. 
Each RNA sample was then subsequently measured and recorded as ng/μL. The 
purity of the RNA was also determined using the ratio of the absorbance at 260 
and 280 nm, where RNA with an A260/280 ratio greater than 1.8 was deemed to be 
of high enough quality for gene expression studies.  
5.3.6.3 Real time PCR analysis using RT2 Profiler PCR Array 
Initial gene expression analysis was carried out using real time PCR (qPCR) with a 
custom designed RT2 Profiler PCR Array (Qiagen, Crawley, UK). RT2 Profiler arrays 
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are a SYBR® GreenER™ based real-time PCR that allow for the detection of 
several genes of interest, simultaneously.  
5.3.6.3.1 Reverse transcription by RT2 First Strand kit 
For the generation of complementary DNA (cDNA), genomic DNA (gDNA) was 
eliminated using the RT2 First Strand kit (Qiagen, Crawley, UK). A mixture 
consisting of 2 μL of 5 × gDNA elimination buffer, 55 ng of RNA and the 
remainder of the 10 μL final volume made up with RNase-free water was 
incubated at 42°C for 5 min before immediately chilled on ice. Next, the reverse 
transcription (RT) cocktail consisting of 4 μL of 5 × RT buffer, 1 μL of primer and 
external control mix, 2 μL of RT enzyme mix and 3 μL of RNase free water was 
mixed with 10 μL of the gDNA elimination mixture and incubated at 42°C for 15 
min. The reaction was stopped by heating the samples to 95°C for 5 min 
followed by the addition of 91 μL of RNase free water to each reaction tube. 
cDNA was then stored at -20°C until required.  
5.3.6.3.2  Gene expression analysis using RT2 Profiler 
A mastermix was prepared with SYBR® GreenER™, cDNA and RNase-free water 
and 24 μL was added to each well of the custom RT2 Profiler plate, which already 
contained the forward and reverse primers for the genes of interest (IL-1α, IL-
1β, IL-6, TNF, CSF2, CSF3, IL-8, CXCL1, CXCL3, CXCL5, CCL1 and GAPDH). 
Thermal cycler conditions were as follows: 10 min at 95°C and 40 cycles of 15 s 
at 95°C and 60 s at 60°C. Two replicates of each condition were used in the RT2 
Profiler and the experiment was carried out on two separate occasions.  
Gene expression was then quantified using the 2−ΔΔCt method to calculate the 
expression of gene transcripts relative to the media control. GAPDH was used as 
the endogenous control. The ΔCt value was calculated [ΔCt = Ct (gene of 
interest) − Ct (GAPDH)].  This was performed for each gene tested. The relative 
expression of each gene was then calculated with the formula ΔΔCT = ΔCt (test 
sample) − ΔCt (unstimulated control sample).  This was the expressed in terms of 
fold change relative to the unstimulated control sample with the formula [fold 
change = 2-ΔΔCt] (Livak and Schmittgen, 2001).  
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5.3.6.4 IL-8 qPCR analysis using SYBR® GreenER™ 
IL-8 gene expression was analysed using SYBR® Green (Invitrogen, Paisley, UK) 
based qPCR with GAPDH as a housekeeping gene (Ramage et al., 2012b). The 
primers used are shown in Table 5.2. 
Table 5.2 - Primer sequences used qPCR 
Target Primer sequence (5’-3’) 
IL-8 
 
F - CAGAGACAGCAGAGCACACAA 
R - TTAGCACTCCTTGGCAAAAC 
GAPDH 
 
F - CAAGGCTGAGAACGGGAAG 
R - GGTGGTGAAGACGCCAGT 
 
RNA was extracted from cell lysates and cDNA synthesised using the RT2 First 
Strand cDNA synthesis kit as described in 5.3.6.1 and 5.3.6.4.1, respectively. 1 
μL of cDNA was added to a mastermix containing 12.5 μL of SYBR® GreenER™, 
10.5 μL of RNase-free water and 0.5 μL of forward/reverse primers. The thermal 
profile were as follows: 2 min at 50°C, 10 min at 95°C and 40 cycles of 15 s at 
95°C and 60 s at 60°C. A dissociation curve was also carried out to confirm the 
presence of one product, the thermal cycles was as follows: 60 s at 95°C, 30 s at 
55°C and 30 s at 95°C. Three independent replicates from each parameter were 
analysed in duplicate using MxProP Quantitative PCR machine and MxProP 3000 
software (Stratagene, Amsterdam, Netherlands) and gene expression normalised 
to the housekeeping gene GAPDH according to the 2-ΔCt method (Livak and 
Schmittgen, 2001).  
5.3.6.5 IL-8 protein analysis by Enzyme Linked Immunosorbent Assay 
(ELISA) 
Supernatants from OKF6/TERT2 cells challenged with multispecies biofilms for 4 
and 24 h, ± pre-treatment with CHD-FA, were retained to assess the release of 
interleukin 8 (IL-8) by ELISA (Invitrogen, Paisley, UK), as per manufacturer’s 
instructions. Capture antibody (1 μg/mL) was prepared in Na2HCO3 and 100 μL 
was added to each well of a Nunc Maxisorp® flat-bottomed microtitre plates 
(Fisher, Loughborough, UK). Plates were sealed and incubated at 4°C overnight 
and contents discarded and plates washed with 300 μL of wash buffer (8 g NaCl, 
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0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 and 500 μL Tween 20 in 1 L of distilled 
water (dH2O). The plate was then blocked with 300 μL of assay buffer (0.5% 
bovine serum albumin [BSA]) for 1 h at room temperature to block non-specific 
protein interactions, before being aspirated and 100 μL of each sample loaded in 
triplicate. In addition, standards of known concentrations of IL-8 (31.25 - 2000 
pg/mL) were prepared and included on each plate in duplicate. Detection 
antibody was diluted to 0.04 μg/mL in assay buffer and added to each well 
containing a sample or standard. Plates were sealed and incubated for 2 h at 
room temperature with shaking at 700 rpm. Following incubation, the plate was 
washed and streptavidin-HRP (1/2500 dilution) was added to each well before 
incubation at room temperature with shaking at 700 rpm for 30 min. Finally, the 
plate was washed and 3,3’,5,5’-tetra-methylbenzidine (TMB, R&D systems, 
Abingdon, UK) was added to each well and incubated in the dark for 30 min. 
Absorbance was read using a plate reader (FLUOstar Omega BMG Labtech, VA, 
USA) at 630 nm. A standard curve was constructed by plotting the mean 
absorbance for each standard against IL-8 protein concentration and R-squared 
calculated. Results were calculated using a 4-parameter curve fit to determine 
the concentration of IL-8 in the samples tested. All samples were tested in 
triplicate, on three individual occasions.  
5.3.6.6 Stimulation of epithelial cells with an inflammatory fungal agonist 
OKF6/TERT2 cells were grown to 90% confluence in 24 well plates in D-KSFM and 
pre-treated with 0.5% CHD-FA (pH 7.0) for 2 min (to simulate an oral rinse) 
before being washed with PBS to remove any residual agent. Cells were then 
stimulated with zymosan (extracted from Saccharomyces cerevisiae), a ligand 
found within the cell walls of yeast such as C. albicans, for a further 4 h and 24 
h at 37°C in 5% CO2. Un-stimulated cells, cells pre-treated with CHD-FA only or 
cells stimulated with zymosan for 4 h and 24 h only served as appropriate 
controls. Following stimulation, supernatants and cell lysates were retained to 
assess the regulation of a panel of pro-inflammatory mediators. RNA was 
extracted as described in 5.3.6.2 and subsequent IL-8 ELISA techniques 
performed as described in 5.3.6.7.  
5.3.6.6.1 qPCR analysis using using Taqman® Low Density Array 
(TLDA) 
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For gene expression analysis custom-designed ABI microfluidic Taqman® Low 
Density Array ([TLDA] Applied Biosystems, Foster City, CA, USA) was used in a 
qPCR process using the ABI Prism 7900 HT Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA). This catered for 384 qPCR reactions to be 
carried out simultaneously in order to determine the transcription of several 
genes. The TLDA used in this study was designed to measure the expression of 
CCL3L1, CSF2, CSF3, CXCL1, CXCL10, CXCL11, CXCL13, ICAM1, IL-1α, IL-1β, IL-6, 
IL-8, ITGB2, NFκB, S100A8 and TNFα. GAPDH was included as the housekeeping 
gene. The reaction mixture contained 20 μL of cDNA template, 30 µL of RNAse 
free water and 50 µL of TaqMan® universal master mix (Applied Biosystems, 
Foster City, CA, USA) and was added to each port of the TLDA card. The thermal 
profile conditions were as follows: 10 min at 94.5°C and 30 s at 97°C and 1 min 
at 59.7°C for 40 cycles. The thermal cycling and fluorescence detection was 
performed on Applied Bio-Systems ABI Prism 7900HT Sequence Detection System 
with ABI Prism 7900HT SDS Software 2.1. Gene expression was calculated based 
upon normalisation to GAPDH and relative to the un-stimulated control, as 
described in 5.3.6.5.2. 
5.3.7 Statistical analysis 
Graph production, data distribution and statistical analysis were performed using 
GraphPad Prism (version 4; La Jolla, CA, USA). After assessing whether data 
conformed to a normal distribution by before and after data transforms, ANOVA 
and t tests were used to investigate significant differences between independent 
groups of data that approximated to a Gaussian distribution. A Bonferroni 
correction was applied to the p value to account for multiple comparisons of the 
data. Non-parametric data was analysed using the Mann-Whitney U-test to assess 
differences between two independent sample groups. Student t-tests were used 
to measure statistical differences between the ΔCt values of the two 
independent groups assessed in gene expression studies, although data may be 
represented as percentage or fold change in the figures. Statistical significance 
was achieved if P<0.05. 
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5.4 Results 
5.4.1 CHD-FA has rapid and broad-spectrum antibacterial activity  
Corsodyl® (0.2% CHX) and Dentradent (0.8% CHD-FA) are oral formulations 
containing the active ingredients CHX and CHD-FA, respectively. All agents 
tested had antimicrobial activity against the oral bacteria evaluated in this 
study, however CHD-FA and CHX had greater activity than their respective 
formulations against planktonic and sessile cells (Table 5.3). When focusing on 
these active ingredients, both were shown to be not only inhibitory but highly 
cidal against these organisms (Table 5.3). PMICs for the oral isolates ranged from 
0.0625% to 0.25% for CHD-FA and from ≤0.00039% to 0.00078% for CHX. The 
PMBC/PMIC ratio for CHD-FA and CHX were ≤4, indicating both compounds 
displayed bactericidal activity. None of the bacterial species tested were 
notably more sensitive or resistant to either of the compounds. Both CHD-FA and 
CHX showed activity against mature biofilms, with SMICs of 0.5% for CHD-FA and 
from 0.003% to 0.025% for CHX. Interestingly, although CHX was effective at 
lower concentrations, the fold-change from PMIC to SMIC ranged from 2 to 64 
whereas CHD-FA ranged from 2 to 8. In addition, all bacterial biofilms were 
equally susceptible to CHD-FA with a SMIC of 0.5%. 
When considering the formulation, the PMIC for Dentradent, that contains the 
active ingredient CHD-FA, ranged from 6.25% to 25% and the SMIC ranged from 
25% to 50%. There was no greater than a 4-fold increase in concentration 
required for killing the bacterial biofilms when compared to planktonic cells. In 
contrast, despite Corsodyl being highly effective against all species in this study, 
the PMIC/SMIC ratio varied greatly and in some cases was up to 64-fold higher. 
Overall, P. gingivalis was the most susceptible organism to the antimicrobial 
therapies tested, particularly for planktonic cells.  
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Table 5.3 - Susceptibility profiles of clinically relevant bacteria to four antimicrobial agents 
MIC (%) 
 CHD-FA Dentradent CHX Corsodyl 
PMIC PMBC SMIC PMIC PMBC SMIC PMIC PMBC SMIC PMIC PMBC SMIC 
A. A* 0.25 0.25 0.5 25 50 50 0.0008 0.0031 0.025 0.39 0.78 12.5 
E. faecalis 0.125 0.25 0.5 12.5 25 50 0.0016 0.025 0.003 0.39 6.25 1.56 
F. nucleatum 0.125 0.5 0.5 12.5 50 25 0.0004 0.0008 0.0125 0.195 0.195 12.5 
P. gingivalis 0.0625 0.5 0.5 6.25 50 25 ≤0.0004 0.0008 0.0063 ≤0.098 0.195 3.125 
S. mitis 0.0625 0.125 0.5 12.5 25 50 0.0008 0.0016 0.0125 0.39 0.39 3.125 
S. mutans 0.25 0.25 0.5 25 50 50 0.0004 0.0008 0.025 ≤0.098 0.195 3.125 
*A. actinomycetemcomitans 
PMIC = planktonic minimum inhibitory concentration 
PMBC = planktonic minimum bactericidal concentration 
SMIC = sessile minimum inhibitory concentration 
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5.4.2 CHD-FA physically alters biofilm structure 
Further analysis of the impact of CHD-FA upon the physical cellular structure of 
S. mutans (dental caries) and E. faecalis (endodontic infection) biofilms was 
assessed using SEM (Figure 5.2).  
 
Figure 5.2 - CHD-FA reduces ECM and compromises cell membrane structure.  
S. mutans (×2000) and E. faecalis (×10,000) biofilms were either untreated (i and ii, 
respectively) or treated with 0.5% (v/v) CHD-FA (iii and iv, respectively) for 24 h on 
Thermanox™ coverslips. These were then processed and viewed on a JEOL JSM-6400 
scanning electron microscope. Note the reduction in extracellular matrix (iii) and 
perturbation of bacterial cell membranes (iv), denoted by arrows on sessile cells. 
Images are representative of three areas of the field. Scale bars represent 10 μm and 2 
μm for S. mutans and E. faecalis, respectively.  
Treatment with CHD-FA was able to reduce the overall quantity of S. mutans 
ECM (Figure 5.2iii) compared to the untreated control (Figure 5.2i), as denoted 
by arrows. Furthermore, perturbation of the cell membrane in E. faecalis cells 
was apparent (Figure 5.2iv), with visible punctures up on the cell surface unlike 
the biofilm that was not exposed to CHD-FA (Figure 5.2ii).  
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5.4.3 CHD-FA is effective against periodontal biofilms 
Before multispecies periodontal biofilms could be quantified (± treatment) by 
qPCR methodologies, DNA from known concentrations of each bacterial species 
were used to prepare a standard curve that could be extrapolated to determine 
unknown bacterial counts (Figure 5.3).  
 
 
Figure 5.3 – Standard curves of each species within multispecies biofilms.  
Ten-fold dilutions of DNA from known concentrations of A. actinomycetemcomitans (i), 
F. nucleatum (ii), P. gingivalis (iii) and S. mitis (iv) were used for qPCR and their 
equivalent Ct used for the preparation of a standard curve. Unknown bacterial counts 
could then be quantified by extrapolating from the appropriate curve. Each DNA 
dilution was assessed in duplicate for each of the four primer sets. 
Given that biofilms of the oral cavity are polymicrobial in nature, a simple and 
reproducible multi-species model representative of sub-gingival plaque was 
developed to test the activity of CHD-FA using a number of techniques including 
the assessment of viability using alamarBlue® and the level of biomass following 
treatment with qPCR techniques (Figure 5.4).  
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Figure 5.4 - CHD-FA kills multi-species periodontal biofilms.  
Multi-species periodontal biofilms were grown on Thermanox™ coverslips and treated 
with 0.5% (v/v) CHD-FA and 0.2% (v/v) CHX for 24 h and metabolic activity measured 
using the alamarBlue® (i). Biofilms were retained after treatment with CHD-FA or CHX 
and DNA was extracted for quantification of each species using SYBR® GreenER™ based 
qPCR (ii). All samples were assayed in triplicate, on three separate occasions. Data 
represents mean ± SD (***p<0.0001). 
The antimicrobial activity of CHD-FA at 1 x SMIC was shown to significantly 
reduce cell viability (Figure 5.4i) to less than 10% (p<0.0001) and was 
comparable to CHX treatment, which also significantly reduced cell viability to 
8% (p<0.0001). No significant difference was found between CHD-FA and CHX 
treatment. Despite this reduction in viability, biofilm biomass remained 
unchanged following treatment with both compounds. The number of each 
bacterium was quantified using qPCR and showed no significant difference in 
bacterial numbers present after CHD-FA and CHX treatment, compared to the 
untreated control (Figure 5.4ii). SEM analysis of these biofilms was then 
performed to evaluate any effect on the biofilm architecture (Figure 5.5). 
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Figure 5.5 - CHD-FA alters multi-species periodontal biofilm architecture.  
Biofilms were also analysed by SEM at both 2000 × (i, iii, v) and 5000× (ii, iv, vi). 
Biofilms were processed and viewed on a JEOL JSM-6400 scanning electron microscope. 
Untreated multispecies biofilms were first compared at low magnification (i) to biofilms 
treated with 0.2% (v/v) CHX (iii) and 0.5% (v/v) CHD-FA (v) for 24 h. At higher 
magnification the biofilms treated with 0.5% (v/v) CHD-FA for 24 h resulted in a fibrous 
ECM, as denoted by arrows (vi), as compared to the control (ii) and CHX (iv). Scale bars 
represent 10 μm and 5 μm for 2000× and 5000×, respectively. 
At low magnification (2000×) both CHX and CHD-FA were shown to disrupt 
biofilm architecture (Figure 5.5iii and v) when compared to the untreated 
control (Figure 5.5i), as shown by areas of sparse disaggregated biofilms. 
Moreover, at high magnification (5000×) CHD-FA also appeared to alter the 
overall physical appearance of the biofilm matrix with greater quantities of 
fibrous ECM observed as denoted by the arrows (Figure 5.5vi), compared to the 
control and CHX (Figure 5.5ii and iv). 
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5.4.4 CHD-FA is non-toxic against OKF6/TERT2 cells 
Toxicity was assessed using an orally relevant epithelial cell line to determine 
whether there were any detrimental effects of the compounds tested prior to 
investigating immunomodulatory investigations (Figure 5.6).  
 
Figure 5.6 - CHD-FA is non-toxic against an oral epithelial cell line.  
An orally relevant epithelial cell line (OKF6/TERT2) was used for toxicity studies. Cells 
were treated with 0.5% (v/v) CHD-FA at pH 2.0 and 7.0 and with 0.2% CHX for 30 min 
and cellular viability assessed using the alamarBlue® assay. All samples were assayed in 
triplicate, on three independent occasions. Data represents mean ± SD (***p <0.0001). 
Both CHX and CHD-FA, at its native pH of 2.0, were shown to be highly toxic 
towards epithelial cells after 30 min exposure. Treatment with CHX and CHD-FA 
at pH 2 reduced viability to 2% and 5% after a 4 h recovery time, respectively, 
when compared to the untreated control (Figure 5.6). Furthermore, after a 24 h 
recovery, both compounds reduced viability to less than 2%. However, when 
CHD-FA was buffered to a neutral pH of 7.0, no toxicity was observed and 
cellular viability remained at 97% and 83% after a 4 and 24 h recovery period, 
respectively. 
5.4.5 CHD-FA alters the expression of pro-inflammatory mediators 
5.4.5.1 Regulation of inflammation associated with periodontal biofilms 
Next it was important to determine whether or not CHD-FA was able to induce a 
biological response from the oral epithelial cell line, principally by measuring 
changes in immune mediators. To evaluate this, the four-species biofilm model 
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previously described in 5.3.3 was used as an agonist ± CHD-FA treatment (Figure 
5.7).  
 
 
Figure 5.7 - CHD-FA modulates biofilm mediated expression of key 
inflammatory mediators by OKF6/TERT2 cells.  
OKF6/TERT2 epithelial cells were used for the effect of CHD-FA on the host immune 
response. Cells were pre-treated with 0.5% (v/v) CHD-FA pH 7.0 for 30 min and 
stimulated with the multi-species periodontal biofilm for 4 h. The RT2 Profiler was used 
to analyse the expression of a panel of pro-inflammatory mediators. Duplicate samples 
from two independent experiments were used in the RT2 Profiler. Data is represented by 
percentage expression mean + 95% CI, relative to untreated control. *p <0.05, **p <0.01. 
Initial gene expression studies using the RT2 Profiler on OKF6/TERT2 cells pre-
treated with CHD-FA prior to biofilm challenge showed a general down-
regulation of pro-inflammatory mediators (Figure 5.7). Significant down-
regulated genes included IL-6 (8.5 fold [p=0.018]), IL-1 (7.05 fold [p=0.012]), 
TNF (5.22 fold [p=0.013]) and IL-8 (4.24 fold [p=0.021]). The down-regulation 
observed in the RT2 Profiler was assessed further by means of IL-8 expression at 
the mRNA and protein level (Figure 5.8). 
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Figure 5.8 - CHD-FA alters biofilm mediated expression of IL-8 by 
OKF6/TERT2 cells.  
OKF6/TERT2 epithelial cells were pre-treated with 0.5% (v/v) CHD-FA pH 7.0 for 30 min 
and stimulated with the multi-species periodontal biofilm for 4 h and 24 h. IL-8 gene 
expression was assessed using SYBR® GreenER™ based qPCR (i), relative to GAPDH. IL-8 
protein release was measured by ELISA (ii). All samples were assayed in triplicate, on 
three independent occasions. Data represents mean ± SD (*p <0.05, **p <0.01). 
IL-8 is one of the significantly affected genes and a key mediator of periodontal 
inflammation. At the mRNA level, biofilm-induced IL-8 expression was 
significantly down-regulated in cells pre-treated with CHD-FA after 4 h, when 
compared to the untreated control (p=0.0383)  (Figure 5.8i). No statistically 
significant difference was observed after 24 h stimulation (p=0.1712). In 
addition, at the protein level, IL-8 release was shown to be significantly down-
regulated when cells were pre-treated with CHD-FA, after 4 h (p=0.008) and 24 h 
(p=0.0037) biofilm stimulation (Figure 5.8ii).  
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5.4.5.2 Regulation of pro-inflammatory mediators associated with fungal 
stimulation 
Finally it was investigated whether CHD-FA impacts the regulation of the same 
pro-inflammatory mediators tested in 5.4.5.1 when a fungal agonist is used to 
stimulate the oral epithelial cell line (Figure 5.9).  
 
 
Figure 5.9 - CHD-FA modulates the zymosan induced mRNA expression of 
inflammatory mediators by OKF6/TERT2 cells.  
OKF6/TERT2 cells were pre-treated ± 0.5% (v/v) CHD-FA for 2 min. Zymosan was then 
used to stimulate the cells for 4 (i) and 24 h (ii). The TLDA was used to analyse the 
expression of a panel of pro-inflammatory mediators. Each sample was carried out in 
triplicate on two independent experiments, with two replicates pooled from each 
experiment used in the TLDA. Data is represented by mean, relative to unstimulated 
control and GAPDH. 
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As identified by the RT2 Profiler, a general trend of inhibition of zymosan 
induced expression of the panel of pro-inflammatory mediators was observed 
after 4 h zymosan stimulation with CHD-FA pre-treatment, compared to zymosan 
only (Figure 5.9i). The greatest reduction with CHD-FA pre-treatment was found 
in CSF3 (2.5×), CXCL3 (1.6×) and IL-8 (1.5×). Of further interest, the expression 
of transcription factor NFκB was 1.7× greater in zymosan only stimulated cells 
compared to cells pre-treated with CHD-FA. In contrast, differences between ± 
CHD-FA pre-treatment were observed after 24 h zymosan stimulation (Figure 
5.9ii).  
To show CHD-FA does not have an effect on the epithelial cell line in the 
absence of an agonist, pre-treatment with the agent was carried out without 
zymosan stimulation. Here it was shown that CHD-FA treatment alone does not 
have an effect on the host immune response after 4 h and 24 h (Figure 5.10). 
 
Figure 5.10 - CHD-FA does not modulate the OKF6/TERT2 cells in the absence 
of an agonist.  
OKF6/TERT2 cells were pre-treated ± 0.5% (v/v) CHD-FA for 2 min and incubated in 
media for 4 h and 24 h. The TLDA was used to analyse the expression of a panel of pro-
inflammatory mediators. Each sample was carried out in triplicate on two independent 
experiments, with two replicates pooled from each experiment used in the TLDA. Data 
is represented by mean, relative to unstimulated control and GAPDH. 
As interleukin-8 (IL-8) was shown to be down-regulated with CHD-FA treatment 
for both the RT2 Profiler and TLDA, the expression of this chemokine was further 
investigated by ELISA (Figure 5.11).  
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Figure 5.11 - CHD-FA down-regulates IL-8 release from OKF6/TERT2 cells 
stimulated with zymosan.  
OKF6/TERT2 epithelial cells were pre-treated with 0.5% (v/v) CHD-FA pH 7.0 for 2 min 
and stimulated with zymosan for 4 h and 24 h. IL-8 protein release was measured by 
ELISA. All samples were assayed in triplicate, on two independent occasions. Data 
represents mean ± SD (**p <0.01). 
Figure 5.11 shows IL-8 release was inhibited when cells were pre-treated with 
CHD-FA, after 4 h zymosan stimulation (1.5 ×) and significantly reduced 
following 24 h zymosan stimulation (1.8 × [p<0.001]). No significant differences 
were observed between CHD-FA treatment alone and the media control.   
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5.5 Discussion 
Oral microbial diseases are typically mediated by biofilms; communities of 
microorganisms that co-aggregate as sticky and tenacious structures and which 
characteristically have increased resistance to antimicrobials (ten Cate and 
Zaura, 2012). Our group recently reported that mouthwashes, including CHX 
were ineffective against a range of clinical MRSA strains (Smith et al., 2013), 
suggesting that alternative antimicrobial agents ought to be investigated. 
Indeed, recent studies by our group, including data presented in the previous 
chapter, have shown that the use of naturally derived molecules are effective 
against both orally and systemically derived isolates of C. albicans (Ramage et 
al., 2012b, Sherry et al., 2012). The data presented herein show that CHD-FA, a 
naturally derived antiseptic molecule, displays rapid broad-spectrum 
antimicrobial activity, and also elicits immunomodulatory activity.  
Firstly, a comparative assessment of CHD-FA and CHX against a range of 
important bacteria associated with oral biofilm infections was undertaken. Both 
molecules were shown to effectively inhibit and kill planktonic cells, and both 
compounds were also effective against biofilms. Antimicrobial activity against 
planktonic bacteria has been reported previously for oxifulvic acid, a derivative 
of CHD-FA, where inhibition was observed against a range of important clinical 
pathogens, including P. aeruginosa, S. aureus and Streptococcus pyogenes (van 
Rensburg et al., 2000).  Notably, only marginally higher concentrations of CHD-
FA were required to kill the biofilm as compared to planktonic cells, whereas for 
CHX the fold change was up to 64 times, a phenomenon also found in chapter 4. 
Moreover, CHD-FA showed a rapid rate of kill for the periodontal pathogens 
tested as polymicrobial biofilms, as after 30 min treatment cellular viability was 
reduced by ≥90%, which was also observed for time kill studies in C. albicans 
biofilms in the previous chapter. It is recognised that a potential limitation of 
this study is that it was performed on biofilms produced from laboratory strains 
of the periodontal organisms in vitro, and it is conceded that further 
investigation may be required to assess the anti-microbial properties against the 
most virulent of clinical strains and biofilms formed in vivo. Equally, it would 
have been useful to test mixed C. albicans and bacterial biofilms. Nevertheless, 
collectively, these data suggest that CHD-FA has potent and broad-spectrum 
activity against polymicrobial biofilms. Furthermore, the SEM images indicate an 
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action against the bacterial cell membrane. Interestingly, the biofilms appeared 
to be disaggregated and displayed a fibrous appearance, presumably as a 
consequence of cell lysis and release of intracellular components. The previous 
studies on C. albicans biofilms in chapter 4 do not corroborate this observation, 
where no disruption of biofilms was observed.  However, the filamentous nature 
of C. albicans biofilms may explain why the compound was unable to 
disaggregate these. Despite this finding, there was no significant difference in 
the number of each species when treated with CHD-FA, when compared to the 
untreated control.  
Given that CHD-FA displayed an excellent antimicrobial profile, the next step 
was to ascertain whether it possesses any other biological properties, as has also 
been demonstrated for other naturals including tea tree oil (Carson et al., 2006). 
It has been reported that CHD-FA has no toxicity in rats and humans, and it has 
been further suggested that it elicits anti-inflammatory and wound healing 
promoting properties (Gandy et al., 2011, Sabi et al., 2011). Periodontitis is 
characterised by chronic inflammation that leads to tissue and bone destruction 
(Berker et al., 2013), and inflammatory processes play a key role in 
erythematous forms of oral candidosis. Controlling inflammation is therefore an 
attractive option for clinical management. The use of in vitro multi-species oral 
biofilms to study the inflammatory processes driven by complex biofilms have 
been shown to be important (Peyyala et al., 2013), therefore a similar system 
was developed to test CHD-FA and other bioactive molecules. Both CHX and 
CHD-FA in their native forms were shown to be toxic, therefore, in order to 
demonstrate subtle biological effects CHD-FA was buffered to pH 7.0 in order to 
test the hypothesis that it was immunomodulatory in vitro. Using an orally 
relevant epithelial cell line stimulated with a polymicrobial biofilm and a fungal 
agonist, it was demonstrated that at the transcript level cells pre-treated with 
CHD-FA showed a significant inhibition of pro-inflammatory molecules when 
induced by an inflammatory agonist, including the chemokine IL-8 (CXCL8). 
Analysis of the IL-8 protein also showed a significant reduction in its release 
from oral epithelial cells. These data indicate that CHD-FA has bioactivity 
against mammalian cells, as has been reported elsewhere (Gandy et al., 2011, 
Sabi et al., 2011). However, it is accepted that these differences are only 
observed when CHD-FA is adjusted to a neutral pH therefore, further studies are 
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required to determine the most suitable formulation of CHD-FA to potentially be 
used clinically, which at present is at pH 2.0. However, the precise mechanism 
of action remains unknown, but it can only be speculated that CHD-FA interacts 
with membrane proteins resulting in blocking signaling pathways, which leads to 
the inhibition of pro-inflammatory mediators upon stimulation with biofilms. 
Further investigations are required to determine the specific mechanism of 
action of CHD-FA. Specifically, NFκB was shown to be down-regulated when 
CHD-FA was used as a pre-treatment therefore, studies investigating if the agent 
has a direct effect on NFκB or whether it blocks binding at the cell surface will 
be carried out next.   
 
 
CHAPTER FINDINGS 
CHD-FA has broad-spectrum antimicrobial activity against a range of clinically 
relevant oral biofilms, including multispecies biofilms. 
CHD-FA is non-toxic when buffered from its native pH 2.0 to pH 7.0.  
Pre-treatment of an oral epithelial cell line with CHD-FA down-regulates a panel 
of pro-inflammatory mediators normally elevated in oral disease.
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6.1 Introduction 
In recent years, Candida species have been identified as the most common 
fungal pathogen in BSI in patients within the ICU (Wisplinghoff et al., 2004), 
where the presence of an indwelling catheter has been associated to biofilm 
formation (Kojic and Darouiche, 2004, Douglas, 2003). Many studies have 
previously identified mechanisms involved in C. albicans biofilm development 
(Blankenship and Mitchell, 2006, Finkel and Mitchell, 2011, Nobile et al., 2012), 
however, these have been restricted by the use of well characterised laboratory 
strains, with few studies investigating the impact of biofilm formation in clinical 
isolates. Recent studies have shown a correlation between C. albicans biofilm 
formation and patient mortality, identifying specific risk factors associated with 
these infections (Tumbarello et al., 2012, Tumbarello et al., 2007). As not all 
clinical isolates have the ability form biofilms to the same degree as one 
another, the mechanisms behind this must be fully understood to improve the 
clinical management of these infections, which has implications both for 
diagnostics and treatment. 
6.2 Improvement C. albicans diagnostics to detect 
biofilm-associated infections 
The underlying molecular mechanisms responsible for C. albicans biofilm 
formation have been studied extensively, where elevated transcription of 
several key genes has been identified as playing a critical role in biofilm 
development (Blankenship and Mitchell, 2006, Cao et al., 2005, Garcia-Sanchez 
et al., 2004, Nobile et al., 2006a). However, to date with exception of a few 
studies very little has been explored with respect to clinical isolates, where 
differential levels of biofilm formation has been shown to exist that significantly 
impact antifungal therapy and clinical outcomes (Tumbarello et al., 2012, 
Walraven and Lee, 2013). As C. albicans is a commensal in over 50% of the 
healthy population (Coronado-Castellote and Jimenez-Soriano, 2013), it would 
be useful to understand whether specific isolates from these individuals have the 
capacity to be more pathogenic than one another and lead to disease, and 
methods to distinguish between these opportunistic pathogens and their levels of 
biofilm growth would be advantageous. Herwald and Kumamoto (2014) analysed 
a number of studies that investigated the regulation of genes in pathogenic 
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(Andes et al., 2004, Garcia-Sanchez et al., 2004, Nobile et al., 2012, Yeater et 
al., 2007) and commensal C. albicans cells (Rosenbach et al., 2010, Pierce et al., 
2013b), and concluded that 1,444 genes were up-regulated in biofilm cells that 
were related to protein translation (Herwald and Kumamoto, 2014). Further 
studies are required in vitro and in vivo to identify a potential set of C. albicans 
genes that could be used as a molecular target for diagnosing biofilm infections.  
Currently, the identification of Candida spp. clinically is reliant on culture based 
tests or the detection of β-1,3 glucans and mannans, all of which do not elude to 
the isolates biofilm forming ability (Mokaddas et al., 2011, Held et al., 2013). In 
addition, a traditional and rapid test also used diagnose C. albicans infections is 
the germ tube test (GTT), whereby isolates are viewed microscopically to 
determine their hyphae forming ability with positive tests indicating the 
presence of C. albicans or C. dubliniensis (Rimek et al., 2008, Sheppard et al., 
2008). Although this test is able to identify the presence of hyphal cells it does 
not give an indication as to whether this isolate is able to adhere to a surface 
and produce ECM, defining features of a biofilm. Furthermore, germ tubes can 
also be found in isolates with LBF albeit not in a great abundance and therefore 
are not indicative of an isolate with HBF.  
The use of molecular diagnostics such as PCR over standard culture methods has 
been shown to be advantageous, with Candida being detected in blood samples 3 
days prior to blood culture techniques, therefore enabling the administration of 
antifungal therapy earlier (Wellinghausen et al., 2009). Molecular methods 
including qPCR have been compared to the XTT assay and although they show 
similar data at early phases of biofilm development, qPCR could quantify 
differences in biomass ± treatment that were undetected by XTT (Xie et al., 
2011). Therefore, the development of a diagnostic that would distinguish C. 
albicans biofilm forming ability is of great importance as it could help direct 
more appropriate antifungal therapy. In this thesis, a number of transcriptional 
targets were investigated with the aim to identify a potential marker for C. 
albicans biofilm formation. Although preliminary data did not identify a defined 
biofilm target, subsequent RNA-Seq analysis concluded 853 genes were 
significantly up-regulated in isolates with HBF, many being cell wall and 
membrane proteins including HWP1. This cell surface protein is highly expressed 
in hyphal cells and is essential for biofilm formation in vitro and in vivo (Fanning 
Ch.6 Final discussion 
 
 197 
et al., 2012, Nobile et al., 2006b). Therefore, there is potential to use this 
protein as a biomarker for diagnosing C. albicans biofilm infections, though 
further studies are required to take this forward.  
6.3 Current anti-biofilm strategies 
In the absence of a biofilm diagnostic, biofilm-related infections must be 
managed efficiently to prevent increased morbidity and mortality rates, as well 
as controlling antifungal therapy. Based on a comprehensive study by the WHO 
investigating antimicrobial resistance it was reported that the overuse of 
fluconazole has led to the increases in azole resistant species, including C. 
albicans and notable C. glabrata (WHO, 2014). Moreover, although azoles are 
active against planktonic cells, they are highly ineffective against C. albicans 
biofilms (Ramage et al., 2012c, Taff et al., 2013). Despite this, these agents 
remain as the first choice antifungal in C. albicans infections, due to safety 
within the host and cost effectiveness compared to other classes of antifungal. 
Studies have investigated the potential of combining azoles with various 
inhibitors of stress responses, including calcineurin (Shinde et al., 2012, Uppuluri 
et al., 2008) and Hsp90 (Cowen et al., 2009, Robbins et al., 2011), where it has 
been shown to improve fluconazole activity against C. albicans biofilms. 
Therefore, the use of azoles in C. albicans biofilm-related infections may need 
to be used as part of a combinational therapy to kill the biofilm.  
Although current guidelines state the removal of an indwelling catheter is the 
most appropriate treatment of invasive candidiasis (Andes et al., 2012, Cornely 
et al., 2012), this is not possible for all patients due to the location of the 
medical device and host status. ALT has received interest as a potential 
alternative treatment for device-associated infections, where polyene agents 
have shown high activity with >60% success rates when used (Angel-Moreno et 
al., 2005, Buckler et al., 2008, Wu and Lee, 2007). Although these agents have 
excellent biofilm activity, it tends to be at concentrations that are also toxic to 
the host (Pierce et al., 2013a, Ramage et al., 2002c). Therefore, alternative 
methods of administrating amphotericin B are under investigation. These include 
the incorporation of AMB within a nanoparticle, which have been shown to be 
successful in a topical in vivo model, where reduced fungal burdens and low 
toxicity was observed (Sanchez et al., 2014a). The relatively new class of 
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antifungals, echinocandins, were initially shown to be highly effective against C. 
albicans biofilms (Bachmann et al., 2002), yet they do not completely kill the 
biofilm and have slower kill kinetics compared to other agents (Cateau et al., 
2011, Ramage et al., 2013). Furthermore, a paradoxical effect is observed in CSP 
that makes it more difficult to determine an appropriate treatment towards C. 
albicans biofilm-related infections, as too little or high concentration would be 
ineffective (Bizerra et al., 2011, Imtiaz et al., 2012, Stevens et al., 2005). 
Tumbarello and colleagues (2012) had identified inadequate antifungal therapy 
as one of the key predictors of patient mortality and hospital length of stay in 
patients with biofilm forming isolates (Tumbarello et al., 2012). One of the main 
challenges with the use of antifungal therapy is that clinicians tend to class all 
C. albicans infections as one and do not consider how individual strain 
characteristics impact treatment. This emphasises the importance of identifying 
isolate characteristics including biofilm susceptibility, before administrating 
therapy that could be completely ineffective.  
In the absence of molecular diagnostics and increasing antifungal resistance, the 
use of alternative agents with high biofilm activity is sought after, particularly 
those derived from a natural source as these tend to be cheap and less toxic to 
the host. Agents with broad-spectrum activity are advantageous due to many 
infections caused by polymicrobial biofilms. 
6.4 Can CHD-FA be used as alternative antimicrobial? 
Increasingly Candida biofilms are becoming clinically important (Ramage et al., 
2009, Tumbarello et al., 2007), particularly because of inappropriate or misuse 
of broad-spectrum antimicrobials that are ineffective against recalcitrant 
biofilms (Niimi et al., 2010). Therefore, the use of natural antimicrobials is 
highly sought after as it is thought to be relatively inexpensive and less toxic 
that conventional agents currently used clinically. Tea tree oil (TTO) is one of 
the most documented naturals currently used as an alternative oral hygiene 
agent (Vazquez and Zawawi, 2002, Soukoulis and Hirsch, 2004), with many 
studies showing its broad-spectrum antimicrobial activity (Thompson et al., 
2008, Hammer et al., 2003b, Garozzo et al., 2011, Hammer et al., 2003a). 
Furthermore terpinen-4-ol, the active agent of TTO, is equally active against 
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Candida planktonic and sessile cells (Ramage et al., 2012b), an advantageous 
property of an antifungal as it has been reported that up to 1000-fold greater 
concentrations of agents are required to kill biofilms than their planktonic 
counterparts (Di Bonaventura et al., 2006, Ramage et al., 2001a).  
Other natural compounds shown to be of clinical importance include garlic 
where it was used as a topical treatment in patients with oral candidiasis and 
was shown to be equally effective as clotrimazole (Sabitha et al., 2005). 
Furthermore, the use of naturals in combinational therapy has also shown to be 
beneficial, whereby curcumin was able to work synergistically with fluconazole 
to inhibit the resistance and restore the sensitivity of the azole (Garcia-Gomes 
et al., 2012). Moreover, curcumin was able to inhibit the adhesion of Candida 
species to buccal epithelial cells to a greater level than fluconazole (Martins et 
al., 2009).  
It is known that fulvic acids are one of the components that make up humic 
substances, which are ubiquitous in the environment and are formed during 
plant decay (Snyman et al., 2002, van Rensburg et al., 2001). A previous study 
has shown oxifulvic acid elicits broad-spectrum activity against a range of 
planktonic bacteria and fungi including E. faecalis, S. aureus and C. albicans 
(van Rensburg et al., 2000) whereby all organisms tested were successfully 
inhibited at ≤1.5%, however its activity against biofilms was unknown. This thesis 
has provided evidence that CHD-FA could potentially be used as an alternative 
natural agent for the treatment of biofilm infections as it is highly effective 
against a panel of oral pathogens, where 0.5% CHD-FA was able to inhibit 
planktonic and sessile growth. Furthermore, this concentration was equally 
effective against a multispecies periodontal biofilm in vitro, reducing viability to 
the same level as ‘the gold standard’ chlorhexidine (Herrera, 2013). However, it 
is accepted that although a four species mixed biofilm model was used in this 
study, antimicrobial activity against this model does not fully represent all 
mixed biofilms that are found within the oral cavity, but only a few of species 
relevant in periodontal disease. Currently our group are developing various co-
culture models that contain up to 11 species of prokaryotes and eukaryotes. This 
provides a greater understanding to how the immune response is regulated in 
the presence of such complex biofilm models (Guggenheim et al., 2009, Peyyala 
et al., 2013), as well as providing a situation that is more reflective of the 
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clinical environment. Furthermore, as CHD-FA is unable to disrupt the biomass of 
biofilms, the combination of this novel agent with a compound such as lauroyl 
glucose could enhance the breakdown of biofilms and improve antifungal 
therapy (Dusane et al., 2008, Martins et al., 2011). Moreover, eDNA has is a 
known component of bacterial and fungal biofilms (Martins et al., 2010, 
Whitchurch et al., 2002), the use of DNase in conjunction with an antimicrobial 
would enhance biofilm disruption (Martins et al., 2011).  
Overall, this data demonstrates that CHD-FA is effective against polymicrobial 
biofilms, independent from biofilm disruption, suggesting it is a useful 
antimicrobial. CHD-FA has already shown to have no sign of toxicity in rats and 
humans, and in fact was reported to have anti-inflammatory and wound healing 
properties, possibly through a free radical scavenging mechanism (Gandy et al., 
2012, Gandy et al., 2011, Sabi et al., 2012), which has been further supported 
by this thesis. One inconsistency of all these studies is the variation in pH of 
CHD-FA ranging from 2.0 to 7.0. This study has shown low pH is toxic against an 
oral epithelial cell line with a similar reduction in viability to CHX treatment, an 
issue reported in many cell types (Chang et al., 2001, Mariotti and Rumpf, 1999, 
Lee et al., 2010). Furthermore, CHX has been responsible for anaphylaxis in two 
individuals within the UK following routine dental treatment (Pemberton and 
Gibson, 2012), resulting in fatalities. This emphasises the extreme side effects of 
this antiseptic agent but awareness of such cases are needed to possibly prevent 
such hypersensitivity reactions in the future.   
In addition to its broad-spectrum antimicrobial properties, this study has shown 
CHD-FA can modulate the immune response and down-regulate the biofilm 
induced expression of pro-inflammatory mediators known to be up-regulated in 
oral keratinocytes (Peyyala et al., 2013). However, a limitation of this study was 
only a selected number of inflammatory mediators were investigated. Moreover, 
this model does not take host factors in to consideration, which may influence 
the inflammatory response even further. Therefore, further studies that 
determine the effect of CHD-FA on the host as well as assessing its ability to 
clear the infection in vivo are of great value. However, it does not take away 
from the fact that CHD-FA is able to modulate the immune response and 
complements other studies that have shown an anti-inflammatory effect of CHD-
FA when used as a topical agent in humans and rats (Gandy et al., 2011, Sabi et 
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al., 2012). Collectively, these properties make CHD-FA an attractive option for 
the development of a topical agent such a mouthwash or denture cleanser to 
treat microbial oral disease. Moreover, the use of this compound as a broad-
spectrum antiseptic agent is desirable, whereby it could be used for the 
treatment of systemic disease as well as potentially being incorporated in to 
biomaterials and wound dressings. However, further studies in vitro and in vivo 
are first required to further define the mode of action of this unique compound. 
6.5 Future work 
This body of work has assessed C. albicans biofilm formation by clinical isolates 
by using a number of techniques and demonstrated that this varies between 
strains. Although the presence of eDNA was identified as a contributing factor 
towards biofilm formation, the depletion of this only led to a minimal impact 
with regards to antifungal susceptibility. Therefore, other mechanisms must be 
involved in C. albicans biofilm variation, and the identification of these could be 
found with further analysis of the RNA-Seq data found in this study. Here, a 
subset of genes found to be up-regulated in LBF and HBF were identified 
however, the roles of many of these genes are unknown. Therefore, further in 
depth analysis of such genes could provide crucial information for explaining the 
differences in C. albicans biofilm formation. Although data in this thesis was 
based around a limited number of isolates, it gives a solid foundation for 
investigating these phenotypic, biochemical and transcriptional differences. In 
fact, our group are currently investigating these findings but on a larger scale 
collaboratively, where all candidaemia cases within Scotland between February 
2012 to January 2013 will be screened for their biological characteristics. The 
advantage of this follow up study is that there is clinical data to match each 
candidaemia isolate, allowing for biofilm formation to be related back to a 
number of clinical parameters. Future work will also continue to examine the 
impact strain variation has on the host to gain a further understanding to how 
these isolates behave. It is acknowledged that the kidneys are one on the main 
organs affected by systemic candidiasis in vivo (MacCallum, 2009, Jacobsen et 
al., 2014), therefore assessing the impact of isolates with LBF and HBF on a 
recently developed renal cell line (Szabo and MacCallum, 2014) would seem a 
reasonable next step before moving on to in vivo studies.  
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As antifungal resistance is an increasing problem, the development of novel 
agents for the treatment of C. albicans infections is of great importance. This 
study has evaluated the antimicrobial and immunomodulatory properties of the 
natural compound CHD-FA. Although it was shown to have excellent anti-biofilm 
activity against fungi and bacteria, its inability to disrupt biofilms is a 
disadvantage. However, further studies plan to investigate the activity of CHD-
FA with a known disruptive agent such as DNAse or lauroyl glucose to further 
increase its activity against biofilms. CHD-FA has also shown potential anti-
inflammatory properties that are of particular interest for an oral hygiene 
product as many oral diseases are associated with inflammation. One mediator 
that was reduced in the presence of CHD-FA was NF-κB. Further investigations 
are required to fully understand the mechanisms behind this and to whether it is 
a direct effect on NF-κB that results in the reduced expression of other pro-
inflammatory mediators or whether CHD-FA is to inhibit toll-like receptors. 
Finally, as CHD-FA was used at various pHs in this piece of work, studies need to 
now focus on an appropriate pH for the product to used within the clinical 
setting. Currently, formulations are being prepared at pH 5.8-6.0 for its use as a 
mouthwash and a denture cleanser, however further studies in vitro and in vivo 
are required to evaluate the activity of these.  
6.6 Summary 
The key findings of the research presented in this thesis are as follows 
 C. albicans biofilm formation is differential  
o Clinical isolates have varied levels of biomass relating to virulence 
and antifungal therapy 
o Chitinases have been shown to be involved in the release of eDNA, 
contributing the C. albicans biofilm formation and stability 
o Various transcriptional targets have been identified as potential 
biomarkers to be utilised as a diagnostic tool for C. albicans biofilm-
related disease 
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 CHD-FA as an alternative antimicrobial agent  
o CHD-FA has broad spectrum activity against bacterial and fungal 
biomass, to similar levels as CHX 
o The agent acts non-specifically against cells membranes and is not 
impacted by known C. albicans resistance mechanisms 
o CHD-FA is able to inhibit inflammatory mediators that are up-
regulated upon bacterial and fungal stimulation 
Overall, these findings have increased the understanding of C. albicans biofilm 
differentiation within clinical isolates and evaluated the antimicrobial activity of 
the novel agent CHD-FA. Together these allow for the development of diagnostic 
tools and alternative therapies for biofilms infections. 
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1 Appendix I – List of C. albicans clinical isolates  
 
 
LBF    HBF    Remaining isolates 
 
27915    2623    42341  2972 
42340    28158    20626  11689  
76369    68518    82942  26839 
88301    77013    78462  20705 
65867    9629    69299  62054 
74174    34106    40144  72419 
50348    58535    91696  62585 
77014    74503    3022  79214 
92228    71114    2974  54821 
31903    39286    29659  91694 
        19032  83889 
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